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BackgrounD
Cancer is one of the most important health problems in the developing world with an 
estimated incidence of 3.5 million per year and 1.75 million deaths in Europe in 2012 (1). 
Thereby cancer attributes to about 28% of all deaths and is the second leading cause 
of death in Europe (2). Although cancer is one of the most important causes of death 
nowadays, survival after cancer has been improved over time (3-5). The improvements 
in survival are caused by earlier detection of cancer and new treatment developments. 
The earlier detection enables a more adequate treatment with higher chances of cure. 
However, the earlier detection can also artificially improve survival as the time to death 
will increase if the diagnosis has been set earlier (4). The new treatment options include 
new technologies and pharmaceuticals.
Due to the large incidence of cancer and the high costs of the new technologies and 
pharmaceuticals to treat cancer, the economic burden of cancer is substantial (6). The 
high mortality and morbidity of cancer also poses a large burden on society in terms 
of productivity loss and informal care costs. It is expected that the costs of cancer will 
increase in the future (7). This increase will be partly caused by an increase in cancer 
incidence due to the aging of the population as cancer occurs more frequently in older 
patients. Furthermore, new developments in diagnosis and treating cancer are often 
associated with high costs. A balance needs to be found between the reduction in 
mortality and morbidity and the rising health care costs due to the new technologies.
One of the new technology developments in the field of cancer is personalized medi-
cine. Personalized medicine is a term that is used for medicine which is targeted to a 
specific patient group. The main reasons for the development of personalized medicine 
is that a one-size-fits-all treatment approach does not always lead to the most desirable 
outcomes as not all patients respond to the treatment. Response rates of cancer drugs 
approved 1995 and 2005 ranged between 10 and 80% (8,9). Currently, new techniques 
enable a better identification of responders and non-responders before the start of the 
treatment (10). If treatment will be restricted to the responders only, the effectiveness 
of the treatment will increase. Furthermore, the costs might decrease as fewer patients 
receive the expensive treatment and fewer side-effects are experienced because non-
responders are no longer exposed to an ineffective and possible toxic treatment.
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PersonalizeD meDicine
The term personalized medicine is often used to characterize treatment tailored accord-
ing to genetic information (11). However, genetic information is not the only information 
source to identify patients who should receive a specific treatment or not. Other relevant 
characteristics may include age, comorbidities, performance status and regular blood tests 
results (12). Intensive cancer treatment is often restricted to younger patients with a good 
performance status and few comorbidities (13-16). It has also been shown that patients 
with comorbidities have a poorer outcome, irrespective of age and stage of the disease 
(17). As other information than genetic test results can also be used to tailor treatment, 
the following definition of personalized medicine is used in this thesis: ‘the use of com-
bined knowledge (genetics, or otherwise) about a person to predict disease susceptibility, 
disease prognosis or treatment response and thereby improve that person’s health’ (12).
The above mentioned definition also distinguishes different applications of personal-
ized medicine. Table 1.1 shows three different applications of personalized medicine as 
well as examples of genetic and non-genetic information used to personalize treatment.
The first application is the use of individual information to predict disease susceptibility. 
This information is especially useful if preventive measures are available to avoid the de-
velopment of the disease, like mastectomy for people with a high risk of breast cancer (24). 
The second application is the use of individual characteristics to identify the prognosis 
of the patient. This information might have important consequences for the treatment 
choice if patients with a good prognosis are treated differently than patients with a poor 
prognosis. Finally, individual information can also be used to predict treatment response, 
development of side effects and adequate dosing of drugs to guide treatment decisions.
Although personalized medicine is not only related to the use of genetic information, 
the knowledge about the human genome has increased the possibilities to individualize 
treatment. Many studies have found genetic heterogeneity in the known cancer types 
and associations between genetic markers and prognosis (25-27). It is therefore ex-
pected that many new personalized medicine strategies will be developed in the future.
The effectiveness and the cost-effectiveness of new strategies needs to be evaluated 
before these strategies can be implemented in daily practice. The rationale for cost-
effectiveness analyses is that resources are scarce and motivated choices are requirered 
for investing these scarce resource in new health care technologies. As it is expected that 
the health care expenditures will rise in the future (28), it becomes even more important 
to make these motivated choices.
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cosT-eFFecTiveness analysis
In cost-effectiveness analyses, both the costs and effects of a new product are compared 
with the costs and effects of current products (29). The cost-effectiveness of a product is 
reported as the incremental cost-effectiveness ratio (ICER), which can be calculated with 
the following formula:
ICER =
Costs New − Costs Old
Effect New − Effects Old
The effects in cost-effectiveness analyses are often measured in quality-adjusted life 
years (QALYs). A QALY is measure which combines mortality and health-related quality 
of life in one measure. Within the QALY concept, health-related quality of life is expressed 
as a utility of being in a specific health state. QALYs are calculated by multiplying the life 
years in a specific health state with the quality of life utility associated with that health 
state. Perfect health is represented by a utility value of 1 and death with a utility value 
of 0.
Many different questionnaires are currently available to measure health-related quality of 
life. Guidelines for cost-effectiveness analyses recommend the use of a generic quality-of-life 
questionnaire, the EQ-5D, for use in cost-effectiveness analyses unless there is evidence that 
the EQ-5D has a poor performance in the selected patient population (30). The main reason 
for this recommendation is to guarantee the comparability of cost-effectiveness analyses 
between diseases as it has been shown that utility values differ between questionnaires (31).
Table 1.1 Different applications and examples of personalized medicine
application of 
personalized 
medicine
example non-genetic information example genetic information
Predict disease 
susceptibility
Healthy lifestyle factors (healthy weight, high 
physical activity, non-smoking, limited alcohol 
consumption and a healthy diet) are associated 
with a lower lower incidence of colorectal cancer 
in Europe (18).
BRAC mutations in breast cancer 
patients (19).
Identify prognosis 
of the patient
Prognostic indices for brain metastases. These 
indices include the following parameters: age, 
performance status, presence of extracranial or 
brain metastases (20).
Risk-stratified treatment for 
acute myeloid leukemia based 
upon cytogenetic and molecular 
abnormalities (21).
Predict treatment 
response or side 
effects
Geriatric factors (cognitive functioning, 
dependence, depression) are predictive of severe 
toxicity or unexpected hospitalization in patients 
with metastatic colorectal cancer (22).
Erlotinib and gefitinib for non-small 
lung cancer patients with mutations 
in the gene encoding the epidermal 
growth factor receptor (EGFR) (23).
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If it has been shown that the EQ-5D has a poor performance in the selected population, 
the utility values needs to be derived from a more valid questionnaire. This questionnaire 
can either be another generic questionnaire or a disease-specific questionnaire. However, 
are often not developed to calculate quality of life utilities. Preference-based utility values 
need to be estimated for these questionnaires. In general, two different methods exit to 
estimate utility values for disease-specific questionnaires. The first method is the predic-
tion of generic quality of life utilities based upon the answers given to the disease-specific 
questionnaire (32). This method is called ‘mapping’. The second method is the direct valu-
ation of health states from the disease-specific questionnaire (33). The direct valuation 
method is recommended if it has been shown that the EQ-5D has a poor performance in 
the selected population. The mapping method is especially useful if quality of life has only 
been measured with a disease-specific questionnaire although evidence is available for 
the validity of the EQ-5D in the patient population under study (34).
Cost-effectiveness analyses are often performed from a life-time perspective including all 
costs and effects in the remaining period of life (29). With respect to personalized medicine 
strategies, it means that not only the costs of testing for specific patient characteristics 
should be measured, but also the costs of the subsequent treatment choices. Furthermore, 
it is recommend that cost-effectiveness analyses are performed from a societal perspective 
and thereby include all costs and effects for the society as a whole (29). This means that 
not only medical, but also non-medical costs should be included. Medical costs include 
the costs of medication, hospital visits, laboratory tests and radiology. Non-medical costs 
include productivity costs, which are costs of absenteeism at work or reduced productivity 
at work due to the disease, traveling costs and informal care costs (35,36).
Cost-effectiveness analyses can be performed alongside a clinical trial (piggy-back eco-
nomic evaluation). Information about costs, quality of life and survival will be collected 
during the clinical trial. However, a clinical trial has often a limited time period (about 3-5 
years), while a lifetime perspective if preferred for cost-effectiveness analyses. Modeling 
methods are often used to extend the results of the trial to a longer time period (29).
The extrapolation of the trial period is not the only role for modeling in cost-effectiveness 
analyses. Modeling is extremely useful if data has been derived from different sources, 
like genomic, clinical and epidemiological studies (37,38). The information from all these 
sources can be synthesized and combined in the model to assess cost-effectiveness of 
new strategies (29). Furthermore, modeling can also be used for the planning of future 
studies, including the type of data collection and the focus in terms of target population. 
Once modeling studies show a substantial impact of changes in certain input param-
eters on the ICER (39), it is important that more information about these parameters will 
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be collected in future studies. As these studies will come with additional costs, model-
ing can also be used to identify the value of additional research (40). A modeling study 
might also identify areas with the largest medical needs. Preferably, new studies should 
focus on those areas. Furthermore, modeling can also be used early in the development 
process to evaluate whether it is worthwhile to continue the development of a product 
(41). This early evaluation includes an assessment of the required effectiveness of a 
new product given a certain price and cost-effectiveness threshold. Furthermore, the 
maximum possible price of future products can be estimated. Continuation of product 
development is only useful if that price will cover all development and production costs.
It is expected that systematic use of cost-effectiveness analyses in the development 
and assessment of personalized medicine strategies in cancer will improve the imple-
mentation of these new strategies in daily practice. However, it needs to be evaluated 
how cost-effectiveness analyses can be systematically applied during the development 
process of new technologies. This thesis aims to answer this question by a thorough 
evaluation in a specific type of cancer with a high potential for personalized medicine, 
namely acute myeloid leukemia (AML). Besides the high potential of personalized 
medicine in the field of AML, the current prognosis of AML is still very poor. Furthermore, 
current treatments for AML are expensive and have a large impact on the health-related 
quality of life. Therefore, new treatment options are needed to improve survival and 
health-related quality life and reduce costs in patients with AML.
acuTe myeloiD leukemia
Acute myeloid leukemia (AML) is a specific type of leukemia which is characterized by 
a proliferation of immature myeloid cells (blasts) in the bone marrow. The proliferation 
of blasts reduces the development of normal blood cells which lead to increased risk of 
bleedings and infections and make patients feel tired and weak (42). The rapid increase 
of blasts in patients with AML requires immediate treatment to reduce the number of 
blasts and restore the normal blood function (26).
The large potential of personalized medicine in the field of AML is caused by the hetero-
geneous nature of the disease (26). Many different subtypes of AML are identified based 
upon cytogenetic and molecular abnormalities. Some of these subtypes are already 
defined as a distinct entity in the most recent classification of the World Health Organiza-
tion (WHO) (43). The prognosis differs between patients with different cytogenetic and 
molecular abnormalities (44-47). Due to the differences in pathogenesis and prognosis 
of the distinct subtypes, treatment already differs between subgroups. One specific type 
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of AML, acute promyelocytic leukemia (APL) is already treated with a targeted treatment 
regimen (48). This targeted treatment regimen has dramatically improved the prognosis 
of APL (49). For all other patients, a risk-stratified treatment is applied with less intensive 
treatments for patients with a low risk of relapse (26,50). However, research is ongoing 
to find targeted treatments for other subgroups of AML (51,52).
In general, treatment for AML consists of chemotherapy and/or hematopoietic stem 
cell transplantation (26). All treatments are very intensive and require hospitalization 
to prevent the development of infections. The long hospitalization is associated with 
high treatment costs. Another negative consequence of the intensive treatments is the 
impact of the treatments on health-related quality of life. AML patients report frequently 
problems with physical, psychological and emotional and sexual functioning (53). Fur-
thermore, it has been shown that the health-related quality of life is more reduced in 
patients receiving more intensive treatments like hematopoietic stem cell transplanta-
tions (54-56). However, not all patients can adequately be treated with current treatment 
options resulting in a poor overall prognosis. Only 20% of the patients with AML is alive 
5 years after the diagnosis (57). The prognosis is better for younger patients; the 5-year 
overall survival is 55% and 9% in patients aged 18-44 and 65-74 years, respectively. An 
important factor for the poor prognosis in older patients is the inability of older pa-
tients to receive the intensive treatments. New treatments are needed to adequately 
treat elderly patients, improve current cure rates and health-related quality of life and 
reduce the treatment costs. As some of the patients with AML can already be adequately 
treated with current treatment options, it is expected that the new treatments will be 
focused on specific subgroups.
Personalized medicine will always reduce the size of the population under study. This is 
more problematic in AML compared to other cancers, due to the low incidence of AML. 
The incidence of AML is 3-4 per 100,000 compared to a breast cancer incidence of 94 
per 100,000 (1,58). Due to the low incidence of AML and its subgroups, international col-
laborations are needed for sufficiently powered trials to detect a significant difference 
in survival or response (52). It is important that future studies are set up as efficiently as 
possible to obtain maximum health gain with a minimum amount of resources.
research quesTions
In order to assess the cost-effectiveness of personalized medicine strategies in AML and 
provide methodological guidance for evaluations in other disease areas, the following 
research questions have been defined:
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- What are the costs of acute myeloid leukemia treatment in the Netherlands?
- What is the quality of life of acute myeloid leukemia patients in the Netherlands?
- Which HRQOL instrument should be used to measure HRQOL in acute leukemia 
patients for the purpose of an economic evaluation?
- What is the cost-effectiveness of personalized medicine strategies for AML patients?
- Which recommendations can be given with respect to future developments in the 
field of AML?
- Which recommendations can be given with respect to the methodology for cost-
effectiveness analyses of personalized medicine strategies in other disease areas?
ouTline oF The Thesis
This thesis consists of two parts. The first part of the thesis (chapter 2-6) focuses on stud-
ies performed to obtain inputs in terms of costs and health-related quality of life for 
use in cost-effectiveness analyses in the field of AML due to limited information in the 
literature. The second part (chapter 7-8) describes the development of a decision model 
for AML and the application of the model in cost-effectiveness analyses.
Chapter 2 reports the results of a microcosting study performed in three hospitals in 
the Netherlands. Resource use was collected for all patients diagnosed with de novo or 
secondary AML and started with induction treatment in 2008 or 2009. The total treat-
ment of AML was distinguished in three phases: induction treatment, post-remission 
treatment and follow-up.
Chapter 3 and 4 describe the results of the two studies performed to estimate utility 
values for the cancer-specific quality of life questionnaire EORTC QLQ-C30. The mapping 
study of the QLQ-C30 onto the EQ-5D is described in chapter 3. EQ-5D utilities were 
predicted according to the answers given to the QLQ-C30. This prediction algorithm was 
developed in patients with multiple myeloma. Multiple myeloma patients have filled in 
both the EQ-5D and the QLQ-C30 at different points in time. For the development, the 
results of all time points were pooled to increase the sample size. The resulted algorithm 
was validated in patients with non-Hodgkin lymphoma.
The results of the direct valuation study are described in chapter 4. First, the QLQ-C30 
has been reduced to an 8-item instrument, the QLQ-PBM, according to expert opinion, 
psychometric criteria and fit to the Rasch model. A selection of the possible health states 
were valued by the general public using the time-trade-off method. The utility values 
of the other health states were estimated with regression methods. Both the mapping 
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and direct valuation study were not restricted to the QLQ-C30, but utility values were 
also estimated for two other disease-specific questionnaires, the HAQ for rheumatoid 
arthritis patients and the MSIS-29 for multiple sclerosis patients.
Chapter 5 shows the results of a cross-sectional quality of life study in AML survivors of 
one academic hospital in the Netherlands. Both the results of the new version of the 
EQ-5D, the EQ-5D-5L, and the QLQ-C30 were reported. The study compared the quality 
of life of AML survivors with that of the general population to assess the impact of AML 
and its treatments on quality of life. Furthermore, the study provided a first assessment 
of factors associated with quality of life in AML.
Chapter 6 reports the results of the study which assess the feasibility, validity and reli-
ability of the EQ-5D-5L and the QLQ-PBM in acute leukemia patients. The study was 
based upon data of the cross-sectional quality of life study described in chapter 5, but 
extended with data from patients with acute lymphoblastic leukemia. This chapter 
provided some guidance regarding the quality of life instrument that should be used in 
cost-effectiveness analyses in the field of AML.
Chapter 7 describes the development and validation of a decision model representing 
the full disease course of AML. A discrete-event-simulation model was developed to 
incorporate relevant patient, disease and treatment characteristics. The validation of the 
model consisted of face validation by clinical expert and an internal and external valida-
tion. The internal validation included a comparison of the clinical outcomes in the model 
with the original data. For the external validation, the clinical outcomes were compared 
with the published results of clinical trials in other countries.
The cost-effectiveness of a revised risk group classification is described in chapter 8. The 
validated model is used to perform this cost-effectiveness analysis. The costs and quality of 
life estimates were derived from the studies performed in the Netherlands. Both univariate 
and probabilistic sensitivity analyses were performed to assess the impact of uncertainty 
in the input parameters on the cost-effectiveness of the new risk group stratification. 
The main results of this thesis are described in chapter 9. This chapter provides practical 
recommendation of future research in the field of AML. Furthermore, the application of 
the methods in this thesis for assessments of personalized medicine strategies in other 
disease areas will also be addressed in the general discussion.
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The costs of initial treatment for patients 
with acute myeloid leukemia in the 
Netherlands
With Hedwig M. Blommestein, Peter C. Huijgens, Nicole M.A. Blijlevens, 
Mojca Jongen-Lavrencic and Carin A. Uyl-de Groot
Published in Leukemia Research 37(3): 245-50
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aBsTracT
The aim of this study was to calculate the costs of the current initial treatment of 
acute myeloid leukemia. Resource use was collected for 202 patients who started with 
intensive chemotherapy in 2008 or 2009. The costs of the first induction course were 
significantly higher than the costs of the second induction course. Allogeneic transplan-
tation from a matched unrelated donor was significantly more expensive than the other 
consolidation treatments. In-hospital stay was the major cost driver in the treatment of 
AML. Research regarding possibilities of achieving the same or better health outcome 
with lower costs is warranted.
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inTroDucTion
Acute myeloid leukemia (AML) is an aggressive disease which requires intensive treat-
ment. Treatment of AML generally consists of several induction chemotherapy courses 
to induce complete remission (CR). Induction treatment is followed by consolidation 
treatment consisting of high-dose chemotherapy or autologous or allogeneic hema-
topoietic stem cell transplantation (HSCT) for patients younger than 60-65 years of 
age. Stem cell sources of allogeneic HSCT are threefold: HLA-identical sibling, matched 
unrelated donor (MUD) or umbilical cord blood (UCB) (26). The choice of consolidation 
treatment depends on the patient’s risk of relapse and treatment-related mortality (59).
Insight into the treatment costs is an essential requirement for adequate reimbursement 
of treatment. In addition, cost calculations are required as input for cost-effectiveness 
analyses of (new) treatments. The cost-effectiveness factor will become increasingly 
important due to rising health care expenditures in Western countries (60). A few studies 
in the 90s and early 2000s have calculated the total costs of AML treatment (61-63). 
However, treatment strategies have changed dramatically (64-67), and an update of the 
treatment costs is therefore essential. The aims of this study were to gain insight into the 
current treatment costs and the different cost components of the total treatment costs.
maTerials anD meThoDs
Patients
All adult patients diagnosed with de novo primary or secondary AML who started with 
induction chemotherapy in 2008 or 2009 in three university hospitals in the Netherlands 
were included in this study. Patients with acute promyelocytic leukemia (APL) were 
excluded because the number of patients was small and these patients were treated 
differently. Data were collected from diagnosis until relapse, death or last day of registra-
tion (June 2011).
Treatment
The initial treatment of AML was distinguished in three treatment phases: induction 
treatment, consolidation treatment and follow-up. Induction treatment started at the 
day of diagnosis. Two different treatment protocols were used based on the patient’s 
age. Younger patients (less than 65 years) received induction and consolidation treat-
ment. Induction treatment consisted of cytarabine and idarubicin in the first course and 
cytarabine and amsacrine in the second course. Five different consolidation treatments 
were administered: high-dose chemotherapy, autologous HSCT, allogeneic HSCT from a 
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sibling donor, allogeneic HSCT from a MUD and UCB transplantation. The choice of treat-
ment depended on the patient’s risk of relapse, performance status and the availability 
of an HLA-identical donor. Older patients received induction treatment consisting of 
cytarabine and daunorubicin in the first course and cytarabine in the second course. In 
both age groups, the second induction course was administered to all patients, irrespec-
tive of achievement of a CR after the first course. The second induction course started 
the day after discharge for the first course. In case of a continuous hospitalization, the 
second course started on the day that cytarabine was given as part of the second course. 
Consolidation treatment started on the day after discharge for the second induction 
course. Follow-up started 42 days after induction treatment in older patients and 42 
days after consolidation treatment in younger patients. Follow-up was set at 1 year or 
ended at the date of relapse or death.
cost calculation
The microcosting method was used to calculate the direct hospital treatment costs of 
AML. All medical resource use related to the treatment of AML and its complications was 
collected and multiplied by the unit cost of each resource use.
Resource use was derived from electronic patient charts and hospital information 
systems used for financial claims. The hospital information systems contained patient-
specific information regarding in-hospital stay, outpatient visits, daycare visits, intensive 
care, laboratory tests, radiology and administration of blood products. Medication use 
was derived from electronic patient charts for a random selection of patients (10% of all 
patients). This selection included both younger and older patients.
Unit prices of laboratory tests, radiology and other hospital activities were derived 
from national tariffs defined by the Dutch Health Authority (68). Reference unit prices 
were used for outpatient visits (€148), daycare treatment (€224), in-hospital stay (€712), 
intensive care days (€2,211) and blood products (69,70). Unit prices of medications were 
derived from the Pharmaceutical Compass (Z-index 2010). Unit prices of HLA-typing and 
donor search were obtained from Blommestein et al. (71). All unit prices included both 
capital and labor costs.
Costs were subcategorized into several cost groups: in-hospital stay, hospital visits, 
diagnostic procedures, medication, blood products, radiation, HLA-typing and donor 
search. Intensive care costs were included in the costs of in-hospital stay. Hospital visits 
consisted of daycare treatment, outpatient visits, emergency unit visits and other con-
sults. Diagnostic procedures consisted of laboratory tests, radiology and other activities.
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Follow-up data were not always available for one year, because only patients diagnosed 
in 2008 or 2009 were included in this study in order to calculate current treatment costs. 
If follow-up data were available for at least 100 days in patients alive without relapse, the 
costs were extrapolated to one year based on the average costs per day.
Missing values were imputed according to the average costs per in-hospital day during 
chemotherapy and transplantation. During follow-up, missing values were imputed 
according to the average costs per day spent in the hospital, including outpatient visits 
and daycare treatment. All costs were based on Euro 2010 cost data. Where necessary, 
costs were updated to 2010 according to the national consumer price index (72).
statistical analysis
Mann-Whitney tests were used to test for significant differences in costs, in-hospital stay 
and treatment duration between treatment protocols, induction courses and consolida-
tion treatments. A probability level <0.05 was considered significant. All analyses were 
performed using Microsoft Excel 2003 and SPSS 17.0.
resulTs
Patients
In total, 202 patients were included in this study, of which 145 were treated according 
to the younger age protocol (Table 2.1). A second induction course was given to 127 
(88%) younger and 40 (70%) older adults. Consolidation treatment was given to 126 
patients. A few patients (N=8) received an allogeneic HSCT or UCB transplantation after 
only one induction course. Most patients received high-dose chemotherapy (N=47) as 
consolidation treatment. Sufficient follow-up data were available for 101 (70%) younger 
and 27 (47%) older adults.
induction treatment
The average costs of the two induction courses were €46,807 for the first course and 
€42,395 for the second course (Table 2.2). Although the first induction course was 
significantly shorter than the second course, the total costs of the first course were 
significantly higher. This difference was mainly related to higher costs of diagnostic pro-
cedures as costs of diagnosis were included in the first course. In addition, blood prod-
ucts and medication costs were significantly higher during the first course. Although 
the chemotherapy dose was higher in the second course, the chemotherapy costs were 
lower due to the lower unit price of the anthracycline used in the second course. Costs 
of hospital visits were significantly lower in the first course. In-hospital stay did not differ 
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Table 2.1 Patients included in the different treatment phases
All patients “Younger age”
protocol
“Older age”
protocol
Induction course 1 202 145 57
Induction course 2 167 127 40
Consolidation treatment 126 126 -
High dose chemotherapy 47 47 -
Autologous SCT 18 18 -
Allogeneic SCT from sibling 35 35 -
Allogeneic SCT from MUD 21 21 -
Cord blood transplantation 5 5 -
Follow-up (1 year) 128 101 27
after induction treatment 27 - 27
after high dose chemotherapy 31 31 -
after autologous HSCT 16 16 -
after allogeneic HSCT from sibling 31 31 -
after allogeneic HSCT from MUD 19 19 -
after UCB transplantation 4 4 -
HSCT = hematopoietic stem cell transplantation
MUD = matched unrelated donor
Table 2.2 costs of induction treatment (in 2010 euros, 1 euro = $1.3257)
All patients “Older” patients “Younger” patients
Course 1
(N=202)
Course 2
(N=167)
Course 1
(N=57)
Course 2
(N=40)
Course 1
(N=145)
Course 2
(N=127)
Average time (days)        44*        60        48*       85†         42*        52
Mean costs
   (SE)
In-hospital stay 24,333 24,837 24,551 25,622  24,247 24,589
    (575)     (729)  (1,210)  (1,231)      (647)     (878)
Hospital visits      342*      586      443*†   1,160*†       302      405
      (29)       (58)       (66)     (158)        (30)       (49)
Diagnostic activities   8,443*   5,583   8,704*   6,013†    8,341*   5,448
    (227)     (247)     (408)     (370)      (273)     (303)
Medication
Chemotherapy   1,520*   1,354      366*†      766*†    1,974*   1,539
    (250)     (138)       (32)       (40)        (67)       (95)
Other medication   5,273*   4,006   6,873*†   4,982*†    4,645*   3,698
    (176)     (189)     (433)     (380)      (149)     (218)
Blood products   6,895*   6,029   6,547   7,067    7,032*   5,702
    (285)     (341)     (445)     (764)      (356)     (378)
Total costs
 mean 46,807* 42,395 47,483 45,610†  46,541* 41,382
 (SE)  (1,076)  (1,362)  (2,113)  (2,463)   (1,251)  (1,609)
 Median 43,355 36,827 42,749 43,638  43,411 35,647
SE  = standard error
* Significantly different from the costs in the second induction course (p<0.05)
† Significantly different from the induction costs of “younger” patients (p<0.05)
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significantly between the two courses. On average patients were hospitalized 33.7 days 
during the first induction course and 34.1 days during the second course.
Not all patients received both induction courses. The majority of the patients who did 
not receive the second course was worse off as they died during the first course or were 
too ill to continue intensive treatment. Although patients receiving only one induction 
course were worse off, no significant difference in the total costs of the first induction 
course were found between patients receiving a second course or not (data not shown).
The total costs of the second induction course were significantly higher in older pa-
tients compared to younger patients. However, the duration of the second course was 
significantly longer in older patients; in fact, the total costs per treatment day did not 
differ significantly between the two age groups. No significant differences in total costs 
of the first induction course were found between the two age groups. In both induction 
courses, the chemotherapy costs were significantly higher in younger patients, while 
the costs of other medications were significantly lower. Duration of hospitalization did 
not differ significantly between the two age groups. The lower chemotherapy dose for 
older patients, and the subsequent decrease in complications, might be an explanation 
for this finding.
consolidation treatment
The average costs of consolidation treatment were €34,225 for high-dose chemo-
therapy, €33,277 for autologous HSCT, €44,070 for allogeneic HSCT from sibling donor 
and €82,041 for allogeneic HSCT from MUD (Table 2.3). The costs of UCB transplantation 
were not calculated, as only five patients received this type of transplantation. No signifi-
cant difference in total costs was found between high-dose chemotherapy, autologous 
HSCT and allogeneic HSCT from a sibling donor. However, some cost components 
differed significantly between the treatments. The costs of diagnostic procedures were 
significantly higher during autologous HSCT and allogeneic HSCT from a sibling donor 
compared to high-dose chemotherapy. The medication costs during autologous HSCT 
were significantly lower than the medication costs during high-dose chemotherapy. 
Although allogeneic HSCT from a sibling donor led to additional costs of radiation 
and HLA-typing, the total costs did not significantly differ from the costs of high-dose 
chemotherapy and autologous HSCT due to a significantly shorter hospital stay (22.5 
days compared to 29.6 and 27.8 days, respectively) and lower blood product costs. The 
significantly shorter in-hospital stay during allogeneic HSCT from a sibling donor is likely 
due to outpatient strategies in allogeneic transplantations in modern times (73). An al-
logeneic HSCT from MUD was significantly more expensive than the other consolidation 
treatments. The higher costs were not only related to the costs of radiation, donor search 
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and HLA-typing. The costs of hospital visits, diagnostic procedures and medication were 
also significantly higher during an allogeneic HSCT from MUD. In addition, the treat-
ment duration was significantly longer during allogeneic HSCT from MUD compared to 
high-dose chemotherapy and allogeneic HSCT from a sibling donor.
Table 2.3 Costs of consolidation treatment (in 2010 Euros, 1 Euro = $1.3257)
High-dose
chemotherapy
Autologous
HSCT
Allogeneic
HSCT sibling
Allogeneic
HSCT MUD
(N=47) (N=18) (N=35) (N=21)
Average time (days)      100      106      101      128*‡
Mean costs
 (SE)
In-hospital stay 21,247 19,944 17,007*† 18,682
    (914)  (1,295)  (2,999)  (2,258)
Hospital visits   1,477   1,706   2,038*†   2,767*†‡
    (148)     (237)     (127)     (172)
Diagnostic procedures   4,263   5,530*   8,099* 10,670*†‡
    (326)     (512)  (1,213)     (778)
Medication   3,389   3,050*   3,883   5,427*†‡
    (103)     (162)     (466)     (566)
Blood products   3,848   3,046   1,436*†   2,462*‡
    (346)     (528)     (437)     (559)
Radiation       -      -   1,638   1,610
    (100)     (140)
HLA-typing       -      -   9,968   9,968
     (NA)      (NA)
Donor search       -      -      - 30,456
     (NA)
Total costs
 mean 34,225 33,277 44,070 82,041*†‡
 (SE)  (1,366)  (2,465)  (4,765)  (3,453)
 Median 33,031 31,951 37,394 83,165
HSCT = hematopoietic stem cell transplantation
MUD = matched unrelated donor
SE = standard error
NA = not available (mean costs derived from Blommestein et al.71)
* Significantly different from high-dose chemotherapy (p<0.05)
† Significantly different from autologous HSCT (p<0.05)
‡ Significantly different from allogeneic HSCT from sibling donor (p<0.05)
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Follow-up
The follow-up costs differed according to the preceding treatment (Table 2.4). The aver-
age 1-year follow-up costs were €11,740 after induction treatment, €5,856 after high-
dose chemotherapy, €5,889 after autologous HSCT, €22,008 after allogeneic HSCT from 
sibling donor and €40,468 after allogeneic HSCT from MUD. The follow-up costs after 
allogeneic HSCTs (both from sibling donor and MUD) were significantly higher than the 
other follow-up costs, mainly because of higher costs of in-hospital stay, diagnostic pro-
cedures and hospital visits. The average days of hospitalization during follow-up ranged 
from 0 days after an autologous HSCT to 16.6 days after an allogeneic HSCT from MUD.
The follow-up costs included both patients who died or relapsed during the first year 
and patients alive without relapse. High follow-up costs might be caused by the high 
costs of patients who died during the first year, because it has been shown that the last 
year before death is the most expensive period in one’s lifetime (74,75). In our study, 
Table 2.4 costs of follow-up (in 2010 euros, 1 euro = $1.3257)
“Younger” patients “Older” patients
Preceding treatment
High-dose
chemotherapy
Autologous
HSCT
Allogeneic
HSCT sibling
Allogeneic
HSCT MUD
Induction
treatment
(N=31) (N=16) (N=31) (N=19) (N=27)
Mean costs
 (SE)
In-hospital stay 390 0 7,227*†§ 16,687*†§ 2,098
(240) (0) (2,556) (5,455) (961)
Hospital visits 1,794 2,595 3,027*† 4,112*†§ 2,702
(234) (1,030) (358) (495) (491)
Diagnostic procedures 3,183 2,330 8,105*†§ 14,395*†‡§ 3,437
(871) (396) (1,119) (1,918) (756)
Medication 200 164* 1,651*†§ 2,450*†§ 357
(26) (58) (232) (416) (87)
Blood products 287§ 800 1,998*† 2,822*† 3,146
(184) (699) (678) (1,454) (1,476)
Total costs
 mean 5,856 5,889 22,008*†§ 40,468*†‡§ 11,740
 (SE) (1,172) (2,000) (4,345) (8,299) (3,630)
 Median 4,476 3,819 14,287 29,416 4,214
HSCT = hematopoietic stem cell transplantation
MUD = matched unrelated donor
SE = standard error
* Significantly different from follow-up after high-dose chemotherapy (p<0.05)
† Significantly different from follow-up after autologous HSCT (p<0.05)
‡ Significantly different from follow-up after allogeneic HSCT from sibling donor (p<0.05)
§ Significantly different from follow-up after induction treatment (p<0.05)
28 Chapter 2
the mortality rate was significantly higher after induction treatment or allogeneic HSCT 
compared to the other treatments. Nevertheless, significant differences in follow-up 
costs were still apparent when the analysis was restricted to surviving patients. The 
higher follow-up costs after allogeneic transplantations are probably related to the 
treatment of graft-versus-host disease and infections. The average number of hospital 
visits after allogeneic transplantations were lower than expected according to treatment 
protocol, because patients who died during follow-up had significantly fewer hospital 
visits. These patients were more frequently admitted for in-hospital stay.
composition of the costs of treatment
In-hospital stay accounted for 52-64% of the total costs of chemotherapy and autolo-
gous HSCT and 24-41% of the total costs of allogeneic transplantations. Other large cost 
components of allogeneic transplantations were HLA-typing and donor search (Figure 
2.1A-B). The composition of the total follow-up costs differed according to the preceding 
treatment. In general, a large part of the follow-up costs consisted of diagnostic proce-
dures (30-50%). The other follow-up costs were mainly related to in-hospital stay after 
an allogeneic HSCT and to costs of hospital visits after induction treatment, high-dose 
chemotherapy and autologous HSCT (Figure 2.1C).
After induction treatment After high-dose chemotherapy After autologous HSCT After allogeneic HSCT sibling After allogeneic HSCT MUD
High-dose chemotherapy Autologous HSCT Allogeneic HSCT sibling Allogeneic HSCT MUD
Induction course 1 Induction course 2
A. 
In-hospital stay
Hospital visits
Diagnostic procedures
Medication
Blood products
Radiation
HLA-typing
Donor search
B. 
C. 
Figure 2.1 composition of the total costs per treatment phase. costs were subcategorized in the fol-
lowing subgroups: in-hospital stay, hospital visits, diagnostic activities, medication, blood products, 
radiation, hla-typing and donor search. (a) induction treatment cost, (B) consolidation treatment 
costs and (c) follow-up costs. hscT = hematopoietic stem cell transplantation, muD = matched un-
related donor
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Discussion
This study provides insight into the current costs of the initial treatment of AML. This 
study shows that the treatment costs of AML are substantial. The average costs of the 
initial treatment of one AML patient are €117,495. Previously estimated initial treatment 
costs were $80,030 in 1990 for younger patients and $52,048 in 1998 for older patients 
(respectively €80,109 and €59,630 in 2010 Euros) (62,63). In a Swedish study, the treat-
ment costs, including relapse, of all AML patients were 356,911 Swedish Krona in 1990 
(€74,508 in 2010 Euros) (61). The treatment costs calculated in this study were 43-67% 
higher than the previously estimated treatment costs. The largest increase in costs was 
found for diagnostic procedures, which increased with 80-220%. This large increase can 
be explained by both the use of new diagnostic technologies like real-time polymerase 
chain reaction and an increase in use of standard diagnostic procedures.
Only a few recent studies reported costs of parts of AML treatment. A French study 
estimated the total induction costs on €43,037 in 2005 Euros (€46,463 in 2010 Euros)
(76). These costs are half of the induction costs calculated in our study. However, the 
French study differs from ours with respect to the treatment protocol and methodol-
ogy of cost calculation. In the French study, a second course was only administered to 
patients without a CR after the first course (28% of all patients, compared to 83% in our 
study). In addition, costs of outpatient visits and related diagnostic procedures were 
excluded in the French study. These costs accounted for about 2.6% of the total costs 
per induction course in our study. The costs of sibling transplantations in our study were 
comparable with the costs estimated by Cordonnier et al. (77), which were €64,600 after 
high-dose conditioning (HDC) and €60,000 after reduced-intensity conditioning (RIC) in 
2001 Euros, respectively (€75,718 and €69,980 in 2010 Euros).
It was not feasible to distinguish between HDC and RIC for allogeneic HSCT in our study. 
In the literature, some disagreement exists regarding differences in treatment costs 
between these conditioning regimens. Cordonnier et al. (77) did not find significant 
differences in costs, while Saito et al. (78) found significant lower transplantation costs 
after RIC due to a shorter hospital stay. The shorter hospital stay might also be related to 
the stem cell source. Peripheral blood transplants were significantly more administered 
in patients receiving RIC (78). As it has been shown that the hospital stay is shorter for 
patients receiving peripheral blood transplants (63), we do not expect that the type of 
conditioning has a large impact on treatment costs.
This study was a retrospective study with resource use collected from registered data. 
Due to the unavailability of data regarding the start and end of treatment phases, the 
30 Chapter 2
total period after hospitalization was defined as preparation of the following treatment 
phase. It is not expected that this definition will have large impact on the calculated 
costs, because the costs between treatment phases were relatively low.
Relapse costs were excluded in our study because only a small proportion of patients 
experienced a relapse in the available follow-time. It is expected that inclusion of relapse 
costs would especially increase the costs after high-dose chemotherapy and autologous 
HSCT, because the risk of relapse is higher after these treatments compared to alloge-
neic HSCT (79).
In general, in-hospital stay was the major cost driver in the treatment of AML. The main 
reason for the long hospital stay is that patients remain hospitalized until blood count 
recovery to avoid infections and bleeding. Several studies have shown that outpatient 
management after treatment is safe and feasible for a selection of patients (80,81). Out-
patient management would not only reduce costs, but might also improve the quality 
of life of patients. Studies including more patients are warranted to investigate whether 
the hospital stay can be reduced without a negative impact on survival and quality of 
life.
The main objective of this study was to calculate costs of initial treatment of AML irre-
spective of patient characteristics. In addition, the costs of different treatment protocols 
were compared. As patients were not randomized between treatments, we cannot 
guarantee the comparability of the patients receiving different treatments. However, we 
do not expect large difference in patient characteristics, since treatment choice is mainly 
determined by the availability of a suitable donor. Additional analyses support this as-
sumption as no significant differences in age were found between the post-remission 
treatments.
The results of this study can support hospitals in their negotiations with health insurers 
to receive adequate reimbursement for the treatment costs. Some concerns might exist 
regarding the transferability of the calculated costs to other countries. Although the 
included patients were only treated in the Netherlands, these patients were treated ac-
cording to international guidelines (26). Further studies should investigate whether the 
costs of the second induction course differs between patients who achieved a CR after 
the first cycle or not. In addition, unit prices might differ between countries. However, a 
comparison of the costs with other recent cost calculations showed comparable results 
(76,77).
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The calculated costs are representative estimates of current treatment costs, because 
resource use was derived from a sufficient number of patients treated according to cur-
rent treatment protocols in several hospitals. Our results show large cost differences 
between the post-remission treatment options for AML patients. These differences 
should also be considered in treatment guidelines. While the effectiveness of AML treat-
ments is established in randomized controlled trials, the cost-effectiveness is not always 
determined. Combining our results to current and future effectiveness studies might 
help to determine whether benefits of allogeneic HSCT outweigh the higher treatment 
costs.
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aBsTracT
Responses on condition-specific instruments can be mapped on EQ-5D to estimate 
utility values for economic evaluation. Mapping functions differ in predictive quality 
and not all condition-specific measures are suitable for estimating EQ-5D utilities. We 
mapped QLQ-C30, HAQ and MSIS-29 on the EQ-5D and compared the quality of the 
mapping functions with statistical and clinical indicators.
We used four datasets that included both the EQ-5D and a condition-specific measure 
to develop ordinary least squares regression equations. For the QLQ-C30, we used a 
multiple myeloma dataset and a non-Hodgkin’s lymphoma one. An early arthritis cohort 
was used for the HAQ, and a cohort of patients with relapsing remitting or secondary 
progressive multiple sclerosis for the MSIS-29. We assessed the predictive quality of the 
mapping functions with the root mean square error (RMSE) and mean absolute error 
(MAE) and the ability to discriminate among relevant clinical subgroups. Pearson cor-
relations between the condition-specific measures and items of the EQ-5D were used to 
determine if there is a relationship between the quality of the mapping functions and 
the amount of correlated content between the used measures.
QLQ-C30 had the highest correlation with EQ-5D items. Average %RMSE was best for 
QLQ-C30 with 10.9%, 12.2% for HAQ and 13.6% for MSIS-29. The mappings predicted 
mean EQ-5D utilities without significant differences with observed utilities and discrimi-
nated between relevant clinical groups, except for the HAQ model.
The preferred mapping functions in this study seem suitable for estimating EQ-5D 
utilities for economic evaluation. However, this research shows that lower correlations 
between instruments leads to less predictive quality. Using additional validation tests 
besides reporting statistical measures of error improves the assessment of predictive 
quality.
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inTroDucTion
Utility values (82), which are required to conduct cost-utility analyses, are usually mea-
sured by preference-based instruments like the EQ-5D, SF-6D or HUI III. Many clinical tri-
als, however, use condition specific instruments, which do not incorporate preferences 
in the scoring algorithms, rather than preference-based instruments (83). Utility values 
can be estimated from the answers on a condition specific instrument when preference-
based instruments are absent (32). This technique is called ‘mapping’ and primarily serves 
the purpose of ‘rescuing’ trial data for economic evaluation when a preference based 
instrument is absent. This paper presents a study that uses data from three condition 
specific questionnaires (Cancer: EORTC QLQ-C30 version 2; Arthritis: HAQ and Multiple 
Sclerosis: MSIS-29) to predict outcomes on a preference based instrument (the EQ-5D). 
We compare the quality of the mapping functions with statistical and clinical indicators 
and explore the influence of overlap in dimensions. Condition specific measures do not 
necessarily measure the same dimensions of health as a preference-based measure. The 
amount of overlap in dimensions between instruments is considered to be of influence 
on the predictive ability of the mapping function (84).
Mapping comes down to giving weight to different independent variables (items of a 
scale, the ‘starting’ measure) to predict the dependent variable (the ‘target measure’, e.g. 
utility index) through regression techniques. The independent variables may be sum 
scores, item scores, demographic variables and/or other (clinical) predictors of health. 
The purpose of such a mapping effort is to enable the estimation of a utility index in 
other datasets that do not have the target measure but do have the starting measure. 
The utility index, derived from the mapping effort, can be used to calculate the quality 
adjustment necessary for the computation of a quality adjusted life year (QALY). Previ-
ous studies have found that mapping is a feasible approach, but mapping models differ 
in predictive ability (32). Disadvantages of mapping are that the estimated utility indices 
have far greater errors for severe health states, and EQ-5D models tend to overpredict 
low utilities and underpredict high utilities (32,85). The performance of a mapping 
function may be tested by applying the algorithm to other (subset) data, which, like 
the sample on which the statistical association between dependent and independent 
variables was estimated, has data for both instruments.
Over the past few years several mapping algorithms have become available. In some 
circumstances, mapping may be the only way to get utility data, but the current growth 
in use of this strategy requires a more critical attitude towards the problems and prom-
ises of its application, as the quality of the mapping algorithms is highly variable (32). 
Assessing the quality of a mapping function, however, is not straightforward as different 
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indicators may hide certain flaws in a mapping function. First, an accurate prediction of 
mean utility values may cover that prediction errors may be larger for particular sub-
groups of patients. Second, (statistical) error indicators may not be easily interpretable 
without a comparator. Third, a measure of error does not directly reflect the external 
validity of a mapping function.
Another issue that deserves attention is the amount of overlap between dimensions 
of health covered by the descriptive systems of the starting and target measure. If the 
instruments focus on different dimensions of health (e.g. pain and mobility) they have 
little overlap and hence a low correlation between the items of the two measures, which 
may negatively influence the quality of the derived mapping function. The EQ-5D index 
values are the result of an algorithm that transforms the answers on five dimensions 
of health: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. 
To predict the index value, the variation of responses on those categories has to be 
predicted. A scale that only measures pain may have difficulty explaining variation in 
answers on a self-care domain. Consequently, the amount of overlap between instru-
ments may influence the predictive ability of a mapping function.
This paper aims to present mapping functions for three condition-specific questionnaires 
onto EQ-5D suitable for use in economic evaluations, and to assess their quality through 
both statistical error measures and clinical indicators. We also test the hypothesis that 
the overlap of health domains is an important predictor for the predictive quality of a 
mapping function. If the amount of overlap between two instruments can be assessed 
at face value, it may inform a quick judgment about the expected quality of the derived 
mapping function.
meThoDs
instruments
Both the condition specific measures and the preference-based generic measure are 
patient reported outcome measures to assess health status. The measures have different 
properties as outlined below.
EQ-5D
The EQ-5D is a preference-based generic measure. It measures health related quality of 
life on five dimensions (mobility; self-care; usual activities; pain/discomfort and anxiety/
depression) with three severity levels each. The measure was developed to provide a 
“simple abstracting device for use alongside other more detailed measures of health-
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related quality of life to serve as a basis for comparing health outcomes” (86). The main 
outcome of interest is the derived utility (or preference) index; a single metric for quality 
of life derived by transforming the dimension scores with country-specific tariff. Utility 
values used in this study were computed using the Dutch EQ-5D tariff (87) and the UK 
EQ-5D tariff (88).
QLQ-C30
The EORTC-QLQ-C30 (version 2) is a cancer specific questionnaire and consists of 30 
items, divided into three categories: functional scales (physical, role, emotional, cogni-
tive and social functioning, for a total of 15 items), symptom scales (fatigue, nausea/
vomiting, pain, dyspnea, sleep, appetite, constipation, diarrhea and financial difficulties, 
for a total of 13 items) and a global health status scale (two items). Scale sum scores are 
transformed so that a high score on the functional scales represents a high level of func-
tioning, a high score on the symptom scales represents a high level of symptomatology 
and a high score on the global health status represents a high quality of life (89). At face 
value it seems all health domains of EQ-5D are present in the QLQ-C30. The QLQ-C30 has 
been successfully mapped on the EQ-5D (UK tariff ) before (90), but not for Dutch utilities 
nor for a lymphoma population.
HAQ
The Health Assessment Questionnaire (HAQ) is a widely used questionnaire in the field 
of rheumatology. The HAQ assesses the functional ability of patients using 20 items 
across eight domains (dressing, rising, eating, walking, hygiene, reach, grip and usual 
activities) (91). Items are scored on a 4-level disability scale from zero to three, where 
three represents the highest degree of disability. Scores are adjusted for the use of aids 
or devices and averaged into dimension sum scores and an overall disability index value, 
which represents the extent of functional ability of the patient. Values between one and 
two represent moderate to severe disability (91). A face value judgment of the items 
and sum scores of HAQ suggests the EQ-5D dimensions pain/discomfort and anxiety/
depression are not represented in the HAQ. The HAQ has been mapped on the EQ-5D 
before and was able to predict mean utility values (92), but such a function has not been 
estimated for Dutch utilities.
MSIS-29
The MSIS-29 is a Multiple Sclerosis (MS) specific questionnaire with 29 items developed 
through reducing an item pool of 129 items concerning the health impact of multiple 
sclerosis (93). The MSIS-29 is a self-reported measure which measures the physical and 
psychological impact of MS on individuals. Items measure disease impact due to limita-
tions in the past two weeks, scored on five levels from ‘not at all’ to ‘extremely’. The first 
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20 items (physical scale) and the last 9 items (psychological scale) form two summary 
scores transformed to a 0-100 scale. The MSIS-29 has not been previously mapped to 
our knowledge. The EQ-5D dimensions mobility, self-care, and usual activities are not 
explicitly represented as dimensions of the scale, but the dimensions are tapped into by 
items like ‘difficulty moving about indoors’, ‘having to depend on others to do things for 
you’ and ‘limitations in your social and leisure activities at home’. MSIS-29 items and sum 
scores suggests the EQ-5D dimension ‘pain/discomfort’ is not present in the MSIS-29.
Table 3.1 Patient characteristics
Sample Development set Test set 1 Test set 2
qlq-c30 N 723 (pooled) 789 (pooled)
Age (range) 54 (37 - 64) 72 (65-84)*
EQ-5D† Mobility % 1/2/3 56.7 / 41.4 / 1.9 48 / 47.3 / 4.7
Self-care % 1/2/3 85.8 / 12.8 / 1.4 81.4 / 13.9 / 4.7
Usual activities % 1/2/3 30.1 / 51.1 / 18.8 38.1 / 43.3 / 18.6
Pain/Discomfort % 1/2/3 39.6 / 59.0 / 1.4 52.2 / 42.9 / 4.9
Depression/Anxiety % 
1/2/3
69.4 / 29.6 / 1.0 70 / 29 / 1.0
EQ-5D-index .742 (.21) .735 (.26)
Cancer type Multiple Myeloma Non-Hodgkin 
lymphoma
QLQ-C30 Physical functioning 64 (24.6) 57.3 (26.8)*
(pooled) Role functioning 59.5 (28.9) 57.4 (31.5)
Emotional functioning 82.8 (18.9) 81.3 (20.6)
Cognitive functioning 82 (20.8) 81.9 (23.7)
Social functioning 76.2 (25.8) 75.7 (28.6)
Global health 68.7 (18.0) 62 (21.7)*
Fatigue 35.7 (25.0) 44.7 (29.4)*
Nausea / Vomiting 6.1 (14.3) 8 (16.9)*
Pain 25.2 (24.7) 18.7 (26.2)*
Dyspnoea 16.1 (24.9) 24.8 (28.9)*
Sleep 21.1 (27.3) 28.7 (31.8)*
Appetite 16 (27.2) 21.9 (32.6)*
Constipation 4 (15.4) 11.8 (22.8)*
Diarrhea 8.3 (18.7) 7 (18.5)*
Financial difficulties 12.5 (23.0) 6.3 (16.9)*
haq N 186 132
Age (range) 51 (16 - 82) 55 (25 – 78)
EQ-5D† Mobility % 1/2/3 38.2 / 61.8 / 0.0 44.4 / 55.3 / 0.0
Self-care % 1/2/3 68.5 / 30.4 / 1.1 58.0 / 41.2 / 0.8
Usual activities % 1/2/3 33.9 / 60.1 / 6.0 27.5 / 67.9 / 4.6
Mapping of disease-specific questionnaires 39
3
Population
The EQ-5D and condition specific measure data were retrieved from three different 
datasets described below. An overview of characteristics of the populations is presented 
in Table 3.1.
QLQ-C30: the HOVON study
Data for QLQ-C30 model were taken from two separate studies carried out by the 
Dutch association for hematology/oncology in adults (HOVON). The HOVON 24 (94) 
Table 3.1 Patient characteristics (continued)
Sample Development set Test set 1 Test set 2
Pain/Discomfort % 1/2/3 8.1 / 78.4 / 13.5 3.8 / 77.3/ 18.9
Depression/Anxiety % 
1/2/3
72.4 / 25.4 / 2.2 80.3 / 17.4 / 2.3
EQ-5D-index 0.67 (0.24) 0.64 (0.26)
DAS 28 4.34 (1.30) 4.30 (1.27)
HAQ-DI 0.75 (0.65) 0.81 (0.65)
HAQ Dressing & Grooming 0.64 (0.72) 0.76 (0.75)
Arising 0.71 (0.77) 0.72 (0.75)
Eating 0.84 (0.84) 0.95 (0.83)
Walking 0.64 (.85) 0.58 (0.81)
Hygiene 0.70 (0.85) 0.79 (0.86)
Reach 0.68 (0.80) 0.74 (0.81)
Grip 0.87 (0.86) 0.93 (0.86)
Activities 0.93 (0.86) 1.04 (0.88)
msis-29 N 661 339 295
Age (range) 40 (18-88) 40 (18 -87) 41 (18-88)
EQ-5D† Mobility % 1/2/3 21.2 / 76.6 / 2.2 26.7 / 70.9 / 2.4 25.0 / 74.3 / 0.7
Self-care % 1/2/3 62.4 / 35.8 / 1.8 68.2 / 29.4 / 2.4 63.0 / 35.6 / 1.4
Usual activities % 1/2/3 21.1 / 70.9 / 8.0 22.9 / 69.4 / 8.3 23.5 / 71.3 / 5.2
Pain/Discomfort % 1/2/3 25.3 / 67.0 / 7.7 27.5 / 61.5 / 11.0 24.7 / 68.2 / 7.1
Depression/Anxiety % 
1/2/3
40.7 / 52.1 / 7.2 41.1 / 50.9 / 8.0 39.2 / 56.3 / 4.5
EQ-5D-index UK / NL 0.58 (0.29) / 0.63 (0.62) 0.57 (0.31) / 0.61 (0.20) 0.60 (0.25) / 0.65 
(0.23)
Type of MS‡ RR = 81% SP = 19% RR = 81% SP = 19% RR = 82% SP = 18%
MSIS-29 Physical scale 47.1 (25.7) 45.4 (25.8) 44.9 (25.7)
Psychological scale 45.4 (25.6) 44.7 (24.9) 44.4 (25.6) 
* Significant difference (2-tailed t-test p < .05) with development set
† % at level 1 / 2 / 3 (not at all / some problems / extreme)
‡ RR= Relapsing Remitting, SP = Secondary Progressive
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and HOVON 25 (95) studies are randomized clinical trials that measure the effective-
ness of different treatments in respectively patients with previously untreated multiple 
myeloma (HOVON 24) and previously untreated non-Hodgkin lymphoma patients (Ann 
Arbor stages II to IV, or intermediate or high-grade malignancy). The sample size of the 
clinical trial is larger than the sample size of patients that had concluded both an EORTC 
QLQ-C30 and an EQ5D instrument.
The mapping algorithm was developed on the multiple myeloma sample, and tested on 
the Non-Hodgkin lymphoma sample. The database for the multiple myeloma sample 
contained 137 patients at baseline with 6 follow-up measurements (three early follow-
ups were missing), the latest two years after baseline. To increase the number of data-
points per EQ-5D utility value – samples are often short on severe health states and thus 
lack predictive ability in the lower range – follow up measurements were pooled for the 
development of prediction models. The database for the Non-Hodgkin’s sample con-
tained 108 patients at baseline and had seven time points at which the EORTC QLQ C-30 
was administered. Three time-points were after the second, fourth and sixth treatment 
cycle, and four follow-up measurements were at baseline, three, six, ten and eighteen 
months after baseline. Predictive ability of the mapping is assessed per time point.
HAQ: the REACH study
The HAQ data were taken from the Rotterdam Early Arthritis CoHort (REACH) with 
patients recruited from the Erasmus Medical Centre in the Netherlands, with arthritis. 
As can be inferred from the name, one of the aims of the study is early detection of 
rheumatoid arthritis. Data are collected through three outpatient visits, during which 
respondents filled out a booklet of self-reported questionnaires including HAQ, Hospital 
Anxiety and Depression Scale (HADS), Short Form-36 (SF-36) and EQ-5D. The mapping 
algorithm is developed on a randomly drawn sub-sample of the dataset (n=186) and 
tested on a remaining sample (n=132) for which most of the data of the questionnaires 
were available, both at baseline. A randomly drawn subsample is not expected to devi-
ate much from the remaining sample.
MSIS-29: the Multiple Sclerosis Risk Sharing Scheme Monitoring Study
The MSIS-29 data were taken from the Multiple Sclerosis Risk Sharing Scheme Moni-
toring Study in the UK (96), which aims to analyze the long term cost effectiveness of 
disease modifying treatments in patients with MS. Data for the study were collected 
from MS patients in 70 specialist MS centers in the UK and includes both relapsing remit-
ting and secondary progressive MS patients. Cross-sectional cost and utility data for a 
subset of these MS patients was collected to enhance economic analysis. The MSIS-29 
was administered once (n= 1,295); hence there are no different time-points for this mea-
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sure. The mapping algorithm was developed on a randomly drawn sub sample (n=661) 
and tested on two samples randomly drawn from the remaining respondents (n=339 
and n=295). As with the HAQ, the randomly drawn samples are not expected to deviate 
much from the rest of the data.
analysis
Pearson’s r and Spearman’s rho determined the amount of overlap between the instru-
ments. Ordinary least squares regression models will be fitted to the data to generate 
mapping algorithms. All models were developed for the Dutch value set of the EQ-5D 
(87). As the MS dataset is based on the English versions of the MSIS-29 and EQ-5D, the 
algorithm was also estimated for the UK value set (88).
The models in this paper serve the purpose of calculating mean utility scores applicable 
in economic evaluation. The mapping models generate individual utility values, but 
these have uncertain estimates (97). Even if the estimates were less uncertain, the EQ-5D 
is a tool for economic evaluation and priority setting in health care (98), not a key health 
indicator of individual health. Thus only aggregated utilities derived from mapping 
studies are to be used. Analyses were run in STATA 10.0 and SPSS 17.0.
Model development
This study follows the suggestions of a recent review of mapping studies which suggests 
estimating different types of models with increasing complexity and decreasing assump-
tions about the properties of the data (32). The strategy implies that a range of models is 
estimated, with increasing levels of complexity. All models that we developed aimed to 
compute EQ-5D utility scores from the condition specific measures with ordinary least 
squares regression. An alternative approach would be to predict the dimension scores of 
EQ-5D through multinomial regression. This implies that the models predict occurrence 
of level 1, 2 and 3 responses on the EQ-5D from which one indirectly computes the 
utility scores. We chose ordinary least squares regression to predict the EQ-5D utility 
index as predicting dimension levels has been shown to have equal or worse predictive 
performance (32) for both QLQ-C30 (90) and HAQ (92).
All models were developed in similar order, relaxing the assumptions about the 
properties of the condition specific measures in each step, while eyeballing model 
performance (described below) as guidance for model selection. First the EQ-5D utility 
index was regressed on sum scores, then on item scores treated as continuous variables. 
Treating items as continuous variables assumes interval properties of the questionnaire, 
because only one coefficient is calculated for all changes in responses of one item (i.e. 
On the question ‘have you been bothered by problems sleeping?’ moving from answer 
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category ‘not at all’ to ‘a bit’ receives the same decrement as moving from adjacent cat-
egories ‘quite a bit’ to ‘extremely’). Lastly, by treating item scores as categorical (dummy) 
variables, this assumption was relaxed. Dummies are computed to let each subsequent 
level represent worse health compared to the reference category ‘no problems’. Models 
were developed using backward selection procedures with probability of F to remove a 
variable at 0.10.
Models were required to be logically consistent meaning that a worse score on an item 
should lead to a larger utility decrement. For reasons of parsimony models were reduced 
to the smallest models that have similar predictive performance as larger models. In the 
final models achieving parsimony was attempted by merging item categories with the 
logically adjacent answer category when they a) did not meet probability <0.10 of F to 
remove or b) were logically inconsistent.
Clinical variables or additional questionnaires may correlate with a given dimension 
(muscle strength may capture mobility). Such variables may improve the mapping 
but might not be available as data in all clinical trials, potentially limiting the use of a 
function. As the HAQ is a measure of disability and not a quality of life questionnaire 
we expected that HAQ based models might not yield favorable prediction results. We 
therefore selected five variables in our dataset that theoretically would correlate with 
EQ-5D dimensions. The variables are: sum scores of the HADS, sum scores of the SF-36 
and the Disease Activity Score (DAS28) and a count of tender and swollen joints. Analysis 
started with all predictor variables as regression coefficients and proceeded through 
backward step wise regression with probability of F to remove at 0.10. Missing values 
were not imputed in any of the datasets.
Model performance
There are no strict criteria for a utility function to be acceptable (32). QALYs are computed 
using mean scores, thus interesting indicators are differences between the predicted 
mean utility score and the observed mean utility score. However, correct prediction of 
a mean may still hide differences between individual observed and predicted values 
across the entire scale. Model performance is therefore reported as root mean squared 
error (RMSE) and mean absolute error (MAE) of the predicted EQ-5D utility values (32,99). 
RMSE is the root of the average of the squared differences between observed and pre-
dicted values, while MAE is the average of the roots of the squared difference between 
observed and predicted values. Lower values of RMSE and MAE indicate better model 
performance. As RMSE averages the squared differences it is sensitive to extreme devia-
tions from the mean (e.g. outliers) and thus always equal to or larger than MAE. There 
is no definition of what level of RMSE or MAE is a threshold for model acceptance (92). 
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Besides that, RMSE and MAE are not comparable for models with different preference-
based instruments as dependent variables or models with a different range of observed 
values since larger scale size usually leads to a larger error figure. For instance: UK EQ-5D 
index values have a measurement range of 1.59 compared to 1.33 for the Dutch values. 
Consequently RMSE is also reported as a percentage of the scale size, the normalized 
RMSE (100). It is expected that a higher prediction error is positively associated with less 
overlap between EQ-5D and the disease specific instrument.
Discriminant validity
Statistical measures such as RMSE and MAE may be difficult to interpret and can be 
small because of the method of testing, caused, for instance by using a randomly drawn 
subsample which does not deviate much from the development sample. Therefore, the 
validity of predicted index values is also inspected by checking the ability of the pre-
dicted values to discriminate between relevant clinical groups. Mean scores of observed 
and predicted EQ-5D index values are calculated per category of a relevant clinical 
indicator. For the cancer data this clinical indicator is the doctor reported World Health 
Organization performance status (or ECOG score) which distinguishes 6 categories from 
0 (asymptomatic) to 6 (death). For the arthritis data the clinical indicator is the DAS28 
and is based on a count of tender joints and the erythrocyte sedimentation rate (ESR). 
It can be used to distinguish between high, moderate and low disease activity and 
remission. Lastly, for multiple sclerosis the data are compared to the categories of the 
Expended Disability Status Scale (EDSS) which range from 0 (no neurological deficit) 
and 10 (death). Pearson r is used to measure the (linear) correlation between the clinical 
indicators and the observed and predicted scores.
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Table 3.2 Pearson’s correlation matrix between sum scores and eq-5D dimensions
EQ-5D domain
QLQ-C30† mobility self care usual activities pain/
discomfort
anxiety/
depression
Physical functioning -0.67** -0.48** -0.64** -0.45** -0.27**
Role functioning -0.54** -0.38** -0.78** -0.47** -0.29**
Emotional functioning -0.22** -0.20* -0.30** -0.24** -0.70**
Cognitive functioning -0.20* -0.17* -0.28** -0.27** -0.37**
Social functioning -0.49** -0.34** -0.55** -0.30** -0.40**
Global health status -0.36** -0.18* -0.47** -0.44** -0.39**
Fatigue 0.35** 0.20* 0.51** 0.39** 0.34**
Nausea and vomiting 0.03 -0.08 0.11 0.21* 0.09
Pain 0.40** 0.17* 0.41** 0.76** 0.19*
Dyspnoea 0.11 0.13 0.26** 0.08 -0.02
Sleep 0.08 0.10 0.19* 0.19* 0.30**
Appetite loss 0.25** 0.15 0.28** 0.25** 0.27**
Constipation 0.05 0.04 0.05 0.26** 0.04
Diarrhoea 0.21* 0.07 0.14 0.08 0.10
Financial difficulties 0.14 0.22** 0.22** -0.01 0.12
HAQ mobility self care usual activities pain/
discomfort
anxiety/ 
depression
Dressing 0.29** 0.63** 0.42** 0.41** 0.17**
Rising 0.44** 0.51** 0.45** 0.37** 0.20**
Eating 0.27** 0.52** 0.44** 0.36** 0.11*
Walking 0.52** 0.48** 0.39** 0.32** 0.21**
Hygiene 0.35** 0.62** 0.41** 0.39** 0.19**
Reach 0.35** 0.54** 0.39** 0.44** 0.23**
Grip 0.27** 0.45** 0.36** 0.40** 0.15**
Usual activities 0.42** 0.54** 0.51** 0.45** 0.18**
MSIS29 mobility self care usual activities pain/
discomfort
anxiety/ 
depression
Physical scale 0.67** 0.59** 0.67** 0.50** 0.40**
Psychological 0.43** 0.37** 0.46** 0.45** 0.68**
** Correlation is significant at the 0.01 level (2-tailed).
* Correlation is significant at the 0.05 level (2-tailed).
† Time point = baseline
Shaded cell > 0.55
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resulTs
Pearson correlations indicate that the condition specific measures differ in the amount 
of overlap with EQ-5D dimensions (Table 3.2). Table 3.2 suggests that Pearson correla-
tions with EQ-5D dimensions were higher for QLQ-C30 and MSIS-29 than for HAQ and 
were nearly identical to Spearman ρ. For instance, none of the HAQ dimensions had a 
correlation coefficient >0.23 with the EQ-5D dimensions ‘anxiety / depression’, whilst this 
dimensions correlates with -0.70 and 0.68 for respectively QLQ-C30 and MSIS-29. The 
QLQ-C30 has the highest correlations with EQ-5D dimensions. Based on these results, 
we would expect the mapping functions based on QLQ-C30 to outperform those based 
on the HAQ and MSIS-29.
mappings
The best functioning models and their performance are summarized in Table 3.3 and 
Table 3.4 (for all developed models see Supplementary material) and further discussed 
Table 3.4 msis-29 uk model
  Predictors B SE p
Model 1 (Constant) 0.949 0.024 0.000
R² (A) =0.57 msi3_3_4 -0.055 0.021 0.009
R² (B) = 0.49 msi3_5 -0.144 0.031 0.000
RMSE =0.19 msi5_5 -0.063 0.033 0.054
msi6_2 -0.067 0.029 0.020
msi6_3_4 -0.075 0.032 0.019
msi6_5 -0.142 0.040 0.000
msi10_2_3 -0.060 0.018 0.001
msi10_4 -0.116 0.025 0.000
msi10_5 -0.130 0.033 0.000
msi15_5 -0.070 0.031 0.023
msi16_3_4 -0.042 0.022 0.057
msi16_5 -0.065 0.032 0.041
msi18_2 -0.061 0.028 0.030
msi18_3 -0.107 0.033 0.001
msi18_4_5 -0.118 0.036 0.001
msi21_5 -0.131 0.028 0.000
msi26_3_4_5 -0.033 0.018 0.068
msi29_3_4 -0.038 0.019 0.044
  msi29_5 -0.188 0.027 0.000
 R² (A) = Adjusted R² in development sample 
R² (B) = Adjusted R² in test sample
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below. QLQ-C30 model 4, HAQ model 3, and MSIS-29 model 4 meet the requirements of 
logical consistency, significance of predictors, parsimony and were able to predict mean 
utility values in the test samples (Table 3.5). Scatter plots of the predicted compared to 
observed values at baseline in the test samples (MSIS-29 test sample 2) are presented 
in Figure 3.1. Box plots of prediction errors per EQ-5D utility category are presented in 
Figure 3.2.
QLQ-C30
Predictions were better when the assumptions concerning data were relaxed. As ex-
pected from the relatively low correlation with EQ-5D dimensions, the sum score of 
cognitive functioning scale was excluded after backward selection in model 1, as cogni-
tive functioning is not represented in the EQ-5D. Using items as continuous predictor 
variables (model 2) reduced prediction errors, but performed worse than model 3 which 
used items as dummy variables. In model 3, after backward selection, it was decided to 
remove items from the model based on illogical signs (item 10, 22 and 25), at the cost of 
2% explained variance. Dummy model 3 consists of items 1 to 5 (physical functioning); 6 
Figure 3.1 scatter plots of observed and predicted values
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and 7 (role functioning); 9 (pain); 16 (constipation); 23 & 24 (emotional functioning) and 
item 27 (social functioning). To achieve a more parsimonious model, non-significant, 
and remaining significant but illogically ordered (items 7 and 9) dummy categories 
were merged and item 16 (constipation) was dropped altogether, without effecting the 
predictive performance of the model. The model developed in the multiple myeloma 
patient sample was able to predict utilities in the non-Hodgkin’s sample. The largest 
RMSE value is at baseline and 10 months follow-up which is due to an outlier as can 
be seen from the relatively low MAE which is less sensitive to outliers. When the model 
could not predict a utility value because the non-Hodgking sample had missing values 
in QLQ-C30 responses, or when the utility value from the EQ-5D was missing, cases 
were excluded leading to minimal differences in RMSE (smaller than 0.01) compared to 
including missing data-points as well.
Table 3.5 summary of model performance in test samples
Model
Observed 
mean EQ-5D 
(SD)
Predicted 
mean EQ-5D 
(SD)
RMSE 
(normalized 
for range)
MAE R2 Min - Max
observed
Min - Max
predicted
QLQ-C30
Baseline 0.66 (0.30) 0.66 (0.26) 0.16 (12.0%) 0.12 0.75 -0.06 - 1 -0.30 - 0.98
2nd treatment cycle 0.70 (0.26) 0.71 (0.22) 0.13 (9.7%) 0.10 0.79 -0.13 - 1 0.10 - 0.98
4th treatment cycle 0.72 (0.25) 0.72 (0.21) 0.12  (9.0%) 0.08 0.79 -0.09 - 1 0.13 - 0.98
6th treatment cycle 0.70 (0.26) 0.69 (0.22) 0.15 (11.3%) 0.10 0.75 -0.13 - 1 -0.06 - 0.98
3 months follow-up 0.77 (0.26) 0.77 (0.21) 0.10  (7.5%) 0.07 0.82 -0.13 - 1 -0.03 - 0.98
6 months follow-up 0.80 (0.20) 0.79 (0.18) 0.11  (8.3%) 0.07 0.74 0.00 - 1 -0.03 - 0.98
10 months follow-up 0.77 (0.27) 0.80 (0.19) 0.16 (12.0%) 0.09 0.68 -0.33 - 1 0.02 - 0.98
18 months follow-up 0.81 (0.18) 0.82 (0.18) 0.09  (6.7%) 0.06 0.8 0.22 - 1 0.01 - 0.98
HAQ
HAQ-only model 0.64 (0.26) 0.65 (0.16) 0.17 (12.2%) 0.07 0.39 -0.13 - 1 0.22 - 0.84
Extended model 0.64 (0.26) 0.65 (0.20) 0.15 (10.8%) 0.04 0.54 -0.13 - 1 0.13 - 1.02
MSIS-29
Test sample 1 0.62 (0.28) 0.62 (0.27) 0.20 (14.4%) 0.16 0.49 -0.13 - 1 -0.05 - 0.96
Test sample 2 0.65 (0.23) 0.65 (0.19) 0.18 (12.9%) 0.13 0.49 0.01 - 1 0.06 - 0.96
MSIS-29 (UK)
Test sample 1 0.57 (0.31) 0.59 (0.22) 0.22 (13.8%) 0.16 0.49 -0.32 - 1 -0.14 - 0.95
Test sample 2 0.60 (0.26) 0.60 (0.21) 0.18 (11.3%) 0.13 0.49 -0.17 - 1 0.00 - 0.95
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HAQ
As the sample was focused on early arthritis the dummy items often lacked respondents 
which scored the lowest answer category (level 4). In a dummy model, the variables 
that represent the fourth category mostly score 0, yielding it impossible to estimate a 
decrement for a level 4 answer. Consequently a model with summed dimension scores 
had better RMSE scores in the test sample. Removing the insignificant sum variables in 
the prediction model did not improve predictions in the test sample. After backward 
stepwise regression, the model with the a priori selected predictor variables (extended 
model) performed better in terms of RMSE, MAE and R2 and was capable of predicting a 
wider range of EQ-5D index values as can be seen in Figure 3.1 and Table 3.5. Stepwise 
selection of variables for the extended model resulted in the removal of all HAQ sum 
scores except usual activities. Tender joint count and swollen joint count did not contrib-
ute to the model but are represented indirectly through the DAS28. The other variables 
are the transformed sum scores of the SF-36 (physical functioning, role-physical, bodily 
pain, and role-emotional) and the depression sum score of the HADS. Added variables 
had significant Pearson correlations between 0.47 and 0.58 with at least one of EQ-5D 
dimensions. Adding a squared term for the SF-36 bodily pain score did not reduce pre-
diction errors. The extended model failed to predict 27 of the 132 EQ-5D index values 
due to missing data for one or more of the prediction variables.
MSIS-29
For the Dutch value set, MSIS-29 models 2 to 4 with items as predictors performed better 
than sum score model 1. Treating items as dummy variables did not reduce prediction 
error in terms of RMSE and MAE. However, the continuous model seemed illogical with 
an intercept of 1.17 while a value of 1 represents full health in the QALY-model. Model 3 
contained many insignificant and illogical items, but removing them increased predic-
tion errors. However, a more parsimonious model with significant predictors could be 
developed without losing predictive performance through merging categories. Only 
MSIS-29 item 10 and 28 could not be further reduced into smaller categories without 
losing predictive performance. Consequently 4 variables in the model are not logically 
ordered, however the largest difference is 0.002 between MSI10_4 and MSI10_5.
Results were similar for the UK value set. The most parsimonious model is presented 
in Table 3.4, which had, however, slightly larger prediction errors. The final algorithm 
contained 10 items, 7 items from the physical dimension and 3 from the psychological 
dimension.
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Discriminant validity
The preferred models were tested for their ability to discriminate between relevant 
clinical subgroups (known-groups analysis). Results are satisfactory for all the preferred 
mapping models (QLQ-C30 model 4, HAQ model 3, MSIS-29 model 4 and the MSIS-29 UK 
model) as presented in Table 3.6. For the QLQ-C30 the predicted values follow a similar 
pattern to the observed EQ-5D values. Both the predicted and the observed EQ-5D 
values can hardly distinguish between WHO categories 0 (fully active) and 1 (cannot 
do heavy physical work but can do everything else), but neither can the self-assessed 
global health sum score from the QLQ-C30.
Table 3.6 comparison of predicted and observed eq-5D index values by clinical indicators
QLQ-C30
WHO N (summed) EQ-5D index Mapped EQ-5D
model 4
QLQ sum score
global health
0 356 0.75 0.75 63
1 304 0.76 0.74 64
2 96 0.69 0.72 59
3 27 0.37 0.42 41
Pearson’s r -0.19** -0.19** -0.095**’
MSIS-29
EDSS N EQ-5D index Mapped EQ-5D
model 4
MSIS-PHY MSIS-PSY
0 9 0.81 0.81 34 21
1 25 0.73 0.72 40 22
2 71 0.74 0.70 44 22
3 51 0.58 0.59 55 26
4 56 0.63 0.58 57 26
5 28 0.61 0.54 64 26
6 53 0.55 0.49 69 28
7 25 0.40 0.40 74 28
Pearson’s r -0.38** -0.47** 0.57** 0.23** 
HAQ
DAS28 N N Model 3 EQ-5D index Mapped EQ-5D
model 1
Mapped EQ-5D
model 3
Remission 11 9 0.76 0.76 0.83
Low DA 15 12 0.70 0.68 0.73
Moderate DA 70 59 0.67 0.68 0.67
High DA 27 23 0.51 0.54 0.49
Pearson’s r -0.37** -0.52** -0.57**
** p<0.00
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The extended model (model 3) of the HAQ can adequately discriminate between the 
4 categories of disease activity. In contrast, the sum score model (model 1) does not 
discriminate between low and moderate disease activity. The extended model, which 
requires data from 3 questionnaires and as a result of missing values in one of those 
questionnaires, fails to predict 20 of the 123 EQ-5D index scores. The consequence is 
a large difference between observed (0.76) and predicted (0.83) scores for patients in 
the remission category due to two missing cases with lower than average utility values 
(both 0.67).
The MSIS-29 is a slightly different story, as the predicted EQ-5D values have more 
discriminative ability than the observed EQ-5D between EDSS categories 3, 4 and 5, 
which was noticed in both test sets and for each of the two EQ-5D country tariffs. Like 
the predicted EQ-5D values, the sum score of the physical impact of MS also indicates 
decreasing health per EDSS category. In the distribution graph (Figure 3.3), it is seen that 
the predicted values do not follow the distribution of the observed values (a similar pat-
tern was observed in the cancer and arthritis data). The EQ-5D seems to have a bimodal 
distribution with the observations between 0.4 and 0.6 either on the low end of 0.4 or 
the high end of 0.5. This is most likely the result of few respondents reporting exactly 
those health problems on the EQ-5D which are transformed into scores between about 
0.45 and 0.55 on the EQ-5D tariff.
Figure 3.3 Distributions of the msis-29 observed and predicted eq-5D index values
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Discussion
This study aimed to develop mapping functions for HAQ, MSIS-29 and QLQ-C30. Quality 
of the functions was assessed with statistical indicators and performance in relevant 
clinical subgroups. It was also explored whether the amount of overlap between instru-
ments could explain differences in predictive performance between mapping functions.
The best functioning mapping models are QLQ-C30 model 4, HAQ model 3 and MSIS-29 
model 4. Based on the ability of the models to predict mean utility scores for the entire 
sample and for clinically relevant subgroups these mapping functions seem suitable 
for predicting utility values to rescue data for economic evaluation when a preference-
based measure is absent. When correlations between the starting measure and the EQ-
5D were relatively low, the mapping function performed worse. The QLQ-C30 had the 
highest correlation with EQ-5D dimensions and produced a function with the smallest 
prediction errors. The HAQ had relatively low correlations with the mobility dimension 
of the EQ-5D thus seemingly measuring other aspects of mobility. The content of the 
questionnaires reveals the differences between the measures. The HAQ sum score for 
mobility is made up by item 8 (walk outdoors on flat ground) and 9 (climb up 5 steps). 
These questions thus measure the ability to perform a specific mobility related task and 
differs from the interpretative EQ-5D level 2 ‘some problems walking about’. It may be 
due to this discrepancy that 114 respondents report ‘no problems’ on HAQ item 8, but 
score ‘some problems walking about’ on EQ-5D. The HAQ model required additional pre-
dictor variables from other questionnaires to successfully discriminate between relevant 
clinical subgroups.
The preferred mapping functions for the QLQ-C30, HAQ and MSIS-29 successfully pre-
dicted mean EQ-5D utility values of the test data sets. In this study, the measures of 
error, RMSE, MAE (and ε in the box plot), represent the average differences between 
all the individual predicted and observed EQ-5D index scores. The interpretation of 
the figures in Table 3.5 is that the mapping functions of MSIS-29 and HAQ-only models 
are less certain to perform well in samples that deviate ‘too much’ from the samples on 
which the models were generated or tested. All models have larger prediction errors 
for patients with low EQ-5D utility values, as is best represented in Figure 3.2. The func-
tions differed in quality, despite successful prediction of the mean and relatively small 
prediction errors. HAQ model 1 predicts the mean correctly and has a relatively suitable 
RMSE, but has a small range and cannot distinguish between relevant clinical categories. 
Drawing on the example of the HAQ mapping function in this study, it seems that only 
presenting statistical measures is not always sufficient to make an educated judgment 
about the quality of a mapping function. Additional (clinical) indicators are more easily 
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interpretable and proved to be of added value for assessing the quality of the mapping 
functions in this study though known-groups analysis.
Improvement of the models was sought by using additional predictor variables, which 
were only available in the HAQ dataset. Improvement of the model was needed as HAQ 
model 3 (with the additional predictor variables from the SF-36, the HADS and the Dis-
ease Activity Scale) outperformed the other HAQ models in terms of RMSE, range and 
ability to discriminate between relevant clinical subgroups. However, here, a tradeoff 
is made between model performance and usability of the model, as it is not likely that 
many other trials included these additional predictor variables. Even in our own study 
the amount of missing predicted values by HAQ model 3 was much larger than for the 
other prediction models.
Several limitations of the study need to be discussed. First and most important, the 
performance of both the HAQ and MSIS-29 models is likely to be overestimated because 
test samples were very similar to the development samples, as they where randomly 
drawn from the same original dataset instead of originating from a different study, as 
was the case with the QLQ-C30 test set. Second, the HAQ was administered in an early 
arthritis cohort with relatively few very ill patients. Consequently a dummy model could 
not be estimated. The presence of very ill patients with low utility values is the biggest 
contributor to prediction errors, as these values are generally overestimated. Absence of 
these values in the HAQ dataset is thus likely to flatter the statistical measures of error. 
The extended model is recommended for use if predictor variables are available. Third, 
the QLQ-C30 test sample was also a lymphoma type cancer. Performance in subjects with 
other cancer types is not tested, which consequently causes uncertainty about model 
performance in different kinds of cancer. Fourth, the quality of the starting measure, 
the condition specific questionnaires, will have effect on the quality of the mapping 
function. A notable issue with the MSIS-29 mapping model was that there where many 
illogically ordered variables. The coefficients of scoring category 2 ‘a little’ were higher 
or equal to category 3 ‘moderate’. A recent Rasch analysis of the MSIS-29 suggests that 
indeed the MSIS-29 would be better of with less answer categories (the authors of the 
Rasch study suggest 3), as the current 5 could not adequately distinguish the levels 
‘a little’, ‘moderately’ and ‘quite a bit’ (101). That issue is a likely cause of the illogically 
ordered variables in the regression analysis.
QLQ-C30 and HAQ have been previously mapped on the UK EQ-5D tariff (90,92). The QLQ-
C30 mapping, developed on a sample (N=199) of patients with inoperable esophageal 
cancer, did not report RMSE but reported the adjusted R2. The adjusted R2 was 0.61 which 
is somewhat lower than was found in this study, but the model could successfully predict 
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mean scores. We applied their mapping model, which performed well in our sample 
(%RMSE range over time points = 7.5-11.3). This result may provide some first support 
for the generalizability of QLQ-C30 mapping models, as %RMSE was relatively favorable. 
However, a more complete analysis involving different mapping functions tested on dif-
ferent types of cancer is required to investigate the important and yet unsettled issue of 
generalizability. The applied model, published by McKenzie and Van der Pol in 2009(90), 
was based on sum scores of the QLQ-C30. It is possible that our model, based on items but 
not all items of all QLQ-C30 dimensions, may be less sensitive in other cancer types. The 
previous mapping of HAQ on the EQ-5D(92) reported %RMSE of a model with dummy 
variables ranging from 11% to 15%, and a limited range of predicted values (0.2 -0.8). The 
values presented here do not deviate strongly, even though a dummy-model could not 
be estimated. In our study the limited range of predicted variables could be overcome 
by adding additional predictors that cover the other domains of general health, but this 
does create a problem with generalizability of the model to other datasets that do not 
hold all variables for instance due to the use of different instruments.
While testing the mapping functions for their discriminant validity it was noticed that 
MSIS-29 mapping model 4 was more sensitive than EQ-5D between categories 4 to 6 of 
the EDSS and had higher correlation with the EDSS. It could be argued that a change be-
tween levels 4 (able to walk 500 meters without aid) to 6 (assistance, like a cane, required 
to walk 100 meters without resting) on EDSS does not have impact on quality of life and 
is therefore not picked up by EQ-5D. However, on these same levels, there is a noticeable 
change on the physical sum score of MSIS-29. It was not anticipated that the predicted 
EQ-5D would be more sensitive to change in this area of EDSS. We hypothesize that the 
explanation for the difference is that the predicted and observed EQ-5D index scores 
have different distributions. The different distributions are most likely the result of only 
few respondents reporting health problems on the EQ-5D which are transformed by the 
country tariff into scores between about 0.4 and about 0.6 on the EQ-5D tariff (85). The 
predicted values of the mapping study have a different distribution than the observed 
values (Figure 3.3) which can be interpreted as an unsuccessful reproduction of true 
EQ-5D values. However, in this case, it results in an anomalous finding where a mapped 
EQ-5D index is more sensitive to changes in clinical categories.
The EQ-5D utility index reflects quality of life as measured on five different dimensions 
of health. Condition specific measures can be used to estimate mean EQ-5D utility 
values, despite covering different dimensions of health. However, research in this paper 
suggests that lower degrees of overlap leads to poorer predictive quality. Face value 
assessment may not necessarily represent true overlap between the dimensions of the 
condition specific and preference-based instrument. Mapping functions derived from 
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condition specific questionnaires with few dimensions may adequately predict a mean 
utility value, but should be used with caution in populations that deviate markedly from 
the population on which the function was estimated. As generalizability is a major issue 
for mapping functions, it ought to be tested how these models perform in different can-
cer, arthritis and multiple sclerosis populations. Because errors of the predicted values 
are larger for patients in poor health, these mapping functions may not perform well in 
such populations. Results from this study suggest that the mapped EQ-5D index values 
of the preferred mapping models can discriminate between relevant clinical subgroups. 
An important next step is to investigate how using mapped EQ-5D values instead of 
observed EQ-5D values influences cost-utility analyses.
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aBsTracT
Some argue that generic preference-based measures (PBMs) are not sensitive to certain 
disease specific improvements. To overcome this problem, new condition specific PBMs 
(CS-PBMs) are being developed, but it is not yet clear how such measures compare to 
existing generic PBMs.
We generated CS-PBMs from three condition specific questionnaires (Health Assessment 
Questionnaire for arthritis, Quality of Life Questionnaire for Cancer 30 for cancer and 
Muliple Sclerosis Impact Scale 29 for multiple sclerosis). First the questionnaires were 
reduced in content, and then, a time trade-off (TTO) study was conducted in the general 
public (N=402) to obtain weights associated with the dimensions and levels of the new 
questionnaire. Finally we compared utilities obtained using the CS-PBMs with utilities 
obtained by using the EuroQol five dimensional (EQ-5D) in four data sets.
Utility values generated by the CS-PBMs were higher than those of the EQ-5D question-
naire. The Health Assessment questionnaire- based measure for arthritis proved to be 
insensitive to comorbidities. Measures based on the Multiple Sclerosis Impact Scale 29 
and the Quality of Life Questionnaire for Cancer 30 discriminated comorbidities and 
side-effect equally well as the EQ-5D questionnaire and were more sensitive than the 
EQ-5D questionnaire for mild impairments.
The introduction of PBMs which are specific to a certain disease may have the merit of 
sensitivity to disease-specific effects of interventions. That gain, however, is traded off to 
the loss of comparability of utility values and, in some cases, insensitivity to side-effects 
and comorbidity. The use of a CS-PBM for cost-utility analysis is warranted only under 
strict conditions.
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inTroDucTion
A preferred method for generating the quality adjustment required for computation of 
QALYs is through generic preference based measures (PBMs) such as the EuroQol five 
dimensional (EQ-5D) questionnaire (88) or the health utilities index (HUI) (102). Some ar-
gue that such generic PBMs are not sensitive to certain disease-specific improvements. 
Consequently, the existing PBMs may not always be the best tool to assess the effect 
of an intervention. To overcome this problem, new condition-specific PBMs (CS-PBMs) 
have been developed, for example, for asthma (103) and urinary incontinence (104). 
Not much is known, however, about how these new instruments compare with generic 
instruments such as the EQ-5D questionnaire. It is feared that using CS-PBMs may lead 
to the exaggeration of health problems due to a focusing effect, render comparison 
of utility values impossible, because utilities are derived from different PBMs, and may 
be insensitive to comorbidities (105,106). Evidence, however, is scarce. In this study, 
three CS-PBMs are developed for the purpose of exploring these and other issues, one 
for arthritis (based on the Health Assessment Questionnaire [HAQ]), one for multiple 
sclerosis (MS) (based on the Multiple Sclerosis Impact Scale 29 [MSIS-29]) and one for 
cancer (based on the EORTC Quality of Life Questionnaire C30 [QLQ-C30])
A PBM is a questionnaire with a scoring function to weight the responses according to 
preferences for certain health conditions over others. These preference weights are elic-
ited in studies where respondents are asked to express their preference for a health state, 
for instance, using time trade-off or standard gamble. Existing generic PBMs such as the 
EQ-5D questionnaire and the health utilities index were developed to have a standard-
ized tool to measure health related quality of life for the quality adjustment part of the 
quality adjusted life year. These generic preference-based instruments aim to measure 
quality of life on a sufficient degree of generality to allow comparisons across condi-
tions. For these instruments the key tradeoff is between generality of the included health 
dimensions to allow cross-disease comparisons and sensitivity to pick up (relevant) 
treatment effects (105). The EQ-5D questionnaire, for example, consists of five items with 
three levels measuring mobility, self-care, usual activities, pain/discomfort and anxiety/
depression. The choice to include only these basic dimensions of health ensures the level 
of generality that is required for comparison across diseases at the potential cost of los-
ing sensitivity for disease specific complaints. For example, the view is widely held that 
the EQ-5D is not an appropriate measure to assess quality of life of patients with sensory 
problems (bad eye sight or hearing problems), because sensory problems are beyond 
the scope of health defined by dimensions of the EQ-5D questionnaire (99). Another 
perceived problem of EQ-5D is that very mild conditions cannot be adequately assessed 
using only three levels of impairment due to low ceiling sensitivity (107,108).
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The increased use of economic evaluations by health authorities seems to have created 
a sense of urgency within the health assessment community to deal with the shortcom-
ings of generic PBMs. In recent years new CS-PBMs have emerged for which the devel-
opment was motivated by either the absence of generic PBMs in a specific context or 
the judgment that generic PBMs would not be appropriate for a condition. Contrary to 
generic instruments, a CS-PBM contains dimensions specifically targeted at the affected 
population. In terms of the trade-off mentioned above, these instruments are expected 
to demonstrate superior sensitivity to specific diseases, although this may come at the 
cost of comparability of utility values across conditions. Because of the difference in 
the scope of different instruments, utility values derived from a CS-PBM may not be 
comparable with those derived from a generic instrument, even though they seem to lie 
on the same 0 to 1 scale. Although the development of CS-PBMs is valuable for research 
purpose, for example to better investigate the shortcomings of generic PBMs, there 
is concern about the application of CS-PBMs in economic evaluations. Unfortunately, 
empirically founded guidance on how and when to apply CS-PBMs is absent.
There has been little reflection so far on the comparability of the obtained quality of 
life weights to those obtained from generic PBMs. Specific issues in comparability are 
described in a recent expert editorial (105). First, CS-PBMs may cause an exaggeration 
of health problems (reflected by low utility values) due to focusing effects. When the 
health states in a preference elicitation study consist of a set of disease-related items, 
rather than general items of health-related quality of life, the context of the valuation 
is narrower, possibly leading to lower utility values. The logic behind this hypothesis is 
that narrow focused items may seem less important when presented in a wider context 
of general health (e.g., having a cold may seem less severe when presented alongside 
problems with mobility), but may seem quite problematic when presented separately. 
This may result in a downward bias on preference values when compared to generic 
PBMs. Second, a CS-PBM might have difficulty capturing comorbidities as the focus is on 
disease-related items. This may result in an upward bias on utility values. Furthermore, 
developing a CS-PBM is not a clear cut exercise. Researchers face many decisions, such 
as the reduction of items in a questionnaire, the selection of health states (how many 
and which?) that have to be valued to develop a PBM (99), on the valuation method 
(e.g., TTO or standard gamble?), and on the modeling approach. How these decisions are 
dealt with may differ per study which decreases comparability.
The primary aim of this paper is to provide empirical evidence about the comparability 
of CS-PBMs and generic PBMs. To do so, three CS-PBMs were developed from existing 
questionnaires. The values generated by these CS-PBMs were then compared with EQ-5D 
questionnaire values for the same patient samples. By providing empirical evidence we 
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hope to provide a better understanding of the effects of using CS-PBMs and contribute 
to development of guidance for their use. This is important, as it can be expected that 
in the nearby future more cost utility analyses will contain utilities based on conditions 
specific measures.
meThoDs
questionnaires for cs-PBm development
The CS-PBMs were developed from the HAQ (91), the MSIS-29 (93) and the QLQ-C30 (89). 
These instruments were selected based on expert advice and commonality of use within 
clinical settings. The HAQ is a widely used questionnaire in rheumatology to measure 
functional abilities using 20 items with four levels spread across eight domains (dress-
ing, rising, eating, walking, hygiene, reach, grip and usual activities). The scale has been 
shown to be unidimensional (109). The MSIS-29 measures the impact of MS on a physi-
cal and psychological dimension. Dimensionality of the subscales has been confirmed 
using Rasch analysis (101). The QLQ-C30 (version 2) is a cancer specific questionnaire 
consisting of 30 items. These items cover five functional scales, nine symptom scales 
and a global health status scale. These questionnaires were chosen because they differ 
in scope and because EQ-5D data was available for the purpose of comparing results. 
For MSIS-29, it has been shown that the physical scale is better capable of discriminating 
among sub categories of the clinically assessed Expanded Disability Status Scale (EDSS) 
than is the EQ-5D questionnaire (110). There was no evidence known to us on a lack of 
responsiveness of EQ-5D or the superiority of the condition-specific measures HAQ and 
QLQ-C30 in arthritis or cancer, respectively.
Reducing the content of the questionnaires
Developing a PBM from an existing questionnaire does not lead to an entirely new in-
strument but attaches weights to some of the items of the existing questionnaire. Such 
an approach generally requires a method to reduce the questionnaire content as only 
a limited number of items can be valued in a preference elicitation study (99). Typically 
only a fraction of the total amount of all theoretically possible health states is valued. 
The values for the remainder of the health states are estimated through modeling tech-
niques.
The optimal number of items in a health state was considered to be in the order of five to 
nine items, because more items may cause difficulties for respondents in the valuation 
study (99). The HAQ, MSIS-29 and QLQ-C30, respectively, contain 20, 29 and 30 items, 
so reduction of content was required. Relevant and well-functioning items from the 
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questionnaires were selected using the following criteria proposed by others (111): i) 
the item had to fit the Rasch model, ii) the item had to meet basic psychometric criteria 
and iii) the selected items had to be approved by a clinical expert. Four datasets were 
available for these analyses: the Rotterdam Early Arthritis CoHort for the HAQ (N=738), 
the Multiple Sclerosis Risk Sharing Scheme Monitoring Study (N=1,295) for the MSIS-29 
and the Hemato Oncology Founcation for Adults in the Netherlands 24 (pooled N=716) 
and Hemato Oncology Founcation for Adults in the Netherlands 25 (pooled N=789) tri-
als for the QLQ-C30. The dataset characteristics are described in detail in Versteegh et al. 
(2011) (110). A set of a priori criteria were used to determine which items were suitable 
for the health state description (111,112). Because it was expected that neither of these 
criteria could be sufficient on its own, the three criteria were employed ‘side by side’ (i.e. 
no hierarchical order).
Criterion 1: fit to the Rasch model
Rasch analysis was used to test the psychometric validity of a scale and to identify well-
functioning items. The Rasch model assumes that the probability of scoring level λ on 
item i is a logistic function of the relative distance between the item location (how much 
disability it represents) and the respondent location (how disabled the patient is) (113).
The main performance criteria within the Rasch model were whether the item: i) has 
ordered thresholds (having more of the latent trait θ results in endorsing a higher level 
answer category (114)); ii) fits the Rasch model (fit residual <2.5 and non-significant 
bonferroni adjusted probability); iii) combined scale fits the Rasch model (described by 
a non-significant item-trait interaction chi-square probability (114)) and iv) shows no 
differential item functioning. After each single scale amendment the analysis was rerun 
for the remaining items. Rasch analysis was performed on the dimensional structure 
originally suggested by the questionnaires.
Criterion 2: psychometric properties
Psychometric criteria were laid alongside the Rasch results to come to a final selection of 
items amenable for valuation. The functioning of the items was tested by investigating 
the loading of items on factors identified by factor analysis; missing data; internal con-
sistency of items with its scale score; distribution of the responses on an item including 
floor and ceiling effects; and regression coefficients between a general health indicator 
and an item. Psychometric analyses were applied to the full data sets.
Criterion 3: expert opinion
The selected items from the questionnaires were presented to experts in the respective 
fields. Experts from the Erasmus Medical Centre and the VU Amsterdam Medical Centre 
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were consulted to gain insight in important aspects of the disease and to evaluate the 
result of the previous selection process.
health state selection
Even after data reduction the selected set can still generate an enormous amount of 
possible health states; therefore, a fractional factorial design was favored over a full 
factorial design. The QLQ design was a level-balanced design, meaning that all levels 
of each item occurred with the same frequency. Within the balanced design health 
states covered the entire spectrum of severity, measured by averaging the item levels 
of a health state. For the MSIS-29 and the HAQ, items and levels were selected with an 
orthogonal main effects plan (OMEP) as is applied in other studies (83,115) to ensure 
zero statistical correlation between the attributes. The set was complemented with a se-
lection of the most observed health states (four or more observations) over the severity 
range of the questionnaire. TTO values estimated with additive main-effect models (one 
based on the OMEP states and one based on the OMEP and the most observed states) 
were compared to the observed TTO values of the most occurring states using standard 
predictive performance measures like mean absolute error (MAE) to see if the addition 
of these states led to improved prediction of the most frequently occurring states.
The final design was blocked. In such a design respondents value a number of health 
states which belong to the same ‘block’. The mean severity of the combination of items 
in a block was similar and measured through summing the level scores of the items in 
a block.
health state valuation with Time trade-off method
The preferences of a sample of the general public were elicited through a TTO exercise 
for each of the selected health states of the questionnaires. To optimize comparability 
to generic PBMs the CS-PBM health states were valued with the same TTO protocol, the 
same computer assisted personal interview tool, the same procedure to measure states 
‘worse than dead’ and the same rescore procedure of negative values (negative TTO 
scores were rescaled to have a range between -1 and 0 with (-t/-x-t) as was adopted 
in the Dutch EQ-5D valuation study (87). Unlike the Dutch EQ-5D valuation study, this 
study was performed in group sessions, which has previously been shown to produce 
comparable TTO results (116).
The TTO exercise was self-administered through a digital tool for TTO elicitation (com-
puter assisted personal interviews) in groups with about 12 to 25 respondents per 
session. Each session was supervised by three to four researchers to offer assistance if 
needed. Prior to the task, respondents received 30 minutes of instructions by research-
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ers M.V. or A.L. including examples of the TTO computer program projected on a large 
screen. The task was piloted by M.V. and A.L. in a sample of 18 respondents to ensure 
the introduction, the computer program and the organization of the task were feasible.
The three questionnaires were presented separately in the TTO exercise and in all pos-
sible orders (e.g. first HAQ, then MSIS then QLQ). Within the TTO exercises, health states 
were presented random to individuals.
respondents
Respondents were selected by a marketing agency which requited a sample resembling 
the Dutch general population in age, gender and education. Respondents were ap-
proached by phone and asked if they were interested in contributing to a task to value 
descriptions of health states. Respondents received a financial reward of € 35, - upon 
completion of the three TTO exercises. Respondents were removed from the analyses 
when the results indicated they valued the majority of logically worse states higher than 
logically better states in a set (i.e. HAQ state 11112 is logically better than HAQ state 
14444).
modeling of the TTo values
Once the TTO study had been performed, the preference values observed for the se-
lected health states were used to estimate values for all potential health states through 
statistical modeling. Because individuals value more than one health state there are 
multiple observations for each individual. Random effects models were estimated to 
assess how the predictors (the items and their levels) influence the dependent variable 
(the mean observed TTO value). In these random effects models, the item levels were 
treated as dummy variables with dummy coding. The constant term was treated as an 
additional decrement for having any item level other than the base case (‘no problems’), 
which is similar to the EQ-5D model. The values predicted by this random effects model 
will be referred to as the PBM results (e.g. HAQ-PBM). Models were required to have 
significant predictors and worse scores on the levels ought to be represented by larger 
utility decrements. Model performance was assessed by comparing the MAE of observed 
and predicted values. Models were estimated until meeting those criteria. Only the most 
parsimonious models are presented. To keep optimal comparability between the devel-
oped CS-PBMs, models were estimated from the items only, without interaction effects 
or a ‘worst-value’ dummy variable which is 1 for every item on the lowest level. Interac-
tion effects were not estimated because the study design was a main effects design.
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hypotheses and analyses
To investigate the properties of preference-based measures developed from existing 
questionnaires several hypotheses were tested. First, it was tested whether the TTO 
values could be successfully modeled. For HAQ and MSIS the TTO random effects 
models were fitted on both the full dataset (including ‘most observed’ health states) 
and on the subset consisting of health states originating from the OMEP. This was done 
to test whether an OMEP alone is sufficient to estimate the utility values of the most 
occurring health states. Second, it was investigated whether CS-PBMs yielded lower 
mean utility values than a generic measure, which was hypothesized to reflect that a 
downward bias on utility values resulting from a focusing effect might outweigh the 
upward bias on utility values resulting from a narrower scope of the CS-PBM. Third, it 
was tested with Wilcoxon rank-sum tests, to account for the non-normal distribution 
of utility values, whether the developed CS-PBMs had a more narrow focus and were 
therefore less sensitive to comorbidities (in arthritis and MS datasets) or side-effects 
(Non-Hodgkin’s lymphoma dataset) than EQ-5D. Side-effects had World Health Orga-
nization performance status 2 or higher, representing the inability to carry out work 
activities due to the condition. Fourth, we assessed discriminative properties of the new 
measures by using clinical indicators. For arthritis the Disease Activity Score-28 was 
used, which is based on a count of tender joints and the erythrocyte sedimentation rate. 
It distinguished between high, moderate and low disease activity, and remission. For 
MS the EDSS was used which, when rounded to integers, distinguishes 11 categories of 
increasing disability. For cancer we used the WHO performance status score (or Eastern 
Cooperative Oncology Group) which distinguishes 6 categories, from 0 to 6 (death). 
Lastly, responsiveness was measured in the cancer population using effect-size (Cohen’s 
d) and mean change in the cancer population, for which follow-up measurements were 
available in the data set.
All results were compared to utilities of the Dutch EQ-5D tariff (22).
software
For Rasch analysis the RUMM2020 software (Rumm Laboratory Pty Ltd) was used. Psy-
chometric analysis was performed in SPSS 17.0 (SPSS Inc.) and all hypothesis testing and 
modeling efforts in STATA 11.0 (StataCorp. 2009).
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resulTs
item and level selection
The selected items per questionnaire are presented in Table 4.1, and all met the criteria 
of the Rasch analysis, psychometric analysis and expert opinion. The full results of the 
selection of items and levels and the results of the Rasch analysis are presented in the 
supplementary material.
Table 4.1 items selected for the TTo valuation exercise
HAQ-DI MSIS-29 QLQ-C30
• HAQ1 Stand up from a straight 
chair
• HAQ2 Walk outdoors on flat 
ground
• HAQ3 Get on / off toilet
• HAQ4 Reach and get down a 
5-pound object (such as a bag of 
sugar) from just above your head
• HAQ5 Open car doors
• MSIS1 Problems with your balance
• MSIS2 Being clumsy
• MSIS3 Limitations in your social 
and leisure activities at home
• MSIS4 Difficulties using your 
hands in everyday tasks
• MSIS5 Having to cut down the 
amount of time you spent on work 
or other daily activities
• MSIS6 Feeling mentally fatigued
• MSIS7 Feeling irritable, impatient 
or short tempered
• MSIS8 Problems concentrating
• QLQ1 Trouble taking a long walk
• QLQ2 Limited in doing either your 
work or other daily activities
• QLQ3 Have you had pain
• QLQ4 Have you felt nauseated
• QLQ5 Were you tired
• QLQ6 Difficulty in concentrating 
on things
• QLQ7 Did you worry
• QLQ8 Has your physical condition 
or medical treatment interfered with 
your social activities
resulting study design
Given the many items and levels in the study we chose a fractional factorial blocked 
design. Health states were presented in blocks, so one individual values one block con-
taining several health states. The design is summarized in Table 4.2.
Table 4.2 TTo study design following item selection
HAQ MSIS QLQ
Number of items 5 8 8
Total amount of health states to be valued 56 100 105
States identified by OMEP (used in study after fold-over) 15 (30) 32 (64) n/a
Number of most occuring states included 26 36 n/a
Number of states valued by one individual (total = 33) 8 10 15
Number of blocks¹ 7 10 7
Expected number of observations per health state (N=400 / number of blocks) 57 40 57
¹ One block consist of a number of states and all of the states in one block are valued by one individual
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Data quality
Four hundred two respondents participated in the computer assisted TTO study and 
resembled the Dutch population (Table 4.3). Respondents were excluded from the 
analyses because they had valued the majority of logically better states lower than 
logically worse states in one block (8 exclusions for HAQ, 17 for MSIS and 7 for QLQ). 
Average time to value one health state in the TTO exercise was about 1 minute. Total 
time per block was highest for QLQ (15 health states, about 12 minutes), followed by 
MSIS (10 health states, 10 minutes) and HAQ (8 health states, 8 minutes). Although two 
separate researchers took turns in holding the introductory talks this did not bias the 
TTO responses (Wilcoxon rank test p>0.05). On average, women had higher utility values 
(t-test, p<0.00) for all three questionnaires. The mean utility of the health states and 
the percentage of responses indicating a state to be worse than dead are presented in 
Figure 4.1A and B.
Table 4.3 respondent characteristics
TTO study sample Dutch population norms¹
N 402 -
Gender M/F 46% / 54% 49.5% / 50.5%
Age
mean (SD) 45 (15.5) 40.1
min-max 15-76 -
Agegroup
<20 4.8 23.7
20-40 37.6 25.3
40-65 46.9 35.7
65-80 10.4 11.4
>80 0.3 3.9
Education
High 34 27
Medium 35 31
Low 25 33
Missing / Else 6% 9%
Mean (SD) time to complete TTO
HAQ 8 states 8 min (4.6min) -
MSIS 10 states 10 min (5.8min) -
QLQ 15 states 12.7 min (5.8min) -
¹ Statistics Netherlands, 2009 figures.
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modeling
TTO values were modeled for each of the three questionnaires with random effects 
mean prediction models. For the HAQ, using only the OMEP based health states had 
too much variation in TTO scores between respondents to estimate a model with 
significant predictors and logical negative signs for each of the dummy variables (in-
creasing negative decrements per item level of severity). Estimating the model on all 
the available data (thus including the ‘most observed’ states) yielded a well-functioning 
Figure 1A: Mean utility values of health states
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Figure 1B: Percentage of respondents that 
classifies a state as worse than dead
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Figure 4.1 a. mean utility values of health states, B. Percentage of respondents who classified a state 
worse than dead
MSIS = Multiple Sclerosis Impact Scale, HAQ = Health Assessment Questionnaire, QLQ = Quality of life ques-
tionnaire,
Table 4.4 Final random effects model characteristics
HAQ-PBM† MSIS-PBM* MSIS-PBM† QLQ-PBM
Random effects mean models
R† 0.94 0.68 0.78 0.88
MAE 0.028 0.034 0.04 0.033
MAE most observed states 0.022 0.057 0.043 -
Illogical sign or order of variables 0 0 0 0
Insignificant predictors 0 0 0 0
Possible range 0.32 - 1 0.40 - 1 0.42 - 1 0.34 - 1
* Model based on states from the orthogonal design
† Model based on states from the orthogonal design and the most observed states
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mean prediction model. The prefinal MSIS-29 model had insignificant predictors for 
three variables MSIS3; the pre-final QLQ-C30 model had insignificant predictors for 
two variables. In all instances merging the levels with the adjacent categories resolved 
the problem. Model characteristics are summarized in Table 4.4 and full models are 
presented in Table 4.5.
When the MSIS-29 prediction model was based on all the states (thus including the 
most observed states), the prediction error for the most observed states was reduced 
(MAE=0.043 compared to MAE=0.057). When the MSIS-29 TTO values were modeled 
without the ‘most observed’ states the utility values were generally higher which caused 
that the utility values of some of the ‘most observed’ states were overestimated (Figure 
4.2).
Table 4.5 coefficients of random effects models with TTo value as dependent variable
HAQ-PBM MSIS-PMB† QLQ-PMB
Coefficient Std. Err. Coefficient Std. Err. Coefficient Std. Err.
haq1_2 -0.005 0.001 ms1_2 -0.016 0.003 qlq1_2 -0.027 0.001
haq1_3 -0.031 0.002 ms1_3 -0.043 0.003 qlq2_2 -0.020 0.002
haq1_4 -0.121 0.002 ms1_4 -0.089 0.003 qlq2_3 -0.047 0.002
haq2_2 -0.029 0.001 ms2_2 -0.018 0.003 qlq2_4 -0.068 0.002
haq2_3 -0.091 0.002 ms2_3 -0.047 0.003 qlq3_3 -0.079 0.002
haq2_4 -0.144 0.002 ms2_4 -0.047 0.003 qlq3_4 -0.213 0.001
haq3_2 -0.042 0.001 ms3_3 -0.055 0.002 qlq4_2 -0.018 0.002
haq3_3 -0.055 0.002 ms3_4 -0.071 0.002 qlq4_3 -0.055 0.002
haq3_4 -0.213 0.002 ms4_2 -0.061 0.002 qlq4_4 -0.089 0.002
haq4_2 -0.022 0.001 ms4_3 -0.101 0.003 qlq5_2 -0.021 0.002
haq4_3 -0.041 0.002 ms4_4 -0.108 0.003 qlq5_3 -0.031 0.002
haq4_4 -0.074 0.002 ms5_2 -0.032 0.003 qlq5_4 -0.037 0.002
haq5_2 -0.016 0.001 ms5_3_4* -0.057 0.002 qlq6_2 -0.004 0.002
haq5_3 -0.038 0.002 ms6_2 -0.020 0.003 qlq6_3 -0.039 0.002
haq5_4 -0.044 0.002 ms6_3 -0.035 0.003 qlq6_4 -0.052 0.002
Constant 0.918 0.002 ms6_4 -0.059 0.003 qlq7_3 -0.009 0.002
ms7_3 -0.024 0.002 qlq7_4 -0.047 0.002
ms7_4 -0.038 0.002 qlq8_2 -0.008 0.002
ms8_2 -0.037 0.003 qlq8_3 -0.041 0.002
ms8_3 -0.059 0.003 qlq8_4 -0.060 0.002
ms8_4 -0.073 0.003 Constant 0.944 0.002
Constant 0.959 0.005
* Both ms5_3 and ms5_4 have the same decrement
† Msis model with most observed health states included
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comparability of mean utility values
In the four datasets, the developed CS-PBMs based on the models presented in Table 4.5 
produced higher mean utility score for patients than did the EQ-5D questionnaire (Table 
4.6). Especially the HAQ-PBM (mean = 0.91) had a much higher mean utility value than 
did the EQ-5D questionnaire (mean = 0.68). Furthermore, the difference between the 
mean EQ-5D questionnaire score in arthritis and the mean EQ-5D questionnaire score in 
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Figure 4.2 utility values for most observed msis states in patient dataset
Table 4.6 comparison of utility values derived from the new PBm measures with eq-5D and sF-6D
HAQ MSIS QLQ_MM‡ QLQ_NH‡
N 738 1,295 716 789
Mean utility (SD) [range]
EQ5D 0.68 (0.23) [-0.134 - 1] 0.62 (0.26) [-0.220 - 1] 0.74 (0.21) [-0.058 - 1] 0.73 (0.26) [-0.330 - 1]
SF6D 0.66 (0.10) [ 0.370 - 1] - - -
PBM* - 0.69 (0.13) [0.400 - 1] 0.84 (0.09) [ 0.440 - 1] 0.82 (0.11) [ 0.340 - 1]
PBM† 0.91 (0.09) [ 0.570 - 1] 0.67 (0.14) [0.420 - 1] -
Intraclass correlations
EQ5D-PBM*†  0.45 0.62 0.64 0.67
* Model based on states from the orthogonal or balanced design
† Model based on states from the orthogonal design and the most observed states
‡ MM= Multiple Myeloma, NH = Non-Hodgkin
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MS was 0.06 while the differences between the HAQ-PBM and the MSIS-PBM are 0.24. The 
QLQ-C30-PBM based utility values had the highest correlation with EQ-5D utility values. 
Both the MSIS-PBM and the QLQ-PBM, however, have increased sensitivity compared 
to EQ-5D. Where EQ-5D scores full health (a utility value of 1) the MSIS-PBM and the 
QLQ-PBM report decrements in utility for respectively 99 and 185 patients (Table 4.7).
comorbidities and side-effects
The HAQ-PBM could not discriminate between patients with and without comorbidity 
(other vascular disorders and psychiatric disorders) when EQ-5D could (Table 4.8). For 
arthritis patients with diabetes, hypercholesterolemia or thyroid disease the HAQ-PBM 
showed higher utility values for individuals with the disorder while EQ-5D signaled the 
expected direction of differences. The MSIS-PBM also showed higher utilities for patients 
with asthma and high blood pressure (rather than without) but this was concordant with 
the differences indicated by the EQ-5D questionnaire. Both the MSIS-PBM and the EQ5D 
picked up significant differences between MS patients with and without depression 
(p<0.05). In the non-Hodgkin’s lymphoma dataset, patients with side-effects and infec-
tions as result of treatment had lower (p<0.05) utility values in both EQ-5D and QLQ-C30 
than patient without side-effects and infections, except for hair loss. All significant dif-
ferences were at least half a SD except for comorbidity ‘depression’ in the MS dataset and 
‘other side-effects’ in the non-Hodgkin’s lymphoma dataset.
Discriminative ability and responsiveness
Utilities of all instruments decreased with an increase of severity as assessed by the 
clinical indicator (Table 4.9). The utilities of the HAQ-PBM, however, failed to distinguish 
between low and moderate disease activities. EQ-5D did so accurately. As has previ-
ously been shown, EQ-5D was unable to distinguish between categories 3, 4 and 5 on 
EDSS (15). This signifies the inability of EQ-5D to distinguish between fully ambulatory 
MS patients (EDSS 3) and patients whose disability is severe enough to impair full daily 
working activities (EDSS 5). The MSIS-PBM, of which the physical scale was known to be 
sensitive to changes between level 3 4 and 5, did pick up the deterioration in health. 
Table 4.7 msis-PBm and qlq-PBm have increased sensitivity at the ceiling of eq-5D
Total sample size EQ5D =1 EQ5D <1 Worst state for which EQ-5D = 1
738 HAQ-PBM < 1 n = 7 - 21211
HAQ-PBM = 1 - n = 252
1,295 MSIS-PBM < 1 n = 99 - 33111222
MSIS-PBM = 1 - n = 2
1,505 QLQ-PBM < 1 n = 185 - 24334324
QLQ-PBM = 1 - n = 4
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Neither the QLQ-PBM nor the EQ-5D adequately reflected the deterioration between 
level 0 and level 1 of the WHO performance status.
The QLQ-C30 was, in terms of effect-size measured with Cohen’s d, at times more, and at 
times less sensitive to changes over time (Table 4.10). However, the absolute differences 
indicated that even when the QLQ-PBM had a larger mean difference relative to the 
standard deviation, the EQ-5D still reported larger mean change scores.
Table 4.8 comorbidities and side-effects by PBm and eq-5D
HAQ-PBM EQ5D
Comorbidity No comorbidity Comorbidity No comorbidity
Mean (sd) Median Mean (sd) Median Mean (sd) Median Mean (sd) Median
Diabetes 0.92 (0.08) 0.90 0.89 (0.10) 0.89 0.66 (0.24) 0.79 0.71 (0.16) 0.78
Hyper-
cholesterolemia
0.90 (0.09) 0.88 0.89 (0.10) 0.89 0.57 (0.27) 0.65 0.72 (0.15) 0.78
Thyroid disease 0.90 (0.10) 0.89 0.89 (0.10) 0.89 0.60 (0.29) 0.71 0.72 (0.16) 0.78
Other cardiac disease 0.86 (0.05) 0.88 0.89 (0.10) 0.89 0.60 (0.21)   0.68* 0.72 (0.15)   0.78*
Psychiatric disorder 0.84 (0.13) 0.89 0.89 (0.10) 0.89 0.54 (0.30)   0.67* 0.72 (0.16)   0.78*
MSIS-PBM EQ5D
Comorbidity No comorbidity Comorbidity No comorbidity
Mean (sd) Median Mean (sd) Median Mean (sd) Median Mean (sd) Median
Depression 0.61 (0.12)   0.59* 0.68 (0.14)   0.68* 0.54 (0.26)   0.64* 0.63 (0.26)   0.67*
Asthma 0.67 (0.14) 0.71 0.67 (0.14) 0.68 0.63 (0.22) 0.68 0.62 (0.26) 0.67
HPB 0.68 (0.14) 0.73 0.65 (0.13) 0.68 0.64 (0.25) 0.64 0.60 (0.26) 0.67
QLQ-PBM EQ5D
Side-effects No side-effects Side-effects No side-effects
Mean (sd) Median Mean (sd) Median Mean (sd) Median Mean (sd) Median
Neurotoxicity† 0.76 (0.09) 0.76* 0.81 (0.09) 0.83* 0.56 (0.27) 0.65* 0.73 (0.25) 0.81*
Hair loss† 0.80 (0.08) 0.79 0.81 (0.10) 0.83 0.70 (0.23) 0.78 0.72 (0.26) 0.79
Nausea† 0.73 (0.13) 0.74* 0.81 (0.09) 0.83* 0.56 (0.31) 0.65* 0.72 (0.25) 0.81*
Other side-effects† 0.79 (0.09) 0.80* 0.81 (0.09) 0.83* 0.66 (0.23) 0.69* 0.72 (0.26) 0.81*
Infection No infection Infection No infection
Ear / Nose / Throat¹ 0.72 (0.11) 0.72* 0.81 (0.09) 0.83* 0.42 (0.32) 0.31* 0.73 (0.25) 0.81*
* = significant difference between comorbidities / no comorbidities at (p<.05) Wilcoxon sum rank test
† WHO grade ≥ 2
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Table 4.9 Discriminant validity
DAS28
HAQ-PBM EQ-5D
NMean SD Mean SD
Remission 0.98 0.04 0.76 0.20 11
Low DA 0.90 0.08 0.70 0.25 15
Moderate DA 0.90 0.09 0.67 0.22 70
High DA 0.83 0.07 0.51 0.29 27
EDSS
MSIS-PBM EQ-5D
NMean SD Mean SD
0 0.80 0.14 0.81 0.22 35
1 0.78 0.14 0.78 0.23 74
2 0.73 0.14 0.72 0.23 262
3 0.68 0.14 0.63 0.25 206
4 0.66 0.13 0.63 0.23 248
5 0.63 0.10 0.64 0.19 103
6 0.60 0.11 0.54 0.25 201
7 0.58 0.11 0.46 0.27 78
8 0.57 0.07 0.40 0.31 17
9 0.47 0.07 0.09 0.10 5
WHO
QLQ-PBM EQ-5D
NMean SD Mean SD
0 0.83 0.11 0.75 0.25 356
1 0.83 0.10 0.76 0.24 304
2 0.80 0.11 0.69 0.24 96
3 0.71 0.10 0.37 0.27 27
DAS-28 = Disease-activity score-28, EDSS = Expanded Disability Status Scale, WHO = World Health Orga-
nization
Table 4.10 responsiveness of utilities in non-hodgkin sample
Follow-up
Cohen’s d Mean change
QLQ-PBM EQ-5D QLQ-PBM EQ-5D
 2nd treatment cycle 0.13 0.17 0.02 0.05
 4th treatment cycle 0.02 0.08 0.00 0.02
 6th treatment cycle -0.09 -0.06 -0.01 -0.01
 3 months follow-up 0.33 0.22 0.03 0.06
 6 months follow-up 0.25 0.10 0.02 0.02
10 months follow-up -0.01 -0.09 0.00 -0.02
18 months follow-up 0.00 0.19 0.00 0.04
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Discussion
This study developed three CS-PBMs from existing questionnaires HAQ, MSIS-29 and 
QLQ-C30 to provide evidence concerning comparability of CS-PBM derived utility val-
ues with generic PBM-derived utility values. CS-PBMs had different mean utility values 
within a disease and did not report equal differences in mean utility values between 
diseases. The CS-PBMs in this study did not seem to exaggerate health problems, but 
rather reported higher mean values. Capturing comorbidities and along that line: 
side-effects of interventions appeared problematic for the HAQ-PBM, but not for MSIS-
PBM and QLQ-PBM. The MSIS-PBM and QLQ-PBM were more sensitive than the EQ-5D 
questionnaire to very mild impairments. The physical scale of the MSIS-29 questionnaire 
is known to be more sensitive in discriminating between clinical categories in multiple 
sclerosis than is the EQ-5D questionnaire. The MSIS-PBM, derived from the MSIS-29, also 
has better discriminatory properties.
Because the mean utility values of all three CS-PBMs were higher than those of generic 
instruments, it seems that a potential downward bias of a focusing effect may be smaller 
in size than the upward bias that results from a narrower scope of the condition spe-
cific measures. This is most clearly seen in the performance of the HAQ-PBM, which is 
developed from the HAQ-Disability Index which measures functional ability (91). Conse-
quently the HAQ-PBM indicates the utility decrements associated with these functional 
(dis)abilities. In the HAQ-PBM there is no dimension such as ‘pain’ or ‘psychological state’. 
Because pain is a frequently occurring symptom in arthritis, it is not surprising that the 
mean utility value of the early arthritis cohort as measured by the HAQ-PBM is much 
higher than the mean utility value of the generic instruments; any additional utility 
decrement besides functional disabilities, such as pain, is not captured directly, if at all. 
In the case of the HAQ, this result could have been anticipated based on the fact that 
the HAQ-Disability index aims to offer a unidimensional assessment of functionalities 
and does not attempt to measure other dimensions of health since these are captured 
by other instruments that are part of the minimum dataset internationally agreed on. 
The unidimensionality of the HAQ caused some problems in the valuation task. Because 
all items aim to measure the same underlying latent variable (functional ability) they 
are highly related. OMEP generated states have favorable statistical properties, but do 
not consider the sensibility of the combination of item levels. Consequently, one health 
state in the valuation study consisted of the counterintuitive combination “able to get 
up from a chair” and “not able to get up from the toilet”. This particular state caused 
confusion with some of the respondents.
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The HAQ-Disability index does not intend to form a comprehensive assessment of 
relevant disease specific health outcomes in patients with rheumatoid arthritis, and 
therefore could be rejected as offering a suitable basis for development of CS-PBMs. The 
large deviations in mean utility values presented in this study between the HAQ-PBM 
and EQ-5D support this view. More generally, it can be concluded that instruments with 
a narrow scope, often identifiable through inspecting items or dimensions, are unsuit-
able as a base for CS-PBMs used for resource allocation.
The perceived insensitivity of existing generic instruments is an important motive for 
developing CS-PBMs. In this study sensitivity of the CS-PBM and EQ-5D was compared 
by investigating ceiling effects and discriminative ability of the instruments between 
patients with and without comorbidity or side-effects. A ceiling effect found in EQ-5D 
for mild impairments was not found in the MSIS-PBM and QLQ-PBM (Table 4.7). One 
reason for this difference may be the descriptive system of the questionnaires: the three-
level system of EQ-5D might result in a lower likelihood of reporting problems than the 
four-level systems of the CS-PBMs. Nevertheless, using CS-PBMs did not result in an 
exaggeration of health problems on average when compared to generic instruments 
in this study. Rather, the mean utility value of MSIS-PBM and QLQ-PBM was higher than 
EQ-5D. This may be a reflection of the smaller range in obtainable utility values, which 
skews the average upwards. Bad EQ-5D health states reflect very poor health, which is 
perhaps not captured in MSIS-PBM and QLQ-PBM. Indeed, the negative range of utility 
values as produced for EQ-5D has rarely been reproduced for other instruments. EQ-5D, 
MSIS-PBM and QLQ-PBM performed equally well in distinguishing patients with comor-
bidities / side-effects from patients without it. Only the HAQ-PBM performed poorly in 
this aspect. Interestingly, the MSIS-PBM and the QLQ-PBM displayed equal discrimina-
tive ability as EQ-5D despite having a much smaller total scale size due to a higher ‘floor’ 
(i.e. the lowest attainable value).
Superiority of CS-PBMs compared to EQ-5D in regard to their discriminative ability is 
not demonstrated for HAQ-PBM and equivalence has been shown for QLQ-PBM. MSIS-
PBM showed better discriminative properties than did the EQ-5D questionnaire in EDSS 
subcategories. With additional evidence on known-group differences this could prove 
the MSIS-PBM to be a contribution to cost-utility analyses. The original preference-based 
questionnaire MSIS-29 was the only measure for which empirical evidence indicated 
better discriminative properties than EQ-5D in a multiple sclerosis data sets.
While a CS-PBM may have desirable statistical properties, such as expressed in effect-
size or the ability to identify significant differences between groups with or without side 
effects, partly due to a small SD of mean values, these properties may not be reflected 
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the absolute size of differences in utility values between groups. This has consequences 
for QALY computation. Imagine a new drug that reduces nausea from cancer treatments. 
Using the figures from Table 4.8, the population not having nausea would have a higher 
utility with an effect-size (Cohen’s d with pooled SDs) of 0.57 for EQ-5D but a larger 0.73 
for QLQ-PBM. The absolute difference, however, would be 0.16 for EQ-5D and 0.08 for 
QLQ-PBM. An implication of these results is that if a CS-PBM is developed in order to 
increase sensitivity compared to EQ-5D, statistical sensitivity is not a sufficient criterion.
Rather than due to concerns about the sensitivity of an existing generic PBM, a CS-PBM 
may also be developed because a PBM was not administered in, for example, a clinical 
trial. In this case one could also choose to use the variation in responses on a condition-
specific measure to estimate what a generic utility instrument like EQ-5D would have 
been had it not been absent, a process called mapping (32). It is important to reflect on 
the question which strategy for deriving utilities from a disease-specific instrument is 
most appropriate. The main difference between mapping and constructing a CS-PBM is 
that the development of a PBM assigns population weights (via TTO) to the item levels of 
a questionnaire, while a mapping function assigns weights to the items that are depen-
dent on the generic measure it aims to estimate. As such, issues with insensitivity of the 
generic instrument are not resolved when mapping a condition specific measure onto 
a generic PBM. In our view, a well conducted and validated mapping function may be 
preferred to the development of a CS-PBM, because it yields utility values that compare 
better to the more frequently used generic instruments used in other economic evalua-
tions, but only under the following circumstances: 1) there is no empirical evidence for 
insensitivity of the generic instrument, and 2) only use of mean utility values is intended 
rather than subgroup analysis (85) and 3) the health status or disease subtype of the 
sample on which the function was estimated is comparable to the sample on which the 
function is applied (111).
Findings here underline that the TTO health state values as modeled from a fractional 
factorial design can differ from direct TTO valuations of those states. Often but not always 
an OMEP is applied to allow the estimation of TTO values for all theoretically possible 
health states from only a fraction of health states. This study adopted that technique but 
also valued directly a selection of states that were observed frequently in patients. Using 
these states in the estimation of the preference algorithm resulted in lower scores for 
at least some of these states (Figure 4.1). These results suggest that discrepancies exist 
between modeled TTO values and directly observed TTO values for the most occurring 
health states which may affect the validity of the measure. Little guidance is available 
for researchers who wish to design a valuation study for a CS-PBM using state-of-the-art 
techniques, so it is not surprising that practices vary and this deserves more attention to 
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ensure that high quality CS-PBMs are produced. Ideally the process of constructing the 
CS-PBM is supported by the original developers of the questionnaires. This is relevant for 
example to avoid wild grow of value sets (e.g. for the QLQ-C30 now multiple value sets 
exists derived via mappings (90,100,111,117), to further guarantee quality, and to offer 
support to users of the CS-PBM .
Constructing and using a CS-PBM for the purpose of resource allocation could be consid-
ered when the following conditions are met: empirical evidence disproves sensitivity of 
existing generic instruments, empirical evidence proves the superiority of the condition-
specific measure from which the new preference-based measure will be derived, and 
the derived CS-PBM is shown to be superior to the existing CS-PBM, not just in terms of 
statistical sensitivity, but also in terms of absolute differences. The development of CS-
PBMs is welcome from an academic point of view as it pushes methodological frontiers 
and introduces new data for comparing measures in a field where no gold standard 
PBM exists. Use in resource allocation of these instruments, however, is only warranted 
when the above mentioned conditions are met. The introduction of preference-based 
measures which are specific to a certain disease has the presupposed merit of sensitivity 
to disease-specific effects of interventions, but this article shows that such an advantage 
is not necessarily achieved. Furthermore, the possible increase in sensitivity is traded 
off to the loss of comparability of absolute differences in utility values, which are most 
important for economic evaluations. It is argued here that without convincing empirical 
evidence on the insensitivity of a generic instrument, using a CS-PBM introduces confu-
sion about the appropriate outcome measures in cost-utility analysis and health-care 
decision making.
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suPPlemenTary maTerial
results from the process of item selection
Item selection: HAQ
The 20 items of the HAQ did not have disordered thresholds. The HAQ had some misfit 
to the Rasch model, caused by item 10 (‘wash body’) and 16 (‘open jar’) with significant 
fit residuals (>3). Removal of these items improved the fit of the scale to the Rasch model 
(Item fit residual = -0.37, SD = 1.36, Item trait interaction χ2=91, DF=90, p=0.44, Person 
separation index = 0.94). All remaining 18 items performed nicely in the Rasch model, 
and none of the remaining 18 items showed differential item functioning for gender or 
age group (consisting of two groups under and over the median age of 53).
Employing further psychometric criteria did not aid the selection of items as all HAQ 
items had >37% of the responses on the highest level. Linear correlation between 
individual HAQ items and EQ-5D index was <0.29, with an average of 0.21 (SD = 0.03) 
without any marked deviation.
On the basis of the analysis of three previous Rasch analyses (109,114,118) it was decided 
to go with the five items that are included in both the HAQ and its successor the HAQ-II. 
These items were ‘Get on and off the toilet’, ‘Open car doors’, ‘stand up from a straight 
chair’, ‘walk outdoors on flat ground’ and ‘reach and get down a five pound object (such 
as a bag of sugar) from just above your head’. The last item (5 pound object), is different 
in the Dutch translation of the HAQ, where 5 pounds is changed in to 1 kg, meaning that 
it represents less disability than the original item (3), which may yield a smaller utility 
decrement in a TTO study for that item than when using the original English version.
Item selection: MSIS-29
The Rasch analysis was applied separately for the physical and psychological function-
ing scales of the MSIS-29.Nearly all items of the physical scale showed difficulty for 
respondents to differentiate between the categories ‘a little’, ‘moderate’ & ‘quite a bit’ and 
some had reversed thresholds (no ordinal order of categories). All items were rescored 
to a 4-point scale merging ‘moderate’ with one of the adjacent categories. Rescor-
ing improved the fit considerably but the scale continued to misfit the Rasch model. 
Several items were deleted for different reasons (Table S4.1). Applying psychometric 
criteria suggested to the removal of item 17 ‘trouble using transport’ for which 45% of 
respondents reported no problems. Item 15 was retained despite 29% of respondents 
reporting no problems on the item, as removal worsened scale fit. The resulting scale 
was found to be unidimensional, showed no DIF and fit the Rasch model. On the basis 
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of the spread of difficulty represented by the item, and advice from the clinical expert, 
5 out of 8 items were selected for the vignette. The selected items are 4 (‘Problems with 
your balance’), 6 (‘Being clumsy’), 13 (‘Limitations in your social and leisure activities at 
home’), 15 (‘Difficulties using your hands in everyday tasks’), 16 (‘Having to cut down the 
amount of time you spent on work or other daily activities’).
The psychological scale of the MSIS-29 showed disordered thresholds for item 26. Items 
showed difficulty for respondents to distinguish between level ‘moderate’ and the two 
adjacent categories. All items were rescored to a 4-point scale merging either with the 
adjacent higher or lower level of level ‘moderate’. Rescoring slightly improved model 
fit. Table S4.1 shows the process of deleting items and the effect on the total fit of the 
psychological scale. The resulting items fit the Rasch model individually and as a scale, 
showed no DIF and were unidimensional. On the basis of the psychometric criteria, item 
22 (‘problems sleeping’) and 29 (‘feeling depressed’) were not considered to be a can-
didate for the selection on the vignette as 30% of respondents reported ‘no problems’. 
Item 28 was not considered for the vignette on the basis of spread of difficulty of the 
item. The linear correlation (R2) between the items (i) and sum of the other (not selected) 
items in the domain was used to inform a final decision. Linear correlation was high-
est (>.6) for item 25 (‘feeling anxious or tense’), 26 (‘feeling irritable, impatient or short 
tempered’) and 27 (‘problems concentrating’). Despite the high correlation for item 25, 
it was decided to go with items 26 and 27 as item 25 had a high fit residual (Fit. Res. 
-2.1, χ2(df=5)= 9.7, p=.08). Upon consultation of the clinical MS expert it was decided to 
add item 23 ‘feeling mentally fatigued’ to the final list, as this item was deemed a crucial 
element in MS.
Item selection: QLQ-C30
The QLQ-C30 questionnaire consists of five functional scales, nine symptom scales and 
one global health status. The aim of the item selection was to include only one item of 
each QLQ-C30 scale, and to have the health state represent all the dimensions identified 
by factor analysis. Rasch analysis was not performed on all of the scales, as some scales 
consist of only one item. Therefore, psychometric criteria combined with expert opinion 
were used as the main criteria for selection of the items.
A principal component analysis was performed on all items but global health status. 
The global health status scale is an assessment of the quality of life in general rather 
than a specific aspect of quality of life and was therefore not considered for the health 
state description. Five different factors were identified, which we summarize with the 
following factor identifiers: physical functioning, vitality, mental functioning, discomfort 
and pain (Table S4.2). The fourteen QLQ-C30 scales loaded on five factors. Within these 
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factors, we aimed to select items that belonged to different QLQ-C30 scales to obtain 
a maximum representation of relevant items that impact on quality of life. When items 
loaded on the same factor but belonged to different QLQ-C30 scales, we accepted a 
maximum correlation of 0.6 between the two items.
The 14 QLQ-C30 scales were rank ordered based on their linear correlation with the 
global health scale. An arbitrary cut off point was that scales had to explain 15% of the 
variance in the global health scale to be selected for the health state. Following this 
strategy the following QLQ-C30 scales were not considered for the vignette ‘Nausea and 
vomiting’, ‘Dyspnoea’, ‘Constipation’, ‘Diarrhea’ and ‘Financial difficulties’ Some of these 
scales consist of multiple items so items were also rank ordered on the percentage of 
variance explained on the global health scale and on their distribution of responses on 
the item levels. We based our final selection of items within a QLQ-C30 scale on this rank 
order. In one instance we deviated from our strategy. We chose to include ‘have you felt 
nauseated’ rather than ‘appetite loss’. Although the item ‘have you felt nauseated’ did 
not meet our prior requirements, the item ‘appetite loss’ was replaced with ‘have you felt 
nauseated’ on the advice of the cancer expert.
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aBsTracT
The purpose of this study was to assess the impact of acute myeloid leukemia (AML) and 
its treatment on health-related quality of life (HRQOL) by comparing the HRQOL of AML 
survivors with the HRQOL in the general population.
Two HRQOL questionnaires (EQ-5D and QLQ-C30) were sent to patients diagnosed with 
AML between 1999-2011 at a single academic hospital and still alive in 2012. HRQOL 
in AML survivors was compared with general population reference values. Multivariate 
analysis was used to identify factors associated with HRQOL in AML survivors.
Questionnaires were returned by 92 of the 103 patients (89%). AML survivors reported 
significantly worse functioning, more fatigue, pain, dyspnea, appetite loss and financial 
difficulties and lower EQ-VAS scores than the general population (P<0.05). Impaired 
HRQOL in AML survivors was mainly found in survivors without a paid job. Other factors 
associated with a poor HRQOL were allogeneic hematopoietic stem cell transplantation 
and the absence of social support.
This single-center study showed that the HRQOL in AML survivors is worse than the 
HRQOL in the general population. HRQOL in these patients can be improved by ad-
equately treating and preventing fatigue, pain, dyspnea and appetite loss.
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inTroDucTion
Treatment outcome of acute myeloid leukemia (AML) has improved over the past 
decades. This improvement can be attributed to changes in chemotherapy regimens, 
the introduction of allogeneic and autologous hematopoietic stem cell transplantation 
(HSCT), better supportive care to prevent treatment-related mortality and risk-adapted 
treatment approaches (119-121). As a consequence of the increasing number of AML 
survivors, it is becoming more important to assess the impact of AML and its treatments 
on health-related quality of life (HRQOL).
Health-related quality of life is a broad concept which covers different domains such 
as physical, mental, social and role functioning (122). Information about the impact on 
HRQOL can be used for different purposes. First, this information is useful for treatment 
allocation. Currently, treatment allocation in AML depends solely on the effectiveness 
of the different treatments in terms of survival (50). Due to the aggressive nature of 
the available treatments, HRQOL should be included as additional criterion in treatment 
decisions. Furthermore, HRQOL information also provides insight into specific health 
problems and treatment needs of patients with AML. The identification of these health 
problems can help in the effort to improve current treatments and develop new treat-
ment modalities (123,124).
Despite the importance of evidence-based information about HRQOL in patients with 
AML, only limited information of HRQOL in AML is currently available (53,125). A few 
studies have found that patients who received allogeneic HSCT had significantly worse 
HRQOL compared to those who received autologous HSCT or high-dose chemotherapy 
(54-56). Furthermore, it was found that HSCT recipients had poorer physical and mental 
health compared to the general population (126). However, only 22% of the patients in 
that study were treated for AML. Specific information regarding the impact of AML and 
its treatments on HRQOL is therefore lacking. The aim of our study was to compare the 
HRQOL of AML survivors with that in the general population. An additional aim was to 
gain further insight into the impact of AML on HRQOL by exploring factors associated 
with HRQOL in AML survivors.
PaTienTs anD meThoDs
Patient selection
Questionnaires were sent in 2012 to all AML patients who participated in clinical trials 
HOVON-29, HOVON-42(A), HOVON-43, HOVON-81, HOVON-92(127-131) between 1999 
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and 2011 and were diagnosed and had received first-line treatment at the Erasmus 
University Medical Center (Erasmus MC) in Rotterdam (N=103). Patients were only in-
cluded if they had still follow-up visits planned at the Erasmus MC. The main reasons for 
loss to follow-up were migration to other areas within or outside the Netherlands and 
scheduled follow-up visits in other hospitals closer to their homes.
Together with the questionnaires, patients received an invitation to participate by 
mail. Patients were informed that they gave permission to participate in the study by 
returning the questionnaire. The study protocol had been approved by the institutional 
medical ethics committee.
sociodemographic and clinical data
Sociodemographic data, including age, sex, education, employment status, living ar-
rangement and social support, were collected via the questionnaire. Social support 
was measured by asking whether the patient received social support from family and/
or friends. Clinical data were obtained via the HOVON Data Center, including date of 
diagnosis, last treatment received and leukemia recurrence.
quality of life measurement
HRQOL was measured with the EuroQol-5 Dimension (EQ-5D) and the European Orga-
nization for Research and Treatment of Cancer quality of life questionnaire (QLQ-C30). 
The EQ-5D is a generic quality of life questionnaire and consists of two parts: the EQ-5D 
descriptive system and the EQ - visual analogue scale (EQ-VAS). The descriptive system 
comprises five questions related to the dimensions ‘mobility’, ‘self-care’, ‘usual activities’, 
‘pain/discomfort’ and ‘anxiety/depression’ (132). The most recent version of the EQ-5D 
contains five response levels for each question (133,134). The descriptive system was 
converted to a health utility index with 0 representing death and 1 perfect health (135). 
The EQ-VAS asks respondents to rate their current health state on a scale from 0 (worst 
imaginable health) to 100 (best imaginable health).
The QLQ-C30 is a cancer-specific questionnaire and consists of 30 questions represent-
ing five functional scales (physical, role, cognitive, emotional and social functioning), a 
global quality of life scale and nine symptom scales (fatigue, nausea & vomiting, pain, 
dyspnea, insomnia, appetite loss, constipation, diarrhea and financial difficulties). All 
scale scores range between 0-100. A higher score on the functional scales and the global 
quality of life scale indicates a better quality of life, while a higher score on the symptom 
scales indicates more symptoms and thereby a poorer quality of life (89,136).
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hrqol in the general population
Published studies were used to estimate general population HRQOL for the patients in 
this study (137,138). The QLQ-C30 reference values were estimated by matching age 
and gender. The EQ-VAS reference values were calculated by using a regression adjust-
ment including age, gender, years of education, paid employment, income and living 
arrangement. Education and income were not measured in the AML population. In order 
to estimate general population values, it was assumed that the distribution of education 
and income was similar to the distribution in the general population. General popula-
tion values for the EQ-5D with five answer levels were not yet available.
exploration of factors associated with hrqol in patients with aml
Several factors that are possible associated with HRQOL in patients with AML have been 
identified based upon theoretical HRQOL models found in the literature (139,140). The 
following characteristics were included as predictor variables in the analyses: current 
age, gender, education level, living arrangement, leukemia recurrence, type of last 
treatment received, time since diagnosis, employment status and social support. These 
characteristics are either personal, environmental or biological factors which influence 
quality of life according to Wilson & Cleary (139) or personal or social support factors 
identified by Holland (140).
statistical analysis
Descriptive statistics were generated to describe the sociodemographic and clinical 
characteristics and the HRQOL scores of the study sample. The two sided (paired) t-
test and chi-square test were used to test for differences in patient characteristics and 
HRQOL scores between the AML survivors and the general population (significance 
criterion: P<0.05). Significant differences in QLQ-C30 scores ≥ 10 points were considered 
clinically relevant (141). Univariate analyses, using Mann-Whitney U test, Kruskal-Wallis 
test, Spearman rank correlation test, t-test or ANOVA, were used to assess whether sub-
groups with a poorer HRQOL could be identified.
Multivariate linear regression analyses using backward selection were performed to 
identify patient and clinical characteristics associated with the HRQOL in patients with. 
Correlation coefficients between all independent variables were evaluated to test for 
multicollinearity. No strong correlations existed between the variables, with exception 
of the correlation between age and retirement. These two variables were combined in 
the multivariate analyses. Three different groups were identified: age <=55 years, age 
>55 years and retired, age >55 years and not retired. Due to the small sample size and 
the exploratory nature of this study, only variables with a P-value > 0.1 were excluded. 
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Separate analyses were performed for the EQ-5D utility score, the EQ-VAS score and the 
different scales of the QLQ-C30.
A bootstrap sensitivity analysis was performed to assess the robustness of the results of 
the backward selection procedure (142). The backward selection procedure was repeat-
ed in 1000 bootstrap samples with 92 patients each (i.e., the number of patients in the 
original study population). These samples were randomly drawn with replacement from 
the original sample. We identified the total number of unique models in the bootstrap 
analysis as well as the most frequently selected model. Furthermore, we determined 
how often individual variables were included in the selected models.
resulTs
Patient characteristics
In total, 92 patients with AML (89%) returned the HRQOL questionnaire. The sociode-
mographic and clinical characteristics of the patients are shown in Table 5.1. The mean 
age in the AML sample was 52.7 years (median (range): 55(25-78) years). The age was 
comparable with the mean age in the QLQ-C30 reference population, but significantly 
higher than the mean age in the EQ-VAS reference population. No significant differences 
were found in living arrangement and gender between the AML sample and reference 
populations. The percentage of retired patients or patients with a paid job was signifi-
cantly lower in the AML study sample compared to the QLQ-C30 reference population. A 
large proportion of the AML patients without a paid job were unable to work due to the 
disease or other health problems. About 60% of the patients had received an allogeneic 
HSCT, either as part of the first line of treatment or following leukemia recurrence. In 
total, 18% of the patients in our cohort had experienced a leukemia recurrence.
generic health-related quality of life (eq-5D)
Only a minority of the patients reported problems with self-care (9%) and about a quar-
ter of the patients (27%) reported anxiety. Relatively speaking, patients more frequently 
reported pain and problems with usual activities or mobility. Less than 10% of the pa-
tients reported severe or extreme problems on any of the health dimensions (Figure 5.1).
The EQ-5D utility of all patients with AML in this study ranged from 0.21 to 1.0, with 
a mean of 0.82 (Table 5.2). The average EQ-VAS score of the patients was significantly 
lower than the predicted general population EQ-VAS (74.6 and 78.8, respectively). 
Patients aged < 65 years without a paid job had a significantly lower EQ-5D utility and 
EQ-VAS score compared to other patients (Table 5.3). The lower utility score was related 
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Table 5.1 Patient characteristics
AML 
patients
N=92
Healthy controls(137,138)
(QLQ-C30)
N=1,731
(EQ-5D)
N=2,367
Age (years)
Mean (SD) 52.7 (12.8) 52.9 (15.7) 48.4 (16.4)***
Median (Range) 55 (25-78)
Time since diagnosis (years)
Mean (SD) 5.9 (2.7)
Median (Range) 6 (2-13)
Time since last treatment (years)
Mean (SD) 5.3 (2.8)
Median (Range) 5 (1-12)
N % N % N %
Sex
Female 45 49 796 46 1,337 51
Male 47 51 935 54 1,030 49
Level of education
Elementary school or secondary education 28 30 774 44.7
Vocational school 37 40 318 18.4
University 26 28 635 36.7
Unknown 1 1 4 0.2
Employment status
Paid job 40 43 880 50.8**
Retired 19 21 439 25.4**
Other 32 35 412 23.8**
Unknown 1 1
Ethnicity
European 81 88
Other 9 10
Unknown 2 2
Living arrangement
Living with a partner 72 78 1,333 77 1,581 71**
Living without a partner 20 22 373 22 786 29**
Unknown 25 1
Presence of social support
Yes 87 96
No 4 4
Last treatment received
Chemotherapy 29 32
Autologous HSCT 9 10
Allogeneic HSCT 54 59
Relapse (%)
Yes 17 18
No 75 82
** Statistical significant at α = 0.05
*** Statistical significant at α = 0.01
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to more problems with mobility and usual activities and more anxiety/depression. Al-
logeneic HSCT, younger age and absence of social support were also associated with a 
lower EQ-VAS score.
cancer-specific quality of life (qlq-c30)
The majority of the patients with AML reported problems on the five functioning scales 
of the QLQ-C30 (Table 5.2). The average scores on all functioning scales were signifi-
cantly lower in patients with AML compared to adjusted general population scores. The 
differences in physical, role, cognitive and social functioning were also clinically relevant. 
Despite these differences, no significant difference was found for the global quality of 
life.
Table 5.2 qlq-c30 and eq-5D mean scores in aml survivors and the general population
n % reporting
problems
Mean score (SD)
AML patients
Predicted 
score general 
population*
Difference 
in score
P-value
QLQ-C30
Physical functioning 91 73 80.4 (18.7) 91.3 -10.9 a <0.0001
Role functioning 92 55 74.8 (26.9) 89.3 -14.5 a <0.0001
Emotional functioning 90 60 83.1 (20.2) 89.0 -5.9 0.0075
Cognitive functioning 90 61 77.6 (24.1) 92.7 -15.1 a <0.0001
Social functioning 89 57 81.3 (23.8) 94.5 -13.2 a <0.0001
Global quality of life 91 82 75.3 (19.5) 78.0 -2.7 0.1922
Fatigue 91 78 35.3 (27.6) 17.1 18.2 a <0.0001
Nausea/Vomiting 91 19 6.2 (18.4) 2.7 3.5 0.0688
Pain 91 47 21.8 (28.9) 14.8 7.0 0.0248
Dyspnoea 91 36 18.3 (27.3) 6.9 11.4 a 0.0002
Insomnia 90 39 19.6 (28.2) 13.8 5.8 0.0521
Appetite loss 91 21 9.2 (19.9) 3.2 6.0 0.0054
Constipation 90 12 5.2 (14.9) 4.5 0.7 0.6835
Diarrhoea 91 11 5.5 (18.1) 3.9 1.6 0.4167
Financial difficulties 90 33 19.2 (31.2) 3.1 16.1 a <0.0001
EQ-5D
EQ5D utility score 88 - 0.82 (0.17)
EQ VAS score 91 - 74.6 (17.4) 78.8 -4.2 0.0333
* The scores are matched according to relevant patient characteristics. These characteristics were sex and 
10-year age group for the QLQ-C30 and age (centered at median), sex, living arrangement, employment, 
education and household income for the EQ-VAS score. As years of education and income level were un-
known in the AML population, a weighted average was calculated for the EQ-VAS assuming a similar distri-
bution as in the general Dutch population, a Indicates a clinically relevant change (>10 points)
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Fatigue was the most frequently reported symptom in patients with AML (78%). Other 
frequently reported symptoms were pain, dyspnea, insomnia and financial difficulties. 
Patients with AML had significantly more problems with fatigue, pain, dyspnea and ap-
petite loss than the general population. Furthermore, financial difficulties were more 
frequently reported by patients with AML. Only the differences in fatigue, dyspnea and 
financial difficulties were clinically relevant.
Table 5.3 subgroup analysis for the three global quality of life measures
QLQ-C30 - QL EQ5D utility EQ-VAS
Age
<=55 years 72 P=0.02 0.81 P=0.39 72 P=0.01
> 55 years 78 0.83 78
Gender
Female 74 P=0.57 0.79 P=0.15 73 P=0.46
Male 76 0.85 76
Education level
Primary or secondary education 74 P=0.67 0.79 P=0.39 75 P=0.82
Vocational school 76 0.83 75
University 76 0.86 74
Living arrangement
Living without a partner 77 P=0.31 0.83 P=0.22 75 P=0.49
Living with a partner 71 0.77 72
Employment status
Paid job 80 P<0.01 0.88 P<0.01 80 P<0.01
Retired 81 0.81 79
Age < 65 years, no paid job 65 0.75 65
Social support
No social support 48 P=0.07 0.62 P=0.11 53 P=0.09
Social support 77 0.83 76
Time since diagnosis
<= 5 years 74 P=0.85 0.81 P=0.99 73 P=0.65
> 5 years 76 0.83 77
Last treatment received
High-dose chemotherapy/Autologous HSCT 81 P=0.02 0.83 P=0.77 78 P=0.08
Allogeneic HSCT 71 0.82 72
Relapse
No relapse 76 P=0.65 0.83 P=0.19 75 P=0.57
Relapse 72 0.78 73
QL = global quality of life scale, HSCT = hematopoietic stem cell transplantation
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Factors associated with quality of life in aml patients
The multivariate analysis showed that about 20-30% of the variance in scores on overall 
HRQOL could be explained by differences in patient and disease characteristics, includ-
ing age, employment status, social support and last treatment received (Table 5.4). The 
absence of a paid job was associated with a poorer HRQOL in almost all scales. Older, 
non-retired patients had better physical and role functioning scores and reported fewer 
problems with fatigue and dyspnea. Furthermore, a better overall HRQOL was indicated 
for these patients. The availability of social support was associated with better physical, 
role and social functioning, fewer symptoms of dyspnea, less financial difficulties and bet-
ter overall HRQOL. Patients who had received an allogeneic HSCT reported worse physical 
and social functioning, more problems with fatigue and dyspnea and a significantly lower 
overall HRQOL. Leukemia recurrence was not significantly associated with functioning 
or overall quality of life. However, patients with recurrence of leukemia reported fewer 
symptoms of diarrhea. A longer time since diagnosis was significantly associated with 
better social functioning and fewer problems with diarrhea, nausea and vomiting.
The bootstrap analysis resulted in 200-350 unique models selected by backward selec-
tion in the 1000 bootstrap samples. The models from the original patient sample (see 
Table 5.4) were selected in 2-16% of the bootstrap samples. Inconsistencies were mainly 
found in variables with a P-value close to 0.1 in the original model. Most variables in-
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cluded in the original model were selected in at least 50% of the bootstrap samples. 
Results for the three overall HRQOL scales are shown in Figure 5.2. The variable ‘no paid 
job’ was the most frequently selected variable for all three scales. The direction of the 
coefficients was not always consistent in the selected models. The inconsistency was 
larger for variables which were less often selected.
Discussion
This study is the first one to compare HRQOL in AML survivors with the HRQOL in the 
general population. We found that AML survivors reported more severe problems 
related to fatigue, pain, dyspnea and appetite loss. Furthermore, they reported more 
financial difficulties and a lower level of functioning than the general population.
The impaired HRQOL was especially found in patients without a paid job. The majority of 
these patients is unable to work due to health problems. This is an important problem as 
the group accounts for about 25% of all AML survivors in our study. Clinicians should try 
to identify and treat the underlying health problems to avoid problems with returning 
to work. HRQOL questionnaires such as the QLQ-C30 can be used as diagnostic tool to 
identify the existing problems.
This study showed that fatigue is one of the most frequently reported health problems in 
AML survivors. Fatigue is also an important problem in other cancer survivors (143,144). 
Recent systematic reviews and meta-analyses showed that exercise programs are able to 
reduce fatigue for cancer survivors and patients treated with HSCT (145,146). However, 
further research is required to identify which type of physical activity program is most 
effective to reduce fatigue in AML survivors.
This study also provides some insights into factors associated with HRQOL in AML. The 
following factors were associated with a poor HRQOL in our study: lack of social sup-
port, allogeneic HSCT as post-remission treatment and younger age. However, due to 
the insufficient power of this study no definite conclusions can be drawn. Nevertheless, 
some of our findings might be reasonable based upon other available evidence.
The relationship between social support and quality of life has frequently been observed 
in other cancer types.(147-149) Patients with social support might be better able to cope 
with the disease, and consequently, have fewer problems with performing social ac-
tivities than patients without social support. Consideration about how to improve social 
support is therefore worthwhile.
102 Chapter 5
A poorer HRQOL after allogeneic HSCT is also found by other studies (54-56). The im-
paired HRQOL is mainly caused by graft-versus-host-disease (150). An allogeneic HSCT is 
often the preferred treatment option because it has the highest anti-leukemic effect and 
thereby the highest cure rate (65). However, a meta-analysis showed that an allogeneic 
HSCT has no survival benefit for all patients (151). As several studies have shown that 
the HRQOL is also impaired after allogeneic HSCT, it is recommended to combine both 
mortality and HRQOL in a comparison of post-remission treatments. Further research 
in larger patient samples is required for more evidence about the impact of allogeneic 
HSCT on both mortality and HRQOL in different AML subgroups.
The association between younger age and poorer HRQOL is remarkable, because other 
studies have found a better HRQOL in younger AML survivors (55,56). An important 
difference between these studies and our study is that we also included patients aged 
>60 years at time of diagnosis. These patients might use different internal values in the 
assessment of their HRQOL than younger patients (152-154). Younger patients are ex-
pected to have a paid job and take care of their children, while older patients have fewer 
responsibilities. Consequently, the same health problems might make it more difficult 
for younger patients to fulfill their roles at home and at work.
Although expected at the start of this study, no significant association has been found 
between leukemia recurrence and poorer HRQOL. The absence of a significant associa-
tion might be related to the low number of survivors with a leukemia recurrence. The 
smaller the group of interest, the stronger the association needs to be in order to find 
a significant association. Furthermore, it is assumed that most patients with a leukemia 
recurrence have died and are therefore not included in this study. It might be possible 
that the patients who died had a poorer HRQOL than those patients who survived. 
However, longitudinal studies are needed to confirm these assumptions.
This study has several limitations. First, the AML survivors in the single academic hos-
pital might not be representative for all AML survivors. A relatively large proportion 
of the survivors in our sample received an allogeneic HSCT. It might be possible that 
these patients are less often referred to local general hospitals for follow-up than other 
patients with AML. However, the high response rate (89%) in this study supports the 
validity of our results within the single academic hospital. Further research in a larger 
study setting is required to generalize these results to a broader population.
Second, no adjustment for multiple testing was performed and a relatively high sig-
nificance level (0.1) was used to identify any possible associations between patient 
characteristics and HRQOL in our relatively small study sample. Consequently, some of 
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the associations found in this study are simply chance findings and our results need to 
be interpreted cautiously. This study should be viewed as a first exploration of factors 
associated with HRQOL in patients with AML and our findings should be replicated in 
other populations.
Finally, social support was not measured with a validated questionnaire including 
specific questions of the type of support. Instead, we asked generic questions about 
support from family and/or friends. These questions can be differently interpreted by 
the respondents which might bias the measurement of social support and its relation 
with HRQOL. For future studies, it is recommended to measure social support with a 
validated questionnaire, like the Social Provisions Scale, Inventory of Socially Supported 
Behaviors or ENRICHD Social Support Inventory (155).
This single-center study showed that the HRQOL in AML survivors is worse than the 
HRQOL in the general population. As the number of AML survivors will increase due to 
the improved survival rate, it becomes more and more important that new treatments 
not only focus on improvements in survival but also on improvements in HRQOL. Ac-
cording to the results of this study, most improvements are needed for the symptoms 
fatigue, dyspnea, pain, insomnia and for all functioning domains.
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acute leukemia patients? A comparison of 
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aBsTracT
The aim of this study was to assess the feasibility, validity and reliability of two recently 
developed preference-based instruments: the generic EQ-5D-5L and the cancer-specific 
QLQ-PBM, which is derived from the EORTC QLQ-C30, in patients with acute leukemia.
Questionnaires containing the EQ-5D-5L and QLQ-C30 were sent to patients who par-
ticipated in HOVON clinical trials between 1999 and 2011 at a single academic hospital 
and were still alive in 2012. Feasibility was assessed according to the frequency of in-
complete data. Validity was assessed by floor and ceiling effects, correlations with other 
quality of life scales and ability to distinguish between patients with different health 
status. Reliability was assessed by using the Cronbach’s alpha.
Questionnaires were returned by 89% (111/125) of the patients. Only six and seven 
respondents did not fully complete the EQ-5D-5L and QLQ-PBM, respectively. The ceil-
ing effect was much larger for the EQ-5D-5L than for the QLQ-PBM (31% versus 15%). 
Both questionnaires showed a good content validity according to strong correlations 
with other quality of life scales and both questionnaires were able to detect significant 
differences between patients with different health status.
This study showed evidence for the feasibility, reliability and discriminative ability of 
both preference-based questionnaires. The relatively high ceiling effect of the EQ-5D-5L 
is not considered a threat for the validity of the EQ-5D-5L in acute leukemia because 
the questionnaire was able to discriminate between relatively mild severity groups. 
However, our findings need to be confirmed in larger, longitudinal studies.
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inTroDucTion
Many different questionnaires are currently available to estimate health-related quality 
of life for use in economic evaluations. These questionnaires include generic question-
naires like the EQ-5D, the SF-6D and HUI3, as well as disease-specific preference-based 
measures (33). Furthermore, many algorithms have been developed to estimate generic 
preference-based utilities from disease-specific questionnaires (32). It has been shown 
that the utility values of the questionnaires differ due to differences in content of the 
questionnaire, valuation technique and study population (33,107,156-160). These dif-
ferences limit the comparability of economic evaluations if different questionnaires are 
used to calculate quality of life utilities. Therefore, the National Institute of Health and 
Care Excellence (NICE) in the UK has explicitly stated that the EQ-5D should be used to 
measure quality of life utilities, unless there is proof that the EQ-5D is not valid in the 
target population (161).
Evidence about the validity of the EQ-5D in acute leukemia patients is not yet available. 
Studies in other cancer types showed that the EQ-5D is a valid and reliable instrument 
to measure quality of life in cancer patients, although some concerns about content 
validity were reported (134,156,159,162-167). These concerns include the high percent-
age of patients reporting full health (ceiling effect) and the difficulty in detecting small 
changes in health. Since these shortcomings are also observed in other disease areas, 
the EuroQol group has recently developed the EQ-5D-5L, which has 5 instead of 3 levels 
(133).
Several studies have assessed the psychometric performance of the EQ-5D-5L by direct 
comparison with the 3 level instrument (EQ-5D-3L). These studies showed a significant 
reduction in ceiling effect for the EQ-5D-5L in both the general population and several 
disease populations, including cancer (168-170). Furthermore, it was shown that the 
new levels were useful additions to the instrument as the use of the new levels improved 
the discriminative ability of the instrument (168,169). Although these studies indicated 
an improved validity of the EQ-5D, information is needed regarding the validity of the 
EQ-5D-5L in comparison with cancer-specific questionnaires to adequately judge the 
validity of the EQ-5D-5L in specific cancer populations. At this moment, evidence is only 
available from one study which found that the EQ-5D-5L was non-inferior to the Func-
tional Assessment of Cancer Therapy-Breast (FACT-B) questionnaire in Korean breast 
cancer patients (171). Further studies are needed to confirm these findings in other 
cancer populations. Therefore, the primary aim of this study was to assess the feasibility, 
validity and reliability of the EQ-5D-5L in acute leukemia patients in comparison with 
the cancer-specific EORTC QLQ-C30 questionnaire. A secondary aim of this study is to 
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assess the validity of a cancer-specific preference-based instrument, the recently devel-
oped QLQ-PBM (158). This instrument could be used to measure health-related quality if 
EQ-5D-5L proved to be insufficiently valid in acute leukemia patients.
meThoDs
Patient selection
This study was a secondary analysis of a cross-sectional quality of life study (172). Ques-
tionnaires were sent to all acute leukemia patients who participated in clinical trials 
HOVON-29, HOVON-37, HOVON-42(A), HOVON-43, HOVON-70, HOVON-71, HOVON-81, 
HOVON-92 (127-130,173) between 1999 and 2011 and received first-line treatment 
at Erasmus University Medical Center (Erasmus MC) in Rotterdam, the Netherlands 
(N=125). Patients were excluded if no follow-up visits were planned in 2012 at Erasmus 
MC. The main reasons for loss to follow-up were migration away from the region (within 
or outside the Netherlands) and scheduled follow-up visits in other hospitals closer to 
their homes. Patients were informed that they would give permission to participate in 
the study by returning the questionnaire. The study was approved by the institutional 
medical ethics committee.
sociodemographic and clinical data
The questionnaire included questions about the age, sex, education, employment 
status and marital status of the patient. Clinical data, including date of diagnosis, last 
treatment received and leukemia recurrence, were obtained via the HOVON Data Center.
quality of life questionnaires and utility calculation
The EQ-5D-5L consists of the EQ-5D descriptive system and the EQ - visual analogue 
scale (EQ-VAS). The descriptive system includes five questions representing the dimen-
sions mobility, self-care, usual activities, pain/discomfort and anxiety/depression (132). 
All questions have a 5-level response scale (133,134). The utility values were derived from 
an interim value set based upon a cross-walk of the EQ-5D-5L onto the EQ-5D-3L (135), 
because the results of direct valuation studies were not yet available. The EQ-VAS is a 
rating scale ranging from 0 (worst imaginable health) to 100 (best imaginable health).
The QLQ-PBM is a shortened version of the EORTC QLQ-C30 version 2. The QLQ-C30 is a 
cancer-specific questionnaire and consists of 30 questions (89,136). The QLQ-PBM only 
includes 8 items (trouble taking a long walk, limited daily activities, pain, nausea, fatigue, 
difficulty in concentrating, worrying and interference with social activities). These items 
were selected according to criteria of Rasch analysis, psychometric analysis and expert 
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opinion. The QLQ-PBM health states were valued with the time-trade-off method by the 
general public (158). Since a newer version of the QLQ-C30 was included in the current 
study, the question about trouble taking a long walk was recoded to a binary (yes/no) 
question.
statistical analysis
The analysis of the psychometric properties of the two questionnaires included an 
analysis of the feasibility, validity and reliability of the questionnaires. The percentage 
of respondents with incomplete data was used as an indicator for the feasibility of the 
questionnaires. Incomplete data was defined as missing or inconclusive scoring of one 
or more items. The reliability was assessed using the Cronbach’s alpha to assess the 
internal consistency of the scale.
The validity of the two questionnaires was evaluated by the floor and ceiling effects, the 
correlation with other measures of quality of life and the ability to distinguish between 
patients with different health status. The floor and ceiling effects were defined as the 
percentage of patients reporting the worst and best score, respectively.
The other measures of quality of life included two general quality of life scales: the EQ-
VAS and the global quality of life scale of the QLQ-C30 (QL scale). Pearson or Spearman 
correlation coefficients were estimated between the dimension and utility scores of the 
two preference-based questionnaires and the general quality of life scales. We expected 
strong correlations between the preference-based questionnaires and the general 
quality of life scales (r>0.5) (174). Furthermore, Spearman correlation coefficients were 
estimated between the domains of the EQ-5D-5L and the QLQ-PBM to evaluate differ-
ences in content between the questionnaires.
Three different measures were used to distinguish patients with different health status. 
Both the EQ-VAS and QL scale were used as proxies for health status. Quartile scores 
were used to categorize these variables into four subgroups. Furthermore, patients 
aged <65 years were distinguished according to the self-reported ability to work. T-tests 
and ANOVA were used to test for significant differences in utility scores between the 
subgroups. Standardized effect sizes (ES) (Cohen’s d) were calculated by dividing the 
difference in quality of life utility of subsequent categories by the overall standard devia-
tion of the two categories. A small ES was defined as d<=0.2, a moderate ES as 0.2<d<0.5 
and a large ES as d>0.8 (174). All analyses were performed in SAS 9.2.
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resulTs
Patient characteristics
A total of 111 respondents returned the questionnaire (89%). The characteristics of the 
respondents are shown in Table 6.1. The respondents aged between 23 and 78 years with 
Table 6.1 Patient characteristics
N %
Ethnicity
  European 97 87
  Other 12 11
  Unknown 2 2
Gender
  Female 53 48
  Male 58 52
Level of education
  Elementary school or secondary education 32 29
  Vocational school 49 44
  University 29 26
  Unknown 1 1
Employment status
  Paid job 48 43
  Retired 21 19
  Other 41 37
  Unknown 1 1
Marital status
  Living with a partner 84 76
  Living without a partner 27 24
Last treatment received
  Chemotherapy 34 31
  Autologous HSCT 13 12
  Allogeneic HSCT 64 58
Relapse
  Yes 91 18
  No 20 82
Age (years)
  Mean (SD) 51 (13.4)
52 (23-78)  Median (Range)
Time since diagnosis (years)
  Mean (SD) 6 (2.7)
6 (2-13)  Median (Range)
SD = standard deviation, HSCT = hematopoietic stem cell transplantation
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a median of 52 years. The time since diagnosis ranged between 2-13 years with a median 
of 6 years. About half of the respondents were male. The majority of the respondents 
had a European nationality and lived with a partner. About 60% of the respondents had 
a paid job or were retired; the remainder mainly consisted of patients who indicated to 
be unable to work due to cancer.
Feasibility of the questionnaires
Incomplete data was found in six and seven respondents for the EQ-5D-5L and QLQ-
PBM, respectively. Only one respondent had incomplete data for both questionnaires. 
None of the respondents had incomplete data for all items of the questionnaire.
validity
A fairly large proportion of patients reported no problems on the individual items of 
the EQ-5D-5L and the QLQ-PBM (Figure 6.1). The largest ceiling effects are found for the 
‘self-care’ item of the EQ-5D-5L and the ‘nausea’ item of the QLQ-PBM. Overall, 31% of the 
respondents reported full health on the EQ-5D-5L compared to 14% for the QLQ-PBM. 
Of the patients in full health according to the EQ-5D-5L, 50-91% reported less than per-
fect health on the other quality of life scales (Table 6.2); the actual percentage depended 
on the scale used. These patients most frequently reported fatigue and problems with 
physical functioning on the QLQ-PBM. None of the patients reported the worst imagin-
able health according to the two instruments, but some patients reported the worst 
Table 6.2 quality of life for patients with perfect health according to the eq-5D-5l (n=31)
No perfect health Mean (SD) Median (Range)
N %
QLQ-PBM utility score 17 (57) 0.94 (0.06) 0.93 (0.84-1.00)
EQ-VAS 29 (91) 86.0 (13.0) 90.0 (35.0-100)
Global quality of life scale 16 (50) 91.4 (10.5) 95.8 (58.3-100)
QLQ-PBM domains
Physical functioning 10 (31)
Role functioning 2 ( 6)
Pain 1 ( 3)
Nausea 3 (10)
Fatigue 13 (42)
Cognitive functioning 7 (23)
Emotional functioning 5 (16)
Social functioning 6 (19)
SD = standard deviation
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score for individual items. The worst score was more frequently reported on items of the 
QLQ-PBM than on items of the EQ-5D-5L.
The mean utility score from the EQ-5D-5L was significantly lower than the mean utility 
score from the QLQ-PBM (0.83 and 0.85 respectively, p-value=0.005) (Table 6.3). In a 
subgroup analyses according to health status, significant differences between the utility 
scores of the two preference-based questionnaires were only found in the group with 
the poorest health status. In this group, the utility scores of the EQ-5D-5L were signifi-
0
10
20
30
40
50
60
70
80
90
100
Pe
rc
en
ta
ge
  o
f r
es
po
nd
en
ts
0
10
20
30
40
50
60
70
80
90
100
Pe
rc
en
ta
ge
 o
f r
es
po
nd
en
ts
a
B
Figure 6.1 Floor and ceiling effects of the individual items and utility scores of a. the eq-5D-5l and 
B. the qlq-PBm. 
The figure shows the percentage of patients with the best (dark grey) and worst scores (light gray)
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cantly lower than the utility scores of the QLQ-PBM. These differences can be explained 
by the differences in the minimum reported utility scores of the two instruments (0.21 
and 0.51 for the EQ-5D-5L and QLQ-PBM, respectively).
Table 6.3 utility scores for the two instruments, including the known subgroups analysis
EQ-5D-5L QLQ-PBM
P-value* P-value*
All patients
Mean score (SD) 0.83 (0.17)† 0.85 (0.11)
Median score (range) 0.85 (0.21-1) 0.87 (0.51-1)
Severity by EQ-VAS - Mean (SD)
EQ-VAS Q1 (EQ-VAS:  0 -  65) 0.69 (0.20)†
P<0.001
0.76 (0.10)
P<0.001
EQ-VAS Q2 (EQ-VAS: 65 -  80) 0.80 (0.14) 0.83 (0.06)
EQ-VAS Q3 (EQ-VAS: 81 -  90) 0.85 (0.14) 0.86 (0.08)
EQ-VAS Q4 (EQ-VAS: 92 - 100) 0.96 (0.06) 0.95 (0.05)
ES - EQ-VAS Q2 vs EQ-VAS Q1 0.65 0.91
ES - EQ-VAS Q3 vs EQ-VAS Q2 0.33 0.38
ES - EQ-VAS Q4 vs EQ-VAS Q3 0.97 1.25
Severity by QL - Mean (SD)
QL Q1 (QL:  0.0 -  66.6) 0.69 (0.18)†
P<0.001
0.76 (0.11)
P<0.001
QL Q2 (QL: 66.7 -  83.3) 0.77 (0.15) 0.82 (0.06)
QL Q3 (QL: 83.4 -  91.6) 0.87 (0.14) 0.88 (0.09)
QL Q4 (QL: 91.7 - 100.0) 0.96 (0.06) 0.95 (0.05)
ES - QL Q2 vs QL Q1 0.52 0.65
ES - QL Q3 vs QL Q2 0.65 0.77
ES - QL Q4 vs QL Q3 0.87 0.97
Severity by ability to work - Mean (SD) ‡
Not able to work 0.75 (0.17)†
P=0.001
0.81 (0.11)
P=0.0003
Able to work 0.89 (0.14) 0.89 (0.09)
ES 0.71 0.74
QL = global quality of life scale of the QLQ-C30, ES = effect size,
*= comparison of utility scores between severity subgroups,
†= significantly different from the QLQ-PBM utility score (α=0.05)
‡= restricted to patients aged < 65 years
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Both the EQ-5D-5L and QLQ-PBM utility score were strongly correlated with the EQ-
VAS and QL scale (Table 6.4). Similar domains of the EQ-5D-5L and QLQ-PBM were 
also strongly correlated with each other. Furthermore, most domains were strongly 
correlated with the overall quality of life scales, with the exception of the self-care and 
anxiety/depression dimensions of the EQ-5D-5L and the nausea and cognitive function-
ing domain of the QLQ-PBM. It is expected that the weak to moderate correlations for 
these domains were mainly caused by the small variance in responses.
Both instruments were able to distinguish between patients with different health status, 
with higher utilities for poorer health status (Figure 6.2, Table 6.3). However, full health on 
the EQ-5D-5L was reported in all health status categories, while lower utility scores were 
reported by the QLQ-PBM (Figure 6.2). Although the absolute differences in QLQ-PBM 
utilities between health status categories were smaller than the differences in EQ-5D-5L 
utilities, the ES’s were larger for the QLQ-PBM due to the smaller variance. Nevertheless, 
all calculated ES’s were categorized as strong ES (larger than 0.5), except for the ES’s of 
detecting differences between the second and third quartile of the EQ-VAS.
reliability
Both questionnaires showed good internal consistency since Cronbach’s alpha was 0.81 
and 0.84 for the EQ-5D-5L and the QLQ-PBM, respectively.
Table 6.4 correlation coefficients between the quality of life instruments.
EQ-5D-5L EQ-VAS QL-scale
Mobility Self-care Daily
activities
Pain/
Discomfort
Anxiety/
Depressed
Utility
score
Q
L
Q
-
P
B
M
Physical functioning 0.70 0.25 0.57 0.63 0.36 -0.69 -0.68 -0.68
Role functioning 0.68 0.35 0.70 0.67 0.41 -0.77 -0.68 -0.67
Pain 0.60 0.18 0.47 0.75 0.33 -0.70 -0.53 -0.49
Nausea 0.21 0.20 0.20 0.09 0.26 -0.20 -0.24 -0.31
Fatigue 0.40 0.05 0.55 0.42 0.27 -0.50 -0.59 -0.64
Cognitive functioning 0.28 0.13 0.40 0.21 0.34 -0.36 -0.34 -0.35
Emotional functioning 0.32 0.14 0.43 0.29 0.51 -0.45 -0.55 -0.62
Social functioning 0.51 0.24 0.64 0.44 0.34 -0.58 -0.49 -0.56
Utility score -0.67 -0.28 -0.75 -0.65 -0.44 0.78 0.70 0.69
EQ-VAS -0.58 -0.22 -0.65 -0.53 -0.41 0.60
QL scale -0.56 -0.31 -0.67 -0.55 -0.53 0.68
The highlighted correlations indicate strong correlations (i.e. correlations larger than |0.5|). The correlations 
between domain scores and overall quality of life are negative, because a higher domain score indicates a 
worse quality of life
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Figure 6.2 Distribution of utility scores per health status category. a. eq-5D-5l utilities in the eq-vas 
quartiles, B. qlq-PBm utilities in the eq-vas quartiles, c. eq-5D-5l utilities in the global quality of 
life scale (ql) quartiles, D. qlq-PBm utilities in the ql quartiles, e. eq-5D-5l utilities according to 
ability to work, F. qlq-PBm utilities according to ability to work.
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Discussion
This study showed some evidence for the feasibility, validity and reliability of both the 
EQ-5D-5L and the QLQ-PBM in acute leukemia patients. Both questionnaires had strong 
correlations with other quality of life scales and were able to discriminate between 
patients with different health status. Furthermore, the percentage of missing data was 
acceptably low for both questionnaires. The only concern about the validity is the high 
ceiling effect of especially the EQ-5D-5L. In total, 31% of the respondents reported full 
health on the EQ-5D-5L. The ceiling effect was much smaller for the QLQ-PBM (14%).
The high ceiling effect of the EQ-5D-5L might imply that the EQ-5D-5L is not able to 
detect all relevant differences in health as 50% of the respondents with perfect health 
according to the EQ-5D-5L reported problems in at least one of the QLQ-PBM dimen-
sions. However, it can also be argued that the explicit focus on specific problems in 
the QLQ-PBM results in a focusing effect and thereby exaggerates the severity of these 
problems (105). The focusing effect might occur in this study population as the popula-
tion is relatively healthy. The lowest quartiles of both the EQ-VAS and QL scale included 
scores up to 65 (on a 0-100 scale). Despite the relatively good health and the small differ-
ences in EQ-VAS and QL scores between the quartiles, the EQ-5D-5L was able to detect 
significant differences between these quartiles. Therefore, it is concluded that the high 
ceiling effect of the EQ-5D-5L is not problematic in this study population.
This study also showed that the differences in utility scores between health status 
categories were smaller for the QLQ-PBM compared to the EQ-5D-5L. Consequently, a 
similar improvement in health status will be valued differently depending on the type 
of questionnaire used to estimate utilities with smaller QALY gains and incremental 
cost-effectiveness ratios (ICER) for the QLQ-PBM. Similar patterns are found for other 
disease-specific preference-based instruments (33,156,159). In general, differences in 
utility scores between preference-based questionnaires can be explained by differences 
in the descriptive content, valuation method and scoring algorithm of the question-
naires (107).
An important difference in descriptive content between the EQ-5D-5L and the QLQ-PBM 
is the focus of the questionnaires. As the QLQ-PBM is specifically focused on cancer pa-
tients, more cancer relevant domains are included. For example, the QLQ-PBM includes 
cognitive functioning and vitality while these domains are not explicitly measured by 
the EQ-5D-5L. The lack of these domains in the EQ-5D is a well-known problem (159,175) 
and research is ongoing to evaluate whether and how the EQ-5D can be extended with 
these and other relevant domains (166,176-179). In contrast, the cancer-specific focus 
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of the QLQ-PBM might exclude the impact of comorbidities and side effects on quality 
of life (105,158). Other differences in descriptive content are related to differences in 
the formulation of items. The conceptualization of some domains differs between the 
EQ-5D-5L and QLQ-PBM (for example, walking around versus taking a long walk). Fur-
thermore, differences are found in the formulation of the worst level (unable to versus 
many problems) and the recall period (today versus last week).
The major difference in valuation method is that the utility values of the EQ-5D-5L were 
not directly valued by the general public, but derived from the EQ-5D-3L (135). However, 
the valuation method of the EQ-5D-3L was similar to the method used in the valuation 
of the QLQ-PBM (87,158). It is therefore expected that the valuation method has a lim-
ited impact on the difference in utility values. Finally, differences in utility values might 
also result from differences in the scoring algorithm. The scoring algorithm of the EQ-5D 
includes an additional decrement if any of the domains is scored at the worst level, while 
the QLQ-PBM does not include this additional decrement (158).
The relatively good health seen amongst the patients in this study is probably a con-
sequence of including acute leukemia survivors (172). It is assumed that survivors are 
relatively healthy compared to non-survivors as survivors were able to ensure both the 
disease and its intensive treatment. Furthermore, survivors could have adapted them-
selves to their new situation. Consequently, they would report relatively good health 
due to changes in their standards and values (response shift) (153,180). The response 
shift might differ between the EQ-5D-5L and the QLQ-PBM due to differences in the for-
mulation of items. It is expected that a larger response shift would result in higher ceil-
ing effects. Future validation studies should disentangle response shift from objective 
changes in health (180,181) to better interpret the differences between questionnaires.
This study has several limitations. First, the utility values for the EQ-5D-5L were based 
upon a cross-walk study of the EQ-5D-3L, because directly elicited preferences were not 
available at the time of this study. However, it is unlikely that this could have biased the 
results of this study since it is unlikely that directly elicited preferences would result in 
substantially different utilities. Another limitation of this study is that patients completed 
the questionnaires only once, making it impossible to evaluate the responsiveness of 
the EQ-5D-5L and the QLQ-PBM in acute leukemia patients. Furthermore, health status 
was only defined according to self-reported health status and ability to work. Although 
these subjective measures provide useful information about the construct validity of 
the questionnaires, these measures are not perfect in defining different levels of health 
status. It is worthwhile to assess the ability to distinguish between health status accord-
ing more objective measures. Finally, the study only included acute leukemia survivors. 
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It might be possible that the measurement properties differ between survivors and 
patients receiving active treatment.
Although this study did not produce any strong evidence against the use of the EQ-
5D-5L in acute leukemia, final conclusions cannot yet be drawn since this study did not 
cover all aspects of the validity of the EQ-5D-5L. Future studies in acute leukemia should 
address these gaps by studying the quality of life of patients receiving active treatment 
as well as assessing the responsiveness of the questionnaire over time. Furthermore, it is 
recommended to use a more objective measure of health status, like physician-reported 
ECOG performance status or relapse versus remission. As long as these additional stud-
ies confirm our findings, the EQ-5D-5L is recommended to measure quality of life utility 
for acute leukemia patients.
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aBsTracT
The treatment of acute myeloid leukemia (AML) is moving towards personalized medi-
cine. However, due to the low incidence of AML, it is not always feasible to evaluate the 
cost-effectiveness of personalized medicine using clinical trials. Decision analytic mod-
els provide an alternative data source. The aim of this study was to develop and validate 
a decision analytic model that represents the full disease course of AML.
We used a micro simulation with discrete event components to incorporate both patient 
and disease heterogeneity. Input parameters were calculated from patient-level data. 
Two hematologists critically evaluated the model to ensure face validity. Internal and 
external validity was tested by comparing complete remission (CR) rates and survival 
outcomes of the model with original data, other clinical trials and a population-based 
study.
No significant differences in patient and treatment characteristics, CR rate, 5-year overall 
and disease-free survival were found between the simulated and original data. External 
validation showed no significant differences in survival between simulated data and 
other clinical trials. However, differences existed between the simulated data and a 
population-based study.
The model developed in this study is proved to be valid for analysis of an AML popula-
tion participating in a clinical trial. The generalizability of the model to a broader patient 
population has not been proven yet. Further research is needed to identify differences 
between the clinical trial population and other AML patients and to incorporate these 
differences in the model.
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inTroDucTion
The treatment of cancer is currently shifting towards a more personalized treatment 
approach. In general, treatment has always been personal because it has always been 
adjusted to a patient’s individual characteristics and health status. However, as a result of 
the Human Genome Project, new methods are available to further study disease biology 
and variability between patients (182). Many studies have applied these new methods 
and found significant associations between genetic abnormalities and drug response 
or patient prognosis (183-187). These results provide useful information for treatment 
decisions. A familiar example of these new methods is found in estrogen-positive breast 
cancer, where multi-gene assays are able to identify patients who will benefit from 
chemotherapy and those who will not benefit. Consequently, the treatment choice for 
a patient with estrogen-positive breast cancer can depend on the results of the micro-
array (188).
The personalized treatment approach also plays an increasingly important role in 
the treatment of acute myeloid leukemia (AML). AML is a relatively rare blood cancer 
caused by a proliferation of myeloid cells in the bone marrow resulting in a shortage of 
blood cells. The annual incidence of AML is approximately 3-4 per 100,000 (58). AML is 
a heterogeneous disease consisting of many (cyto)genetic subgroups with prognostic 
significance. Currently, patients can be classified into distinct prognostic groups based 
on the presence of cytogenetic and molecular abnormalities. A common way of stratify-
ing patients according to risk considers three prognostic categories (26). Several treat-
ment approaches are available, including various forms of high-dose chemotherapy, 
autologous and allogeneic hematopoietic stem cell transplantation (HSCT). Treatment 
choice differs between the three prognostic risk groups (21). The most hazardous treat-
ments associated with substantial procedure related mortality, e.g. allogeneic HSCT, are 
restricted to patients with intermediate or high risk of relapse (189).
In recent years, new molecular subtypes of AML have been identified with new tech-
nologies. Retrospective studies have found a significant association between these new 
subtypes and prognosis (185,190,191). The translation of these findings into clinical 
practice requires an assessment of the clinical utility, which is the impact on health and 
economic outcomes (192). Preferably, clinical utility should be evaluated in randomized 
controlled trials (RCTs), because RCTs minimize bias by controlling for both known and 
unknown factors which might influence outcome (193). Results of RCTs evaluating the 
impact of the newly developed genetic tests on health outcomes are not yet available. 
In addition, it is questionable whether sufficiently powered RCTs can be performed in 
the future due to the low incidence of AML and its subtypes. Furthermore, it might be 
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unethical to perform an RCT and expose patients to a non-beneficial treatment if retro-
spective studies have shown that patients with a certain genetic deficit do not benefit 
from that treatment (194). The use of decision-analytic modeling provides an alternative 
method to assess the clinical utility of these new genetic tests in absence of RCT results. 
In a decision model, evidence from genomic, clinical and epidemiological data is syn-
thesized to evaluate the risks and benefits of the new tests. In addition, decision models 
enable scenario analysis to evaluate the uncertainty surrounding the clinical utility (37).
Decision models used to evaluate new genetic tests should represent the full disease 
course from diagnosis till death in order to incorporate all relevant clinical effects of 
new tests. Currently available models for AML have only focused on specific parts of 
the disease course (195-198). Consequently, a new model representing the full disease 
course of AML should be developed. Therefore, the aim of this study was to develop a 
decision model representing the full disease course of AML from diagnosis. This paper 
also transparently describes the validation process of the model, which is an essential 
part in the development of a new decision model (199,200).
meThoDs
The development and validation of the decision model was an iterative process. The 
complete development and validation process is shown in Figure 7.1. The first step in 
the development of the decision model was the design of the model structure. Once 
the model structure was designed, the input parameters were calculated from original 
patient-level data. The patient-level data consisted of a representative sample (N=427) 
of AML patients treated according to protocols of the Dutch-Belgian Hematology-On-
cology Cooperative group (Hovon 4,29,42 and 42A, available at www.hovon.nl).(189) All 
of these patients were diagnosed with AML between 1987-2005. Patients received two 
induction chemotherapy cycles consisting of daunorubicin and an anthracycline. The 
treatment arms differed regarding the administration of granulocyte colony-stimulating 
factors and the dosing of chemotherapy. Post-remission treatment depended on the 
patient’s risk of relapse. Favorable risk patients received high-dose chemotherapy, 
intermediate and unfavorable risk patients with a suitable donor received an allogeneic 
HSCT and the other patients received either high-dose chemotherapy or autologous 
HSCT.
The results of the data-analysis were discussed with clinical experts and compared with 
the available literature. If necessary, the data-analysis was refined according to evidence 
in the literature or expert opinion. The model was run once all input parameters were 
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7in accordance with expert opinion and the available literature. The main results of the model were patient characteristics, complete remission (CR) rate, overall survival (OS) 
and disease-free survival (DFS). These outcomes were discussed with the clinical experts 
and compared with the original patient-level data and data sources. Adjustments were 
made to the model if the simulated results deviated from these data sources. All differ-
ent steps are explained in more detail below.
Designing model structure
Disease characteristics
Important disease characteristics were derived from the literature and discussions with 
clinical experts. AML is a heterogeneous disease with a variable prognosis that can be 
distinguished according to a variety of patient and disease related factors at diagnosis 
(26,201). For instance cytogenetic abnormalities present at baseline represent a major 
set of prognostic factors. A risk group classification has been developed which classi-
Figure 7.1 schematic description of the development and validation process
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fies patients into three risk groups according to the presence of specific cytogenetic 
abnormalities (64). Prognosis of AML also becomes less favorable with increasing age 
(13). The poorer prognosis in older patients is caused by comorbidities, different disease 
biology and poor tolerance of chemotherapy (201). High white blood cell (WBC) count 
at diagnosis and AML appearing after other hematological disorders or after previous 
chemotherapy and/or radiotherapy (so called secondary leukemia) are also associated 
with a worse prognosis (202,203).
AML treatment starts with intensive chemotherapy (consisting of cytarabine and an 
anthracycline) to induce a complete remission (CR) by cytoreduction of the number of 
leukemic blasts (64). The induction treatment consists of two chemotherapy cycles of 
about one month each. After each cycle, response evaluation is performed to evaluate 
whether a CR (less than 5% blasts in the bone marrow, disappearance of any known 
leukemic deposits and recovery of blood cell counts) is reached (26,204). This evalua-
tion is scheduled at day 21 as counted from the start of the chemotherapy cycle and 
will be repeated if the marrow is not conclusive. All patients receive the second cycle, 
irrespective of the response after the first cycle. Patients without a CR after two cycles 
have refractory leukemia. These patients have a very poor prognosis with limited treat-
ment options. Some patients are eligible for an allogeneic HSCT, but the majority of the 
patients receive investigational therapy or palliative care (198).
Patients in CR and with a good performance status receive additional post-remission 
treatment to further remove leukemic blasts; these options include high-dose chemo-
therapy, autologous and allogeneic HSCT (26,204). In general, an HSCT is not adminis-
tered to patients with abnormalities which are associated with a favorable prognosis, 
because the benefits of an HSCT do not offset the treatment-related mortality in these 
patients. Patients with intermediate or unfavorable abnormalities are more likely to 
benefit from HSCT (189,205). Despite intensive treatment, the risk of disease relapse is 
still quite high, especially in patients with unfavorable abnormalities, older age and high 
WBC counts. In addition, patients who did not achieve a CR after 1 cycle have a higher 
risk of relapse (206). Prognosis of relapsed patients is poor; 5-year overall survival is 11%. 
Important prognostic factors for survival after relapse are duration of first remission, 
cytogenetic and molecular abnormalities at time of diagnosis, age at time of relapse, 
HSCT in first CR and achievement of a second CR (207).
Model structure
The above described disease characteristics of AML show that AML is a heterogeneous 
disease with several patient- and disease-related factors influencing the chance of CR 
and the risk of relapse and death. In addition, prognosis also depends on patient’s 
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history regarding response to induction chemotherapy and duration of first CR. As the 
inclusion of all relevant prognostic factors in a cohort model would require many differ-
ent health states, a micro simulation with discrete event components was considered 
more efficient in modeling the disease course of AML (208).
The entities in this model were patients with primary AML aged 18-60 years. The model 
focused on this age group, because it is expected that genetic tests provides the most 
value in that age group at this moment. Various treatments are available for this age 
group and the use of genetic tests might change treatment for specific patients due to a 
reclassification of the risk groups. In older patients, treatment is overall far less satisfac-
tory and outcome following different treatments vary within a much smaller range (64). 
Treatment choice in older individuals is more strongly driven by the patient’s perfor-
mance status. Therefore, genetic tests will currently not be used to guide treatment for 
patients older than 60 years. The model was restricted to patients with primary AML 
because the number of patients with secondary AML was limited in the available data-
base. Finally, the current model excluded patients with acute promyelocytic leukemia as 
these patients are treated differently than other AML patients (204).
Relevant attributes of AML patients were cytogenetic risk group, age, sex, WBC count, 
number of cycles needed to achieve CR, post-remission treatment and time to relapse. 
Three cytogenetic risk groups were identified according to the classification proposed 
by Döhner et al.(26): favorable, intermediate and unfavorable risk group. WBC count 
was dichotomized in two categories: low (WBC count < 100 x 10^9/l) and high WBC 
count (WBC >= 100 x 10^9/l)(26). The post-remission treatment options were no post-
remission treatment, intensive chemotherapy, autologous HSCT, allogeneic HSCT from 
sibling donor, allogeneic HSCT from a matched unrelated donor (MUD) and umbilical 
cord blood (UCB) transplantation.
In general, four different events were identified for AML: CR, relapse, second CR and 
death. The achievement of a (second) CR was only evaluated after (re-)induction treat-
ment. Patients were considered to have refractory disease if they had not achieved a CR 
after two induction cycles. Consequently, a continuous survival function for CR achieve-
ment does not provide an accurate reflection of the natural disease course. Therefore, 
it was first determined whether patients achieved a CR, followed by the determination 
of the time to CR. Two different types of deaths were identified: death due to AML and 
death from other causes. Both types of death could occur at different disease stages: 
before CR (in patients never achieving CR), after CR and after relapse.
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The total structure of the decision model is described in Figure 7.2. At the start of the 
simulation a new patient was simulated and the attributes risk group, gender, WBC 
count and age were assigned to that patient. Subsequently, it was determined whether 
or not the patient achieved a CR. If no CR was achieved, time to death was estimated. 
Once a patient achieved a CR, the CR-specific attributes post-remission treatment and 
number of cycles needed to achieve a CR were assigned to the patient and the time to 
relapse and death after CR were calculated. A patient relapsed if the time to relapse was 
shorter than the time to death after CR. In relapse, age was updated. Subsequently, it 
was determined whether a second CR was achieved, followed by the calculation of time 
to death.
calculation of attributes and time-to-events
Patient-level data was used to calculate input parameters for the model. First, it was 
evaluated whether age, gender, WBC count, risk group and post-remission treatment 
were correlated with each other. No significant correlations were found between 
gender and the other patient characteristics. The distributions for WBC count and 
post-remission treatment differed between the three risk groups and patients in the 
favorable risk group were significantly younger than patients in the other risk groups. 
Subsequently, frequency distributions and summary statistics of all characteristics were 
derived from the patient-level data. The frequency distributions for age, WBC count and 
post-remission treatment were derived for each risk group separately.
Logistic regression analyses were performed for achievement of (second) CR and 
whether a CR was achieved after the first chemotherapy cycle. All patient, disease and 
treatment characteristics were included as covariates in the regression models. Non-sig-
WBC = white blood cell ; CR = complete remission
No
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Yes
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Figure 7.2 model structure
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nificant covariates were excluded from the model using backwards selection. However, 
if exclusion of a non-significant covariate resulted in higher Akaike Information Criteria 
(AIC) scores, this covariate was retained in the model. The final model according to the 
above-mentioned statistical criteria was compared with the literature about factors as-
sociated with achievement of a (second) CR and number of cycles needed to achieve CR. 
(13,44,209) Furthermore, the selected covariates were discussed with clinical experts. If 
any excluded characteristics were considered relevant according to the literature or the 
experts, these characteristics were added to model. Table 7.1 shows the covariates in the 
final models with the corresponding coefficients.
Survival analyses were performed on the patient-level data to describe the time to 
relapse and the time to death due to AML. For each event, a piecewise exponential 
regression was first performed to evaluate whether the hazard was constant over time. 
Different cut-off points (6 months, 1 year, 18 months) were tested by comparing the AIC 
of the models using these different cut-off points. The cut-off points were chosen be-
cause most deaths and relapses occur in the first two years.(64) The best fit was achieved 
with a cut-off point at 1 year for death if no CR and death after relapse, a cut-off point at 
6 months for death in CR and a cut-off point at 6 and 18 months for relapse.
Due to the finding of the significant different hazards, different survival models were 
specified for each time period. Patients with a longer follow-up than the specified cut-off 
point were censored at the cut-off point in the analysis of the first time period. For the 
analysis of the second time period, survival was modeled as time since cut-off point. That 
analysis excluded patients with a shorter follow-up than the specified cut-off point. For 
all analyses, four different parametric survival models were tested (exponential, Weibull, 
log-normal and log-logistic distribution) and model fit was determined using the AIC 
score. The models with the best fit are shown in Table 7.1. Relapse and death in CR were 
two competing events. In the modeling of these two competing events, patients who 
experienced the other event were censored at time of that event. The method for selec-
tion of attributes in the logistic regression models was also used to select the attributes 
in the survival models. The final attributes and the corresponding coefficients are shown 
in Table 7.1.
The analysis for the calculation of attributes and time-to-events were performed in SAS 
9.2.
model simulation
The model calculation started with the simulation of one patient and its attributes. 
Input parameters used to assign the attributes are shown in Table 7.2. The assignment 
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of the categorical attributes was based on the comparison of the predefined frequency 
distributions with a random number between 0 and 1 which was drawn from a uniform 
distribution. A separate random number was drawn for each categorical attribute. Age 
was derived from an empirical distribution. This distribution differed between favorable 
risk and other patients.
After the assignment of the attributes at start of simulation, the personalized chance of 
CR achievement was calculated with formula (1):
Table 7.2 Base-case estimates and corresponding distributions for the attributes in the modela
Base-case estimate Distribution Distribution estimates
Risk group
Favorable risk group 14.5% Dirichlet α1=62
Intermediate risk group 68.6% α2=293
Unfavorable risk group 16.9% α3=72
Male 51.1% Beta α=218, β=209
High WBC Count
Favorable risk group 17.7% Beta α=51, β=11
Intermediate risk group 23.2% Beta α=225, β=68
Unfavorable risk group 8.3% Beta α=66, β=6
Age (Years) Empirical
Post-remission treatment
Favorable risk group
- no post-remission treatment 8.3%
- chemotherapy 91.7% Beta α=55, β=5
Intermediate risk group
- no post-remission treatment 13.6% Dirichlet α1=33
- chemotherapy 48.6% α2=118
- autologous HSCT 14.8% α3=36
- allogeneic HSCT from sibling 23.0% α4=56
Unfavorable risk group
- no post-remission treatment 18.8% Dirichlet α1=9
- chemotherapy 18.8% α2=9
- autologous HSCT 8.3% α3=4
- allogeneic HSCT from sibling 35.4% α4=17
- allogeneic HSCT from MUD 16.7% α5=4
- UCB transplantation 2.1% α6=17
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e(β0 + β1X1 + … + βnXn)
 (1)
1 + e(β0 + β1X1 + … + βnXn)
The relevant beta coefficients are shown in Table 7.1. If a patient achieved a CR, the next 
step was to determine whether the patient achieved a CR after one cycle or not. The 
probability of achieving a CR after one cycle was also calculated with formula (1) using 
the beta coefficients shown in Table 7.1. The time to CR was derived from an empirical 
distribution which was observed in the original patient-level data. Two different distri-
butions were developed: one for CR after one cycle and one for CR after two cycles.
The times to death due to AML and relapse were derived the survival functions shown in 
Table 7.11. Time to death from other causes was derived from life expectancy estimates 
of Statistics Netherlands according to the patient’s age and gender (72). For patients in 
CR, the subsequent event was determined by the shortest time-to-event; if the time to 
relapse was shorter than both times to death, the patient relapsed. If a patient relapsed, 
it was determined whether the patient achieved a second CR with formula (1) and the 
coefficients shown in Table 7.1. Subsequently, times to death were estimated. Death was 
considered as the only possible event for patients without CR and patients in relapse. 
Cause of death was determined by which of the two times to death (time to death due 
to AML or time to death from other causes) was shorter.
Finally, the OS and DFS time were calculated for each simulated patient. OS was mea-
sured as time from diagnosis till death and DFS was measured as time from CR till relapse 
or death in CR.
In order to test the validity and reliability of the model, it was decided to simulate a 
sample size equal to the sample size in the original data (N=427). Subsequently, the 
simulation process was repeated 200 times to ensure stable estimates of CR rates, 5-year 
OS and DFS. The same input parameters were used in all 200 iterations. This analysis is 
called the base-case analysis.
Probabilistic sensitivity analysis (Psa)
A second order Monte Carlo simulation was used to perform a probabilistic sensitivity 
analysis to assess the impact of parameter uncertainty. In total, 250 different runs were 
modeled using different input parameters in each run. These parameters were randomly 
drawn from predefined distributions. Beta distributions were used for bivariate variables, 
1.  Lognormal distribution: log(survival time ) is normally distributed with mean= β0+β1X1+…+βnXn, and 
standard deviation= shape parameter
Loglogistic distribution: survival time = scale * (p/(1 − p))(1/shape), where scale = exp(β0+β1X1+…+βnXn)
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Dirichlet distributions for multivariate variables and multivariate normal distributions 
for coefficients of logistic regression and survival models (Table 7.2). Each run consisted 
of 200 iterations in which 427 patients were simulated.
The decision model was programmed in Excel 2010 with macros programmed in Visual 
Basic for Applications.
model validation
Three different approaches of validation were used to test the validity of the decision 
model (199,200,210). During the development process, the decision model was con-
tinuously discussed with two hematologists(BL and PS) to ensure face validity. BL is a 
specialist in the field of acute myeloid leukemia and PS is the head of the hematology 
department of the academic hospital in Rotterdam. Regular meetings were scheduled 
with these clinical experts. These meetings were scheduled in the beginning of the 
development process, once the model has been structured, once input parameters 
were estimated and once results were available regarding simulated survival outcome. 
During the meetings all steps of the development process were presented in detail. 
The experts critically assessed the composition and results of the model. In addition, 
the experts had to answer some specific questions about the model. For example, the 
experts were asked whether all relevant prognostic factors were included in the model, 
how cytogenetic abnormalities should be classified and whether patients with a second 
CR had a prognosis that was similar to that of patients with a first CR. The specific impact 
of the prognostic factors on the different input parameters were also discussed with the 
experts. For each input parameter, the selected prognostic factors were presented to the 
experts. The experts assessed whether these factors were indeed relevant prognostic 
factors in their opinion and whether some other important factors were excluded. In 
most instances, the clinical experts agreed with each other about relevant health states 
and prognostic factors for AML. Some contentious points were related to the inclusion of 
prognostic factors for the specific outcome measures. In case of contentious point, BL’s 
opinion was considered paramount as he was most experienced in AML. If necessary, 
the model was adjusted according to the commentary of the clinical experts. The final 
outcomes of the decision model in terms of CR rate and survival were also discussed 
with the clinical experts.
Second, internal validation of the model was performed by comparing the patient 
characteristics and clinical outcomes of the decision model with the original data. In the 
base-case analysis, patient characteristics and clinical outcomes were described with a 
mean value over the 200 iterations and a 95% confidence interval using the standard de-
viation of the 200 iterations as standard error of the mean. The estimates in the original 
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data were interpreted as the true value, and therefore it was evaluated whether these 
true values fell within the 95% confidence intervals of the model outcomes.
The external validation of the model was the last validation approach of this study. First, 
we considered whether the model could also be applied to other countries by comparing 
the estimated 5-year OS from the simulated dataset with 5-year OS results from clinical 
trials performed in other countries. Clinical trials were selected if the patient population 
consisted of patients aged 18-60 years and if the results were published between 2007 
and 2012. Secondly, we considered whether the model results could be generalized to 
the total AML population by comparing the OS estimates from the base-case analysis 
with population-based OS estimates. These population-based estimates were derived 
from the national cancer registry and included all patients diagnosed with AML in the 
Netherlands between 2001 and 2010.(211) More specific information regarding risk 
group classification and received treatment was not available for this dataset.
resulTs
internal validation
Table 7.3 shows the patient and treatment characteristics in both the original and 
simulated data, including the 95% confidence interval for the simulated data. The simu-
lated characteristics were almost all identical to the values in the original data, with the 
exception of post-remission treatment and time to relapse. A slightly higher, but not 
significant, percentage of patients received high-dose chemotherapy in the simulated 
data. However, the treatment distribution within the three risk groups did not differ 
significantly between the simulated and original data (data not shown). The difference 
in the total treatment distribution might be related to differences in the risk group 
distribution of patients in CR due to the exclusion of patients who were not treated ac-
cording to protocol in the original data. Although no significant differences were found 
regarding the timing of relapse, there was a trend towards fewer relapses in the first 6 
months and more relapses after 18 months in the simulated data.
CR rates for the total population were similar in the original and simulated data (Table 
7.4). The survival curves of the two datasets shows that the simulated OS and DFS were 
slightly higher compared to the original data (Figure 7.3). However, these differences 
were not significant since the estimates of the original dataset fell within the 95% CI of 
the simulated results. Subgroup analysis regarding the three cytogenetic risk groups 
also showed no significant differences in CR rates, OS and DFS between the simulated 
and original dataset (Table 7.4 and Figure 7.4). The inclusion of uncertainty surrounding 
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the input parameters resulted in considerable ranges of CR rates and 5-year OS and DFS 
estimates, especially in the favorable and unfavorable risk group (Table 7.4).
external validation
In total, 6 articles were selected which reported 5-year OS results from clinical trials per-
formed in several European countries, the United States, Korea and Japan (212-217). A 
summary of these studies is shown in Table 7.5. The simulated study is based on patients 
Table 7.3 Patient and treatment characteristics
Original data Simulated data
Mean 95% CI Mean 95% CI
All patients
Mean age (years) 43.1 (42.0 – 44.2) 43.1 (42.0- 44.1)
Gender (%)
Male 51.1 (46.2 – 55.9) 51.1 (47.1 - 55.1)
Female 49.0 (44.1 – 53.8) 48.9 (44.9 – 52.9)
White blood cell count (%)
<= 100 x 10^^9/l 80.1 (76.0 – 83.8) 80.1 (76.4 - 83.8)
> 100 x 10^9/l 19.9 (16.2 – 24.0) 19.9 (16.2 – 23.6)
Cytogenetic risk group (%)
Favorable cytogenetics 14.5 (11.3 – 18.2) 14.4 (10.9 – 17.9)
Intermediate cytogenetics 68.6 (64.0 – 73.0) 68.8 (64.3 - 73.3)
Unfavorable cytogenetics 16.9 (13.4 – 20.8) 16.8 (13.1 - 20.6)
Patients with a complete remission
Number of cycles before CR (%)
1 cycle 72.3 (67.2 – 76.9) 72.1 (67.0 – 77.1)
2 cycles 27.8 (23.1 – 32.8) 27.9 (22.9 – 33.0)
Post-remission treatment (%)a
High-dose chemotherapy 47.7 (42.0 – 53.1) 51.2 (45.8 - 56.5)
Autologous HSCT 12.4 ( 9.0 – 16.5) 11.4 ( 8.2 – 14.7)
Allogeneic HSCT from sibling donor 22.6 (18.2 – 27.6) 21.2 (17.0 – 25.4)
Allogeneic HSCT from MUD  2.5 ( 1.1 –  4.8)  2.4 ( 0.9 –  3.8)
Cord blood transplantation  0.3 ( 0.0 –  1.7)  0.3 ( 0.0 –  0.9)
Patients with relapse
Time of relapse (%)*
<= 6 months after CR 30.6 (23.9-38.1) 25.7 (18.9 – 32.4)
7-18 months after CR 53.2 (45.4-60.8) 53.1 (46.2 – 60.0)
> 18 months after CR 16.2 (11.0-22.5) 21.2 (14.9 – 27.6)
* patients who were not treated according to protocol were excluded in the original patient-level data 
(N=34)
CR = complete remission
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diagnosed from 1987-2005, while most selected trials included patients diagnosed since 
2001. Only Mandelli et al. (214) and Wheatley et al. (216) reported the results of patients 
diagnosed in the 1990s. The median age in the studies ranged from 43-49 years. The two 
studies in the UK (212,216) were not restricted to patients aged 15-60 years. All but one 
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Figure 7.3 comparison of overall and disease-free survival between original and simulated data
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study (214) used a risk-adapted treatment protocol with more intensive treatment for 
patients in the intermediate and unfavorable risk group.
According to patient and treatment characteristics, the simulated study was most com-
parable with the trials from Burnett et al. (212) and Lee et al. (213) The 5-year OS in these 
studies was slightly higher than the 5-year OS in the simulated study (41-43% and 38% 
respectively). A possible explanation for the difference in 5-year OS is the time of patient 
accrual. A trend for a better OS in more recently diagnosed patients was also found in 
the original patient-level data on which the simulation is based. Despite comparable 
treatment protocol, it might be possible that the better OS in more recently diagnosed 
patients is caused by improvement in supportive care (212). This is also supported by 
the fact that the 5-year OS in the two other studies with patients diagnosed since 2001 
was similar or higher than the 5-year OS in the simulated study (215,217). The similar 
Table 7.4 complete remission rates, 5-year overall and disease-free survival in original and simu-
lated data
Original data Base-case analysis Probabilistic analysis
Mean 95% CI Mean 95% CI Mean Range
Events
First complete remission (%)
- All patients 81 (77 – 85) 81 (77 - 85) 81 73-85
- Favorable risk group 89 (78 – 95) 89 (80 - 97) 88 69-96
- Intermediate risk group 83 (78 – 87) 83 (79 - 87) 83 73-88
- Unfavorable risk group 67 (55 – 77) 67 (56 - 78) 65 50-80
Second complete remission (%)
- All patients 39 (32 – 47) 41 (34 - 48) 41 28-50
- Favorable risk group 56 (28 – 85) 63 (39 - 88) 62 29-88
- Intermediate risk group 40 (32 – 50) 40 (32 - 49) 40 26-51
- Unfavorable risk group 28 (13 – 46) 32 (17 - 46) 32 13-58
5-year overall survival (%)
- All patients 36 (31 – 41) 38 (34 - 43) 38 27-46
- Favorable risk group 65 (51 – 79) 66 (54 - 78) 64 43-77
- Intermediate risk group 37 (31 – 43) 38 (33 - 44) 38 28-47
- Unfavorable risk group 16 ( 7 – 24) 14 ( 6 - 22) 14 6-30
5-year disease-free survival (%)
- All patients 35 (30 – 40) 38 (33 - 44) 37 25-44
- Favorable risk group 61 (45 – 77) 62 (50 - 74) 60 42-75
- Intermediate risk group 35 (29 – 41) 38 (32 - 44) 36 24-47
- Unfavorable risk group 15 ( 4 – 25) 15 ( 6 - 25) 13 3-27
95% CI = 95% confidence interval
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Figure 7.4 comparison of overall survival (os) and disease-free survival (DFs) between original and 
simulated data per cytogenetic risk group (a and D = favorable risk group, B and e = intermediate 
risk group, c and F = unfavorable risk group).
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survival might be caused by the fact that an allogeneic HSCT was not a standard treat-
ment option in that study.
The 5-year OS in the simulated study varied largely from the 5-year OS in three studies 
(214-216). The two studies with worse survival included patients diagnosed in the 1990s. 
Furthermore, treatment might also be responsible for difference in OS. In one study, a 
second induction cycle was only administered to patients with partial remission, while 
in the simulated study the second cycle was administered to all patients. This might have 
resulted in a lower CR rate in that study (70% versus 81%) and consequently a worse 
5-year OS. In the other study, the 5-year OS was only lower in the arm in which patients 
received G-CSF. A better OS was observed in the Japanese study (215). However, that 
trial included a patient population with a relatively better prognosis as fewer patients 
were classified in the unfavorable risk group.
Figure 7.5 shows the survival in both the simulated and population-based data in three 
separate age groups. The model only simulates comparable survival in patients aged 
45-54 years. The simulated survival was worse in the younger age group and better in 
the older age group. An interpretation of these differences is difficult due to the limited 
information of the population-based data.
Discussion
The aim of this study was to develop a decision model for AML which can be used to 
evaluate the clinical utility and cost-effectiveness of genetic tests for AML patients in 
order to facilitate the decision-making about the widespread implementation of these 
tests. The decision model developed in this study included patient and disease hetero-
geneity in a micro simulation with discrete event components. The modeled OS was 
comparable with the estimates found in original patient-level data and other clinical tri-
als. However, the generalizability to a broader patient population has not been proven. 
It can therefore be concluded that the developed decision model validly represents a 
clinical trial AML population, but can currently not be used in a broader population. 
Although the model was specifically developed to evaluate genetic tests, its use is not 
only restricted to the evaluation of these tests. Since the model represent the full disease 
course of AML from diagnosis, it is also feasible to use the model in cost-effectiveness 
analyses of new chemotherapies or other treatments.
This study also provides a transparent example of a validation process. Although guide-
lines about decision-analytic modeling state that the validity of the model should be 
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tested, no explicit guidance is provided regarding the suitable methods for validation 
(199,218). In our validation process, we interpreted the CR and survival rates in the 
original data as true values and evaluated whether the simulated rates differed signifi-
cantly from these true values. None of the patient characteristics and outcome measures 
differed significantly from the true values. However, the simulated outcomes measures 
were not always identical to the original values. It can be argued that these differences 
might have important implications for cost-effectiveness analyses. For example, the 
percentage of patients with a relapse in the first 6 months after CR was lower in the 
simulated data, while a higher percentage of patients had a relapse after 18 months. 
This means that the average time to relapse is longer in the simulated data which might 
results in differences in resource use, quality of life and survival. The slightly better OS 
and DFS in the simulated data might be a consequence of the problems in estimating 
the time of relapse. Another explanation for the better OS and DFS is that the simulated 
dataset consists of relatively more favorable risk patients.
The large range in outcome measures which was found in the PSA is not surprising as the 
input parameters were derived from a relatively small patient population. Especially the 
favorable and unfavorable risk group contained a small number of patients. However, 
the average results of the PSA were comparable with the original data. If the model will 
be used in future cost-effectiveness analyses, a PSA should definitely be performed as it 
has been shown that changes in the input parameters have a significant impact on the 
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outcome measure. Furthermore, it might be useful to perform a value-of-information-
analysis to assess whether it is valuable to collect more information regarding the input 
parameters.
The added value of this model compared to previously existing models in the field of AML 
is that the scope of previous models was either restricted to post-remission treatments 
or to the treatment of specific complications of AML (i.e. fungal infections) (195-198). 
One could argue that instead of developing a completely new model, we could have 
modified the existing models to cover the full disease course of AML. However, some 
important aspects of AML were not included in the previously developed models. For 
example, the two studies that focused on post-remission treatments only evaluated al-
logeneic transplantation compared to no allogeneic transplantation. No distinction was 
made in type of allogeneic transplantation or between chemotherapy and autologous 
transplantation. In addition, not all relevant prognostic factors were included in the 
decision models. While Kurosawa et al. (196) used different transition probabilities for 
the three cytogenetic risk groups, they did not take into account the prognostic value of 
age, WBC count or number of cycles needed to achieve CR.
The main reason for choosing a micro simulation instead of cohort simulation was the 
heterogeneous nature of the disease. Several patient and disease characteristics have 
an impact on prognosis. This heterogeneity will only grow in the future as many studies 
are now trying to identify new (genetic) markers with prognostic value. This trend is not 
only apparent in the field of AML, but is also seen in other disease areas (188,219,220). 
Although a micro simulation was considered necessary because of the need to incorpo-
rate the heterogeneity of the disease, the use of discrete event components was in retro-
spect not essential; a micro simulation Markov model could also have been developed.
(208) However, we do not believe that the model choice will influence model outcomes, 
because no differences in model outcomes have been found in direct comparisons 
between Markov cohort models and discrete event simulations (DES) (221,222).
Since models represent a simplification of the real world, it is never feasible to include 
all differences found in the real world. An important simplification in our model is that 
graft-versus-host-disease (GVHD), a complication of an allogeneic transplantation, was 
not explicitly modeled. However, the consequences of GVHD were implicitly included 
in the estimation of life expectancy after allogeneic transplantations. If a new AML 
treatment particularly influences the incidence or consequences of GVHD, it could be 
important to model GVHD explicitly.
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Another simplification was made in the analysis of the two competing events ‘death in 
CR’ and ‘relapse’. These two events were analyzed separately. Patients who experienced 
the event not of interest in that specific analysis were censored at time of the experi-
enced event. However, an important assumption here is that censored patients do not 
differ from non-censored patients. One can doubt whether this assumption holds in this 
specific situation as there might be differences between patients who die in CR and 
patients who relapsed. However, since the model results corresponded well with the 
original data, it was not considered necessary to use more sophisticated methods in the 
decision model.
The impact of the structural uncertainty of the model has not explicitly been evaluated 
in this study. It was assumed that the chosen model structure reflects reality as clinical 
experts have confirmed that structure. A limitation of the reliance on these two experts 
is that they were both located in the same hospital. Their opinions might therefore not 
necessarily represent (inter)national opinions. However, this lack of generalizability is 
likely to be minimal as the experts collaborate with different centers all over the world.
(223,224) Furthermore, no large differences were found between the modeled 5-year 
OS and the 5-year OS reported in comparable clinical trials conducted in other parts 
of the world (212-214,216,217). Nevertheless, it is recommended to discuss the model 
structure with other experts in the future and, if necessary, assess the impact of changes 
in structure on the survival outcomes.
Another limitation of this study is that all input parameters are derived from one 
relatively small study. This is further complicated by the fact that the hazard of death 
and relapse was not constant over time. As a result, some distributions are based on a 
small group of patients who experienced the specific event. Due to the small numbers, 
it might be possible that relevant effects have been missed. Furthermore, a trend was 
found for an improved survival in more recently diagnosed patients Due to the small 
number of patients in the total study sample, it was decided to also include patients who 
have been diagnosed more than 15 years ago. However, the model might be improved if 
more recent data of a substantial study sample were to be included.
The generalizability of the model to a broader patient population than patients partici-
pating in clinical trials has not been proven in this study. Possible explanations for the 
deviations between the simulated study and the population-based data might be re-
lated to the patient characteristics or the time of diagnosis. Further research is required 
to identify differences between study populations and to adjust the model to ensure 
generalizability to a broader population.
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conclusions
This study showed a new valid decision model for AML patients in a clinical trial setting. 
The existence of a validated model facilitates assessments of the clinical utility and cost-
effectiveness of new genetic tests for AML. Since it is not often clear how genetic tests 
will alter disease management, the model can also be used to evaluate the impact of 
different scenarios regarding treatment change in newly identified subgroups of AML 
on survival, quality of life and costs. Furthermore, the model can also be used for other 
cost-effectiveness analysis in the field of AML.
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aBsTracT
An adequate assessment of the health and economic consequences of personalized 
medicine strategy is crucial for the implementation of personalized medicine strategies 
in clinical practice. Different methods are currently used in cost-effectiveness analyses 
of personalized medicine strategies due to the absence of specific methodological 
recommendations. The aim of this study was to propose specific methodological recom-
mendations for cost-effectiveness analyses of personalized medicine strategies based 
upon findings from a case-study in acute myeloid leukemia (AML).
A previously validated decision-analytical model was used to assess the cost-effective-
ness of two personalized medicine strategies in AML patients aged 18-60 years. These 
strategies include the reclassification of patients to either the favorable or unfavorable 
risk group and the subsequent treatment change. The cost-effectiveness analyses were 
first restricted to an assessment of the consequences of a treatment change in the newly 
identified subgroups. Subsequently, the consequences of the test were added to the 
analyses. The impact of the exclusion of the test was assessed by comparing the results 
of the two approaches.
We found that the exclusion of the testing costs in cost-effectiveness analyses over-
estimates the cost-effectiveness of personalized medicine strategies. The severity of 
overestimation depends upon the costs of the test, the prevalence of the subgroup with 
a treatment change and health effects of the treatment change. According to this find-
ings, we developed a formula for use in future cost-effectiveness analyses of personal-
ized medicine strategies.
This study showed that cost-effectiveness analyses of personalized strategies should 
always include the costs and performance of the test to avoid an overestimation of 
the cost-effectiveness. Nonetheless, insight in the separate effect of the treatment and 
test on health and economic outcomes is required for adequate reimbursement deci-
sions. This can be achieved by using the postulated formula in future cost-effectiveness 
analysis.
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inTroDucTion
A general trend in the field of medicine is the personalization of medical treatment. 
As it is known that treatment response and side effects differ between patients,(8) 
many studies focus on the identification of the underlying causes of these differences 
(225,226) to improve health outcomes by treating patients according to their expected 
response and risk of side effects (227).
Despite the promising results of personalized medicine strategies, only a small num-
ber of personalized medicine strategies have been implemented in daily practice. A 
major barrier of implementation is the limited evidence of the impact of personalized 
strategies on health outcomes and costs (228-230). Direct evidence from randomized 
controlled trials (RCTs) is often missing since that information is not specifically required 
for market access, except for companion diagnostics (228).
Furthermore, RCTs are not always feasible due to ethical reasons and time and costs 
constraints (194). Therefore, the available evidence regarding impact is often derived 
from retrospective studies using modelling methods to combine different sources 
(37,194,231,232). A disadvantage of the latter approach is that it furnishes indirect evi-
dence and differences in health outcomes and costs cannot be attributed to differences 
in treatment with certainty (233).
Another difficulty in the successful implementation is the lack of standardized meth-
ods in the evaluation and reporting of cost-effectiveness analyses of personalized 
medicine strategies. Many published cost-effectiveness analyses excluded the costs of 
testing and only evaluated the consequences of a new treatment in a narrowly defined 
subgroup of patients (234,235). Other studies performed cost-effectiveness analyses of 
the combination of the test and treatment strategy (236-238). The results of the latter 
studies are often not comparable with the more narrow cost-effectiveness analyses 
as the separate effect of the test and treatment on health outcomes and costs is not 
reported.
Specific recommendations regarding the appropriate methodology for cost-effective-
ness analyses of personalized medicine strategy are currently not available. Detailed 
cost-effectiveness guidelines were developed for the assessment of new drugs and lack 
information about the evaluation of the test (29,239,240). Nonetheless, several authors 
indicated that the method for cost-effectiveness analyses of drugs also apply to analyses 
of personalized medicine strategies. The analyses should only be expanded with an as-
sessment of the costs and effects of the test strategy (241,242). However, none of these 
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authors explicitly describe the required adjustments in the methodology to allow for the 
assessment of both the test and treatment strategy.
It is expected that stricter recommendations regarding the methodology of cost-
effectiveness analyses of personalized medicine strategies improves the comparability 
between studies. A better comparability may improve the judgments about the added 
value of new personalized medicine strategy. Since new personalized medicine strate-
gies may incorporate adjustments in both the test and treatment, it is essential that the 
methodology allows for the separate assessment of the test and treatment strategy. The 
aim of this study was to examine whether specific methodological recommendations 
for cost-effectiveness analyses of personalized medicine strategies could be proposed 
based upon findings from a case-study in acute myeloid leukemia.
meThoDs
Description case study
Acute myeloid leukemia (AML) represents a highly heterogeneous disease in terms of 
clinical and molecular features and disease outcome. It offers an interesting case study 
for personalized medicine due to its heterogeneous nature and the involvement of vari-
ous different cytogenetic and molecular subgroups which are associated with a differen-
tial prognosis (26). Since it has been shown that patients with a good prognosis can be 
cured with less intensive treatments than patients with a poor prognosis, a risk-stratified 
treatment protocol is currently applied to treat patients with this disease (21,26,189). 
Evidence about the prognosis of newly identified subgroups resulted in a reclassifica-
tion of patients to other risk groups. According to the reclassification, two types of 
personalized medicine strategies can be identified at this moment. Patients reclassified 
to the favorable risk group receive a less intensive treatment, while a more intensive 
treatment is administered to patients identified with unfavorable risk group. More infor-
mation about the personalized medicine strategies can be found in the supplementary 
material. The cost-effectiveness of the two types of personalized medicine strategies are 
separately evaluated in this study. Both analyses are restricted to patients aged 18-60 
years because treatment only differs between risk groups for these patients.
Decision model
A validated decision model (243) was used to perform the cost-effectiveness analyses 
of the personalized medicine strategies. The model is an individual patient simulation 
in which transitions between health states were based upon estimated time to (second) 
CR, relapse and death. These estimates were derived from patient-level data (189) and 
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differed between relevant patient and disease characteristics including risk classifica-
tion.
input parameters
The cost-effectiveness analyses were performed from a Dutch health-care perspective. 
All input parameters were derived from previous studies (Table S8.1 in the supplemen-
tary material). Treatment effects were included by the hazard ratios (HR) for treatment-
related mortality (TRM), relapse risk and survival after relapse. The HRs were either 
directly taken from the literature or estimated according to the method of Parmar et al. 
(244). A random-effects meta-analysis was performed if more than one HR was available. 
Costs were categorized as diagnostic, induction, post-remission, follow-up and relapse 
costs. Follow-up costs were distinguished in standard follow-up visits for regular visits 
to test for leukemia recurrence and complication costs. The complication costs included 
costs of additional visits, hospital stay and medication. All costs were converted to 2013 
Euros. Quality of life utilities were derived from EQ-5D estimates in AML patients aged 
18-60 years. The estimates consisted of a baseline quality of life utility and decrements 
for patients with relapse/refractory AML and patients treated with an allogeneic hema-
topoietic stem cell transplantation.
sensitivity analyses
Probabilistic sensitivity analyses (PSA) with 1,000 simulations were performed to assess 
the impact of uncertainty in the input parameters on the cost-effectiveness. Within 
each simulation, the values of the input parameters were randomly drawn from distri-
butions shown in Table S8.2 of the Supplementary Material. Acceptability curves were 
constructed to identify the likelihood that the personalized medicine strategies were 
cost-effective given the uncertainty in the input parameters.
evaluation of the required methodology for cost-effectiveness analyses of 
personalized medicine strategies
The cost-effectiveness analyses were first restricted to an assessment of the conse-
quences of a treatment change in the newly identified subgroups (defined as treatment-
only approach). Subsequently, the consequences of the test were added to the analyses 
(defined as test-treatment approach). It was assumed that the tests had no direct effect 
on health, but only impacted health by means of a treatment change. The formulas in 
Box 8.1 were used to calculate the incremental cost-effectiveness ratio (ICER) of the 
treatment and test-treatment approach.
For the sake of the illustration, it was assumed that perfect tests (100% sensitivity and 
specificity) were used to identify the new subgroups in AML. However, a reduced per-
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formance of the test is easy to include in the analysis. Assuming that a positive test is 
associated with a treatment change, it is required to assess the health and economic 
consequences of that treatment change separately for true and false positive tested 
patients. The overall incremental costs and effects is estimated a weighted average of 
the consequences in the two patient groups (formula 2.1 in Box 8.1). Since treatment 
does not change for negatively tested patients, a lower specificity impacts the cost-
effectiveness analyses of personalized medicine strategy by reducing the size of the 
subgroup with a treatment change (formula 2.2 in Box 8.1).
Box 8.1 Formulas initially used to estimate the cost-effectiveness of personalized medicine strat-
egies.
ICER treatment-only approach =
∆ Costs (treatment change)
 (1)
∆ Effectiveness (treatment change)
ICER test-treatment approach =
Costs of the test + p* ∆ Costs (treatment change)
 (2)
p * ∆ Effectiveness (treatment change)
Δ Costs (treatment change) =
TP
 * Δ CostsTP +
FP
 * Δ CostsFP (2.1)1
TP+FP TP+FP
Δ Effectiveness (treatment change) 
=
TP
 * Δ EffectivenessTP +
TP
 * Δ EffectivenessFP (2.2)1
TP+FP TP+FP
p =
TP+FP
 (2.3)
TP+FP+TN+FN
1 These formulas assume that treatment changes for patients with a positive test results. If otherwise, the 
costs and effects are weighted according to the proportion true and false negative patients.
Δ costs treatment change = Differences of all health care costs, except costs of testing, between the 
new and old treatment strategy
Δ effectiveness treatment change = differences in both life expectancy and quality-adjusted life years 
(QALYs) between the new and old treatment strategy
p = proportion of patients in the total tested population whose treatment changes
TP = proportion of patients in the total tested population with a true positive test result (correctly clas-
sified as mutant)
FP = proportion of patients in the total tested population with a false positive test result (incorrectly 
classified as mutant)
Tn = proportion of patients in the total tested population with a true negative test result (correctly 
classified as not mutant)
Fn = proportion of patients in the total tested population with a false negative test result (incorrectly 
classified
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The impact of the exclusion of the test was assessed by comparing the base-case results 
and acceptability curves of the treatment-only and test-treatment approach. Within 
this evaluations, four generic parameters in cost-effectiveness analyses of personalized 
medicine strategies were varied to assess the consequences of these parameters on the 
difference in ICER between the two approaches. These four parameters were 1) incre-
mental costs of treatment change, 2) incremental health effects of treatment change, 3) 
prevalence of the subgroup with a treatment change and 4) testing costs.
resulTs
case study results
Table 8.1 shows the results of the cost-effectiveness analyses of the two personalized 
medicine strategies. The less intensive treatment for favorable risk patients resulted in 
lower medical costs (€152,536 and €158,154 for the new and current protocol, respec-
tively). Health was improved as indicated by the increased life years and QALYs (health 
gain is 0.851 life years and 1.005 QALYs). The more intensive treatment for unfavorable 
risk patients was associated with larger medical costs (€246,838 versus €168,898), im-
proved life expectancy (5.48 versus 4.56 years) and increased QALYs (4.25 versus 3.65).
The incremental effects decreased substantially in the test-treatment approach, be-
cause health gains were only observed for the small group of patients with a treatment 
change (Table 8.1). The observed health gain in patients with a treatment change did 
not differ from the treatment-only approach. The impact of the inclusion of the test on 
the incremental costs differed between the personalized medicine strategies for the 
newly favorable and unfavorable risk patients. Since both patients with and without a 
treatment change need to be tested, the incremental costs for all patients increase with 
the costs of testing. The impact on the overall incremental costs depends on the costs 
of the test relatively to the incremental costs of a treatment change. The costs of the 
test were larger than the incremental costs of a treatment change in newly favorable 
patients. Consequently, an increase in the overall incremental costs was observed if the 
costs of testing were included in the analysis. Contrary, a decrease in incremental costs 
was observed for the strategy in newly unfavorable patients, because the costs of test-
ing were smaller than the incremental costs of the treatment change for these patients. 
Despite the differential effect on the incremental costs in the two personalized medicine 
strategies, the ICER increased for both strategies if the costs of testing were included in 
the analysis (Table 8.1).
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The probabilistic sensitivity analyses identified the probability that the new personal-
ized medicine strategies are cost-effective given the uncertainty in the input parameters 
and different threshold values. These probabilities were reported in acceptability curves 
as shown in Figure 8.1 Assuming a threshold of €80,000 per QALY, the probability of 
being cost-effective is 97% and 2% for the personalized medicine strategies (including 
costs of testing) in newly favorable and unfavorable risk patients, respectively. These 
probabilities are higher if the analyses is restricted to the treatment-only approach. 
Consequently, the impact of uncertainty in the input parameters is underestimated if 
analyses are restricted to the treatment-only approach.
relationship between the treatment-only and test-treatment approach
The treatment-only approach systematically underestimates the ICER due to the exclu-
sion of the testing costs. The severity of the underestimation depends on the costs of 
the test, the incremental health effects of the treatment change and the prevalence of 
the subgroup with a treatment change (Figure 8.2). The difference in the ICER between 
the test-treatment and treatment-only approach increases linearly with higher costs 
of testing. Furthermore, the difference in the ICER decreases with a diminishing rate if 
the prevalence of the subgroup with a treatment change increases or if the incremen-
tal health effects of the treatment change increases. Although the ICERs of both the 
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Figure 8.1 acceptability curves of the comparison of new personalized medicine strategies versus 
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treatment-only and test-treatment approach increase with larger incremental costs due 
to the treatment change, the difference between the two ICERs remains constant. These 
findings regarding the relationship between the ICER of the treatment change and the 
impact of the test on the cost-effectiveness is expressed in a newly developed formula 
(formula 3, see Box 8.2).
Box 8.2 Formula and illustration of a method to estimate the cost-effectiveness of personalized 
medicine strategies
icer test-treatment approach = ICER treatment-only approach + impact test approach (3)
 

 

Δ costs (treatment change)
+
Costs of test
*
1
Δ effectiveness (treatment change) Δ effectiveness (treatment change) p
Illustration of formula:
Favorable subgroup
ICER of treatment-only approach =
−5,649
= −5,621 per QALY gained
1.005
Impact of test approach =
631
*
1
=  6,976 per QALY gained
1.005 0.09
ICER of test-treatment approach = −5,621+ 6,976 =  1,355 per QALY gained
Unfavorable subgroup
ICER of treatment-only approach =
77,939
= 130,115 per QALY gained
0.599
Impact of test approach =
210
*
1
=  87,646 per QALY gained
0.599 0.004
ICER of test-treatment approach = 130,115 + 87,646 = 217,761 per QALY gained
(All numbers are derived from table 1, differences in the ICER are due to rounding))
Discussion
The aim of this study was to evaluate different methods for cost-effectiveness analyses 
of personalized medicine strategies in order to develop more specific methodological 
recommendations for these analyses. The use of one standardized methodology in 
future analyses may improve the comparability of study results and enable better judg-
ments regarding the added value of new personalized medicine strategies.
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This study showed that the cost-effectiveness is overestimated if the costs of testing are 
excluded from the analysis. The overestimation is especially problematic for personal-
ized medicine strategies with large costs of testing, a small prevalence of the subgroup 
with a treatment change and small health effects of that treatment change. In addition, 
it was shown that the impact of uncertainty in the input parameters was underestimated 
in analyses restricted to the subgroup with a treatment change. According to these 
findings, it is strictly recommended to include the costs of testing in cost-effectiveness 
analyses of personalized medicine strategies. Nonetheless, the primary analyses should 
always be focused on the cost-effectiveness of the treatment change in the selected 
subgroups, because a cost-effective treatment is a prerequisite for a cost-effective 
personalized medicine strategy. Furthermore, it provides insight in the achieved health 
gains for the selected subgroup. We developed a formula to incorporate the test in 
the cost-effectiveness analysis of personalized medicine strategies without losing any 
information regarding the health and economic consequences of the treatment change.
The formula was tested in two personalized medicine strategies for patients with acute 
myeloid leukemia. However, it is expected that it also applies to other disease areas, 
because only generic components of personalized medicine strategies were included in 
the formula. Furthermore, several other studies indicated these components as driving 
factors in the cost-effectiveness of personalized medicine strategies (245-249).
Reimbursement agencies need to be aware of the systematic bias in studies restricted 
to cost-effectiveness of new targeted treatments without including the costs of testing. 
These studies are only allowed if the identification of the subgroup is not associated 
with additional costs because the test is already part of standard clinical practice. The 
developed formula is also useful for reimbursement agencies in the interpretation 
of cost-effectiveness studies and selection of the most appropriate reimbursement 
strategy. For example, in the circumstance that the treatment change in the selected 
subgroup is cost-effective, but the overall personalized medicine strategy not, it might 
be worthwhile to negotiate a price reduction of the test or limit the use of the test to 
allow access to the new treatment. Negative reimbursement decisions would be more 
likely if the negotiations about the costs of the treatment are especially required if the 
treatment change is not cost-effective.
The use of the formula provides also advantages for the analysis and reporting of cost-
effectiveness analyses of personalized medicine strategies. Health outcomes and costs 
only need to be collected and analyzed for the subgroup whose treatment changes. 
This restricted data collection and analysis limits the required time and costs and allows 
faster implementation. Secondly, the formula can easily be applied early in the develop-
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ment process of personalized medicine strategies in decisions about the continuation of 
the development. It may identify areas for improvement in both the test and treatment 
strategy and assess whether it is worthwhile to continue the development given the 
expected cost-effectiveness. These early motivated decisions may result in a better al-
location of resource & development costs (41). Another advantage of the early use of the 
formula in the development process is that these analyses may identify critical param-
eters in the cost-effectiveness analysis for which additional data is required. Adequate 
collection of that data during the development of the personalized medicine strategy 
may increase the available evidence at time of market entrance and thereby improves 
the implementation of personalized medicine strategies (250).
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The case study evaluated the cost-effectiveness of changes in the risk-stratified treat-
ment of AML in patients aged 18-60 years. For many years, risk-classification of AML 
was solely based upon cytogenetic abnormalities (251). Recent studies have shown that 
the risk classification could be improved by including molecular abnormalities.(252) 
Patients with intermediate cytogenetics and CCAAT enhancer binding protein double 
mutations (CEBPAdm) or nucleophosmin-1 gene mutations (NPM1) without internal 
tandem duplication of the fms-like tyrosine kinase-3 gene (FLT3-ITD) have a favorable 
prognosis,(191,253-257) while patients with intermediate cytogenetics and ecotropic 
virus integration-1 (EVI1) overexpression have an unfavorable prognosis.(258) This 
new information results in treatment changes because the choice of post-remission 
treatment differs between risk groups.(26) High-dose chemotherapy is the only post-
remission treatment in favorable risk patients. An allogeneic hematopoietic stem cell 
transplantation (HSCT) from a sibling donor is the preferred post-remission treatment 
option in all other patients. If no sibling donor is available, intermediate risk patients will 
receive an autologous HSCT or high-dose chemotherapy, while unfavorable risk patients 
may receive an allogeneic HSCT from a matched unrelated donor or an umbilical cord 
blood transplantation. In general, the better the prognosis, the least intensive treat-
ment is administered. Consequently, patients with NPM1 mutations without FLT3-ITD or 
CEBPAdm (newly favorable) will no longer receive an allogeneic or autologous HSCT and 
patients with EVI1 overexpression (newly unfavorable) become candidates for an umbili-
cal cord blood transplantation or allogeneic HSCT from a matched unrelated donor.
Figure S8.1 shows the consequences in treatment if all AML patients aged 18-60 years 
are tested for the new abnormalities. As only patients with NPM1 mutations without 
FLT3-ITD CEBPAdm or EVI1 overexpression will be reclassified to another risk group, treat-
ment will not change for all other patients. Furthermore, within the newly identified 
subgroup, treatment does also not change for patients without a complete remission 
because only post-remission treatment differs between risk groups. Finally, even a 
selective group of patients with a complete remission will receive a different treatment 
because stem cell transplantations are not feasible for all patients. Consequently, it was 
found that 9% and 0.4% of all AML patients aged 18-60 received a different treatments 
due to the reclassification to the favorable or unfavorable risk group, respectively.
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Table s 8.1 values and distributions of the input parameters
Base-case Probabilitic sensitivity analysis Source
Distribution Parameters
Effectiveness post-remission 
treatment
HR TRM: allogeneic HSCT 
versus chemotherapy
3.60 Lognormal μ=1.28, σ=0.39 Schlenk et al. 2008(259)
HR TRM: autologous HSCT 
versus chemotherapy
2.58 Lognormal μ=0.95, σ=0.28 Nathan et al. 2004(260), 
Breems et al. 2005(261), 
Vellenga et al. 2011(205)
HR TRM: allogeneic HSCT 
versus autologous HSCT
2.18 Lognormal μ=0.78, σ=0.28 Ringden et al. 2000(262), 
Suciu et al. 2003(263), Brunet 
et al. 2004(264), Lazarus et al. 
2006(265)
HR relapse: allogeneic HSCT 
versus chemotherapy
0.49 Lognormal μ=-0.72, σ=0.29 Schlenk et al. 2008(259)
HR relapse: autologous 
HSCT versus chemotherapy
0.84 Lognormal μ=-0.42, σ=0.22 Breems et al. 2005(261), 
Vellenga et al. 2011(205)
HR relapse: allogeneic HSCT 
versus autologous HSCT
0.66 Lognormal μ=-0.18, σ=0.27 Ringden et al. 2000(262), 
Suciu et al. 2003(263), Lazarus 
et al. 2006(265)
HR death after relapse: HSCT 
versus no HSCT
1.35 Lognormal μ=0.30, σ=0.10 Breems et al. 2005(207)
Costs
- Costs chemotherapy 34,225 Gamma α=13.4, β=2,562.5 Leunis et al. 2013(266)
- costs autologous HSCT 33,277 Gamma α=10.1, β=3,286.7 Leunis et al. 2013(266)
- Costs allogeneic HSCT from 
sibling donor
44,070 Gamma α=2.4, β=18,032.3 Leunis et al. 2013(266)
- Costs allogeneic HSCT from 
MUD
82,041 Gamma α=26.9, β=3,052.0 Leunis et al. 2013(266)
- Costs UCB transplantation 109,675 Gamma α=5.9, β=18,466.9 Blommestein et al. 2012(71)
- Costs complications 
chemotherapy
1,909 Gamma α=0.09, β=22,302 Leunis et al. 2013(266)
- Costs complications 
autologous HSCT
1,942 Gamma α=0.06, β=32,955 Leunis et al. 2013(266)
- Costs complications 
allogeneic HSCT from sibling 
donor
18,061 Gamma α=0.56, β=32,404 Leunis et al. 2013(266)
- Costs complications 
allogeneic HSCT from MUD
36,521 Gamma α=1.02, β=35,832 Leunis et al. 2013(266)
- Costs complications UCB 
transplantation
61,230 Gamma α=0.73, β=83,495 Blommestein et al. 2013(71)
- Costs complication 
induction treatment
7,793 Gamma α=0.17, β=45,653 Leunis et al. 2013(266)
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Table s 8.1 values and distributions of the input parameters (continued)
Base-case Probabilitic sensitivity analysis Source
Distribution Parameters
- Costs standard follow-up 
visit
253 Uniform Min=126, Max=379 Standard Dutch tariffs
- Costs bone marrow 
aspirate
306 Uniform Min=153, Max=458 Standard Dutch tariffs
- Reinduction chemotherapy 
favorable risk
45,610 Gamma α=8.6, β=5,320.2 Leunis et al. 2013(266)
- Relapse treatment 
intermediate or unfavorable 
risk
43,461 Gamma α=8.6, β=5,320 Uyl-de Groot et al. 2001(63)
- Assumption follow-up 
costs after 1 year
0.25 Uniform Min=0, Max=1 van Agthoven et al. 2002(267)
Quality of life utility
- Utility no allogeneic HSCT 
+ no relapse/refractory 
disease
0.86 Beta α=137, β=22 Leunis et al. 2014(172)
- Decrement allogeneic 
HSCT
0.03 Beta α=1, β=24 Leunis et al. 2014(172)
- Decrement relapse/
refractory treatment
0.09 Beta α=4, β=35 Leunis et al. 2014(172)
Risk group distribution
Proportion favorable 
cytogenetics
0.15 α1=62 Leunis et al. 2013(243)
Proportion intermediate risk 
group
0.69 Dirichlet α2=293 Leunis et al. 2013(243)
Proportion unfavorable 
cytogenetics
0.17 α3=72 Leunis et al. 2013(243)
Proportion normal 
karyotype within 
intermediate risk group
0.71 Beta α=199, β=81 Derived from data used in 
Leunis et al. 2013(243)
Proportion CEBPAdm within 
normal karyotype
0.06 Beta α=139, β=2104 Dufour et al. 2010(253), Green 
et al. 2010(254), Schlenk et al. 
2008(190)
Proportion NPM1+/FLT3- 
within normal karyotype
0.27 Beta α=396, β=1052 Thiede et al. 2006(257), 
Boissel et al. 2005(255), 
Döhner et al. 2005(256), 
Schneider et al. 2009(268)
Proportion EVI1 
overexpression within 
normal karyotype
0.05 Beta α=31, β=559 Gröschel et al. 2010(258)
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Table s 8.1 values and distributions of the input parameters (continued)
Base-case Probabilitic sensitivity analysis Source
Distribution Parameters
CR rates new mutations
CR rate CEBPAdm 0.91 Beta α=137, β=14 Dufour et al. 2010(253), Green 
et al. 2010(254), Schlenk et al. 
2008(190)
CR rate NPM1+/FLT3- 0.77 Beta α=297, β=90 Thiede et al. 2006(257), 
Döhner et al. 2005(256), 
Schneider et al. 2009(268)
CR rate EVI1 high expression 0.71 Beta α=44, β=18 Gröschel et al. 2010(258)
Treatment distribution
Chemotherapy favorable 
risk group
0.92 Beta α=55, β=5 Leunis et al. 2013(243)
No post-remission treatment 
intermediate risk group
0.13 α1=29 Leunis et al. 2013(243)
Chemotherapy intermediate 
risk group
0.19 Dirichlet α2=43 Leunis et al. 2013(243)
Autologous HSCT 
intermediate risk group
0.32 α3=74 Leunis et al. 2013(243)
Allogeneic HSCT 
intermediate risk group
0.36 α4=82 Leunis et al. 2013(243)
No post-remission treatment 
unfavorable risk group
0.11 α1=8 Leunis et al. 2013(243)
Chemotherapy unfavorable 
risk group
0.17 α2=13 Leunis et al. 2013(243)
Autologous HSCT 
unfavorable risk group
0.12 Dirichlet α3=9 Leunis et al. 2013(243)
Allogeneic HSCT sibling 
donor unfavorable risk 
group
0.36 α4=27 Leunis et al. 2013(243)
Allogeneic HSCT MUD 
unfavorable risk group
0.23 α5=17 Leunis et al. 2013(243)
CB transplantation MUD 
unfavorable risk group
0.01 α6=2 Leunis et al. 2013(243)
Costs
- Costs new diagnostic tests 
newly favorable
641 Uniform Min=666, Max=1999 Standard Dutch tariffs
- Costs new diagnostic test 
newly unfavorable
240 Uniform Min=120, Max=360 Standard Dutch tariffs
HSCT=hematopoietic stem cell transplantation, MUD=matched unrelated donor, CR=complete remission, 
UCB=umbilical cord blood, HR=hazard ratio, TRM=treatment-related mortality
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Newly favorable
16.48%
Newly unfavorable
2.56%
CR
13.13%
No Cr
3.35%
CR
1.82%
No Cr
0.74%
Original treatment: 
Autologous or 
allogeneic HSCT
8.98%
Original treatment:  
Chemotherapy or no 
post-remission 
treatment
4.15%
Original treatment: 
Autologous HSCT or 
chemotherapy
0.93%
Original treatment: 
Allogeneic HSCT or no 
post-remission 
treatment
0.89%
New treatment: 
high-dose 
chemotherapy
8.98%
UCB donor or donor 
from MUD available
0.35%
No UCB donor donor 
from MUD available
0.58%
New treatment: 
Allogeneic HSCT 
from MUD or UCB 
transplantation
0.35%
Original favorable
14.52%
Original unfavorable
16.86%
Original intermediate
68.62%
Newly intermediate
49.58%
AML patients aged 18-60 years
Figure s8.1 Patient flow of aml patients.
The light-gray blocks indicate no treatment change. The dark-grey blocks indicate treatment change. Origi-
nal favorable = patients with t(8;21) or inv(16) abnormalities. Original unfavorable = patients with complex 
karyotype (≥3 cytogenetic abnormalities), inv(3), t(6;9), -5/del(5q), -7/del(7q), abn(11q23) or t(9;22). Origi-
nal intermediate = all other patients. Newly favorable = patients with normal karyotype and CEBPAdm or 
NPM1+ without FLT3ITD. Newly unfavorable risk group = patients with normal karyotype and EVI1 over-
expression. Newly intermediate = all other original intermediate patients. CR = complete remission. HSCT 
= hematopoietic stem cell transplantation, MUD = matched unrelated donor, UCB = umbilical cord blood 
donor
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inTroDucTion
This chapter describes the main findings in this thesis and indicates areas for future 
research by answering three questions: 1) Which areas for future improvements in the 
field of acute myeloid leukemia have been identified in this thesis, 2) Which elements 
are essential in cost-effectiveness analyses of personalized medicine strategies, and 3) 
Which other aspects should be considered to improve the implementation of personal-
ized medicine strategies?
areas For FuTure imProvemenT in The FielD oF acuTe myeloiD 
leukemia (aml)
Adequate treatment for AML has been a challenge for many decades. The chemotherapy 
regimen has only marginally changed since 1960. However, the introduction of hemato-
poietic stem cell transplantation (HSCT) improved the cure rate of AML (120), but at the 
cost of more severe side effects and higher treatment costs. This thesis showed substan-
tially greater costs for allogeneic stem cell transplantation compared to chemotherapy 
due to a longer hospital stay and the costs of donor searching and treating the post-
transplant complication graft-versus-host-disease. Furthermore, quality of life seems 
to be worse in patients who have received a stem cell transplantation. Since the large 
negative consequences of allogeneic stem cell transplantation are commonly known 
in the field, these procedures are restricted to patients who are less likely to be cured 
with non-transplant therapeutic approaches (26). Patients with a favorable prognosis 
are initially treated with high-dose chemotherapy and only recommended for a stem 
cell transplantation in case of leukemia recurrence (269).
Recent research in the field of AML focuses on the further improvement of treatment 
outcome by new drug development and better stratification of patients for selecting 
therapies. The stratification is based upon both clinical factors and underlying cytoge-
netic and molecular abnormalities of the disease. Evidence about the prognostic impact 
of newly identified molecular subgroups, such as AML’s with nucleophosmin-1 gene mu-
tations (NPM1) without internal tandem duplication of the fms-like tyrosine kinase-3 gene 
(FLT3-ITD)(255-257), CCAAT enhancer binding protein gene double mutations (CEBPAdm) 
(253,254) and overexpression of ecotropic virus integration-1 transcript (EVI1) (258), 
resulted in a reclassification of these patients to either the favorable or unfavorable 
risk group. Since the treatment options differs between risk groups, the reclassification 
causes a treatment change for the patients in the newly identified subgroups.
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This thesis showed that the treatment change due to the reclassification of patients 
towards the favorable risk group (patients with CEBPAdm or mutated NPM1 without 
FLT3-ITD) improves life expectancy and quality of life. The treatment-related mortality 
is lower for high-dose chemotherapy and fewer treatment-related complications arise. 
Furthermore, since high-dose chemotherapy is less expensive than allogeneic HSCT, 
treatment costs are reduced. However, the total costs of the improved stratification 
increased due to the additional costs of molecular testing. Nevertheless, the improved 
stratification of patients with CEBPAdm or mutated NPM1 without FLT3-ITD can be con-
sidered cost-effective given an incremental cost-effectiveness ratio (ICER) of €1,374 per 
quality-adjusted life year (QALY).
Due to the reclassification of AML patients with EVI1 overexpression to the unfavorable 
risk group, these patients became candidates for an allogeneic HSCT from a matched 
unrelated donor or umbilical cord blood transplantation if a suitable sibling donor 
was unavailable. These treatments improved the survival of patients with EVI1 overex-
pression, but the additional life years were spent with a reduced quality of life due to 
complications of the treatment (graft-versus-host-disease). Furthermore, the treatment 
costs were much higher than the costs of the alternative treatments (chemotherapy or 
autologous HSCT). This treatment change costs €130,065 per QALY gained. It can there-
fore be argued that it is not cost-effective to treat patients with EVI1 overexpression 
with an allogeneic HSCT from a matched unrelated donor or cord blood transplantation. 
For these patients, more effective and/or less toxic treatments are needed. Currently, 
research is ongoing to develop such treatments by searching for targeted drugs.
Even if a cost-effective treatment option for patients with EVI1 would be available in the 
future, a personalized medicine strategy to identify and better treat this subgroup is 
not by definition cost-effective. Chapter 8 showed that the inclusion of the testing costs 
always increases the ICER. The rate of the increase depends on the costs of the test and 
the size of the subgroup with a treatment change relative to the total tested popula-
tion. The increase is especially substantial for small subgroups. As EVI1 overexpression 
only occurs in 3% of all AML patients, it may be challenging to develop cost-effective 
personalized medicine strategies for these patients. However, new techniques like gene 
expression profiling and whole genome sequencing might minimize this disadvantage 
as these tests enable the identification of more than one molecular aberration in one 
test. Consequently, the identification of EVI1 overexpression would not require any ad-
ditional costs of testing.
The use of gene expression profiling and whole genome sequencing also enable the 
identification of other (currently unknown) therapeutically relevant subgroups. These 
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new subgroups might lead to the identification of new drug targets for future treatment 
development in AML. At this moment, new agents are already in development that 
target leukemias with FLT3 and IDH (isocitrate dehydrogenase) gene mutations (270). It is 
important that the studies that evaluate new treatment modalities in AML not only focus 
on improved survival, but also evaluate the impact on quality of life. For many years, the 
emphasis has been on improving survival for AML patients. This focus was legitimate 
in that period because AML had a large fatality rate. However, since the cure rate has 
improved over the last decades (119,120), greater attention should be paid to quality 
of life since it has become apparent that survivors of AML experience many problems 
with functioning in daily life. As targeted treatments have a specific mode of action, it 
is expected that these treatments in many instances may have fewer side effects and 
thereby allow for improved quality of life than current treatments.
Since different questionnaires are available to measure quality of life, it is difficult for 
investigators to choose the most appropriate method. Furthermore, the aim of qual-
ity of life assessment may differ between clinicians and others like health economists 
and policymakers. From a clinical perspective, a more detailed and disease-specific 
questionnaire, like the EORTC quality of life questionnaire for cancer (QLQ-C30), might 
be desirable since it provides specific information about clinically relevant problems 
(29). In contrast, a more generic questionnaire, like the EuroQol-5D (EQ-5D), is preferred 
from a societal perspective as these questionnaires enable the comparison of quality of 
life across diseases (161). In order to converge the different aims in one questionnaire, 
this thesis derived quality of life utilities for different disease- specific questionnaires, 
including the QLQ-C30, by mapping and direct valuation. It was shown that the average 
utilities derived from the mapping algorithms were comparable with EQ-5D utilities. 
However, items were only included in the mapping algorithm if these were also cap-
tured by the EQ-5D. This means that certain disease-specific elements are still excluded 
in the utility measurement by means of mapping. These disease-specific elements are 
better included by the direct valuation methods. Nevertheless, the utilities from the 
disease-specific preference based questionnaire were significantly higher with a smaller 
range compared to the EQ-5D utilities. This smaller ranges mean that the total possible 
quality of life gain is smaller for disease-specific utilities. Consequently, the use of utili-
ties from disease-specific preference-based instruments in cost-effectiveness analyses 
may limit the comparability of cost-effectiveness results across diseases. It is therefore 
still recommended to include both generic and disease-specific questionnaires when 
assessing quality of life. Fortunately, since the EQ-5D is short, it is feasible to use both in 
the same study.
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The inclusion of both generic and disease-specific questionnaires in future studies will 
also enable a further assessment of the psychometric properties of these two question-
naires. That information is needed to provide additional information about the validity 
of the EQ-5D in acute leukemia patients. Although, the EQ-5D is the preferred quality 
of life questionnaire for economic evaluations for reasons of comparability, reimburse-
ment authorities like NICE allow for the use of other measures provided that the EQ-5D 
is not valid in that specific population (161), for example in mental health (271). Chapter 
6 of this thesis assessed the validity of the EQ-5D in AML survivors and did not find any 
significant problems regarding the validity. However, more evidence is needed since 
only a selective group of AML patients was included, repetitive measures of quality of 
life were unavailable and no objective measure of disease status was included in the 
study. These shortcomings can be overcome if quality of life will be measured alongside 
prospective clinical trials.
The quality of life of AML can also be further improved by the use of adequate sup-
portive care programs. Clinicians should identify which patients need supportive care 
and select the most appropriate program for each patient. The best approach can be 
selected by using patient-reported outcomes measures, such as the QLQ-C30, to iden-
tify the patient’s quality of life problems. Furthermore, individual patient characteristics 
such as age, ethnicity, social economic status and marital status may also influence the 
effectiveness of different supportive care programs (272,273). At this moment, only a 
few supportive care programs have been evaluated in AML survivors (274). Although 
more evidence is available from other cancer survivors (275), these findings need to be 
confirmed in AML survivors.
Another important patient-reported outcome parameter is patient satisfaction. Satisfac-
tion might be improved by reducing the hospital stay during active treatment of AML. 
Nowadays, patients are often hospitalized for about one month because they are at high 
risk of infections. Nevertheless, outpatient treatment policies may be feasible in at least 
some AML patients (80,81). Further research is needed regarding these outpatient treat-
ment options. A reduction in hospital stay will almost certainly not only improve patient 
satisfaction, but also reduce the treatment costs. It might be possible that new targeted 
treatment can be more easily applied in an outpatient setting, because it is conceivable 
that some of these treatments will be associated with reduced toxicities and medical 
complications. Thereby, the added value of the new targeted treatments might not only 
be found in clinical outcomes such as survival and quality of life, but also in reduced 
costs. Cost-effectiveness of new technologies and therapeutic compounds are needed 
to show this added value and receive adequate reimbursement for these new products.
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Adequate reimbursement is an important prerequisite for successful implementation of 
new products in clinical practice. Hospitals in the Netherlands and other countries expe-
rience more and more financial risk due to the introduction of managed competition in 
the health care sector. Consequently, hospitals need to receive sufficient reimbursement 
for the treatments to compensate the costs of treating patients and remain financially 
viable. Transparency about the actual costs of technologies and treatment is necessary 
for adequate reimbursement is only feasible if information is available about the actual 
costs of technologies and treatments. Findings from the past and present show that 
adequate reimbursement is not only difficult for new treatments but also for existing 
treatments. In 2009, hospitals faced losses regarding the treatment of acute leukemia 
and initiated a costing study to demonstrate the actual treatment costs of acute leuke-
mia. The results of this study are reported in chapter 2. It was shown that the received 
reimbursement of one chemotherapy cycle was only 25% of the actual costs (€10,000 in-
stead of €40,000) (276). This considerable difference was the automatic consequence of 
the use of standard tariffs for a hospital stay. However, the care for AML patients requires 
highly specialized treatment care and equipment and a hospital day is therefore much 
more costly than a hospital day for patients who, for instance, undergo a knee replace-
ment (69,277). Furthermore, the observed hospital stay during the chemotherapy cycle 
was much longer than assumed in the reimbursement tariff. A discussion of the findings 
with the Dutch Health Care authority improved the reimbursement of chemotherapy 
cycles. The reimbursement of stem cell transplantations also changed according to costs 
studies. However, a dramatic drop in the reimbursements of the post-transplantation 
trajectory was observed in 2014 (276). Research is ongoing with respect to the reasons 
and consequences for this discrepancy.
In the Netherlands and several other countries, it is recommended to perform cost-
effectiveness analysis from a societal perspective (278). Therefore, future studies should 
not only measure the direct medical costs, such as the costs of medication, hospital visits 
and laboratory tests, but also the costs of productivity loss due to work absenteeism and 
informal care costs. Chapter 5 showed that a large proportion of surviving patients with 
AML were unable to resume work due to problems caused by cancer. However, more 
research is needed to identify the impact of AML on productivity losses. The exact im-
pact of AML and its treatments on productivity is currently unknown. In order to assess 
the broader societal impact of AML, it is important that productivity losses are explicitly 
measured in addition to quality of life
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essenTial elemenTs in cosT-eFFecTiveness analysis oF PersonalizeD 
meDicine sTraTegies
Although this thesis performed cost-effectiveness analyses of personalized medicine 
strategies for acute myeloid leukemia, it also identified generic methods applicable 
to other diseases. Since the use of personalized medicine is increasing in many other 
diseases (other cancer types, cardiovascular disease and mental health), there is a need 
for generalized methods of analysis. In general, four steps can be identified in the cost-
effectiveness analyses of personalized medicine strategies:
1. Exploration of how treatment will change due to the application of personalized 
medicine strategies;
2. Assessment of the impact of the treatment changes on health outcomes and costs;
3. Assessment of the performance of the diagnostic test;
4. Assessment of the impact of the test strategy on health outcomes and costs.
These four steps are combined in the formula developed in chapter 8. The formula 
enables the assessment of the cost-effectiveness of the combination of the test and 
treatment strategy, but also report the separate effects of the test and treatment to 
improve the interpretation of the results. All four steps are interconnected and should 
therefore not be conducted independently. The following paragraphs describe some 
crucial components of each of the four steps and identifies areas for future research 
to improve the methodology of cost-effectiveness analyses of personalized medicine 
strategies.
exploration of how treatment changes due to the application of personalized 
medicine strategies
The aim of personalized medicine strategies is to select patients who benefit from a 
specific treatment. New insights about the prognostic impact of, for example, a specific 
molecular abnormality may result in changes in the algorithm for selecting patients and 
the subsequent treatment. However, treatment selection is often based on several other 
factors, such as patient characteristics, clinical factors and other molecular abnormalities, 
as well. Cost-effectiveness analyses of personalized medicine strategies should therefore 
not assume that treatment changes for all patients with the specific abnormality. This 
finding can be clearly explained by the case study in AML (Chapter 8). The personalized 
medicine strategies for AML aimed to select patients who benefit from allogeneic he-
matopoietic stem cell transplantations. These transplantation were restricted to patients 
with an intermediate or high risk of relapse. However, not all patients were eligible for 
these transplantations due to comorbidities or a low performance status of the patient 
or the absence of a suitable donor. Consequently, treatment only changed for a subset 
of the newly identified patients.
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A correct assessment of the proportion of patients for whom treatment changes due to 
adjustments in the personalized medicine strategy is crucial for the estimation of the 
cost-effectiveness of the strategy. It was shown that the ICER increases substantially if 
treatment changes for a smaller group of patients. Consequently, the cost-effectiveness 
of personalized medicine strategies will probably be overestimated if analyses assume 
that treatment changes for all patients in the newly identified subgroup.
The proportion of patients with a treatment change also depends upon the uptake of 
the personalized medicine strategy in clinical practice. A limited uptake may be related 
to the application of the test or the choice of treatment according to the test results. 
Both examples have been found regarding the use of erlotinib for lung cancer patients 
with EGFR mutations (279). Despite convincing evidence about the benefits of erlotinib 
in this subgroup of patients, not all hospitals in the Netherlands tested for EGFR muta-
tions in lung cancer patients. Furthermore, even if the test was performed, treatment 
choice was not always in accordance with the test results. The limited uptake of the 
treatment guideline may reduce the proportion of patients with a treatment change 
and increase the ICER. The limited application of the test will only impact the proportion 
with a treatment change if the reasons for deciding to use the test are not random. 
With respect to cost-effectiveness analyses of personalized medicine strategies, it is rec-
ommended to assess the full potential costs and benefit of the personalized medicine 
strategy by assuming perfect implementation of both the test and treatment approach. 
Furthermore, scenario analyses are needed to assess the real-world cost-effectiveness of 
the strategies while assuming imperfect implementation of both the test and treatment 
strategy.
Finally, the proportion of patients whose treatment changes also depends upon the 
qualitative performance of the diagnostic test. Assuming that a positive test results in 
a treatment change, the proportion decreases for a lower sensitivity and increases for a 
lower specificity. The contrary holds once a negative test results in a treatment change.
The assessment of the impact of treatment changes on health outcomes and 
costs
The developed formula presented in chapter 8 shows that only health outcomes and 
costs of patients with a treatment change need to be included in the analysis. In theory, 
time and money can be saved by restricting the data collection and analysis of health 
outcomes and costs to this selected subgroup of patients. However, it is often not fea-
sible to identify the patient group with a treatment change prior to the start of the study. 
Furthermore, in the continuous developing field of personalized medicine, it might be 
more efficient in the long run to collect data of all patients. New evidence about prog-
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nostic subgroup may adjust the personalized medicine strategy and require additional 
information about health outcomes and costs.
Existing methods of cost-effectiveness analyses, including piggy-back studies and 
decision-analytic modeling, can in principle be used to assess the impact of person-
alized medicine strategies on health outcomes and costs. However, some decisions 
regarding type of data sources and decision-analytic model may differ from standard 
cost-effectiveness analyses of new drugs. The most commonly used decision-analytic 
model in cost-effectiveness analyses, the Markov model, can be used for the assessment 
of personalized medicine strategies, but it is less flexible to incorporate future adjust-
ments to personalized medicine strategies than a discrete-event simulation. Therefore, 
the discrete-event simulation was used in this thesis to assess the cost-effectiveness of 
personalized medicine strategies in AML. Nevertheless, the discrete-event simulation 
has also some disadvantages, including the computational and analytical complexity 
and the dependency on individual patient level data. Model selection for future cost-
effectiveness analysis of personalized medicine strategy should result from a deliber-
ated choice to balance complexity, flexibility and feasibility.
The feasibility of a specific model depends largely on the availability of the data. The in-
volvement of health economist at the design phase of new clinical studies may improve 
access to adequate information by including relevant health economic outcomes such 
as costs and quality of life. Notwithstanding, the actual data collection is often restricted 
due to strict budgets. It is expected that clinical studies of personalized medicine strate-
gies are more extensive than studies for new drug entities, because the assessment of 
both the test and treatment is not feasible in standard clinical trial designs. Therefore, 
new types of study design are currently being used to assess the impact of personalized 
medicine strategies. Four of these new randomized controlled trial designs are, respec-
tively, the biomarker-stratified design, the enrichment design, the biomarker-strategy 
design and the adaptive trial design (280-282). The biomarker-stratified design stratifies 
patients according to test result and subsequently randomizes both patients with a 
positive and negative test result to the different treatment arms. The enrichment design 
initially includes all patients. However, only patients with a positive test outcome will be 
randomized to the different treatments. In the biomarker-strategy design, patients are 
randomized between a uniform and stratified treatment according to the test results 
(280). The adaptive trial design is an extended version of the biomarker-strategy design 
and divides the trial period into two phases. The first phase is aimed at selecting the 
most appropriate test to stratify treatment. Nevertheless, in that phase, treatment is 
already randomized between uniform and stratified treatment using a gold standard 
to stratify. In the second phase, stratification is based upon the most appropriate test 
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according to the results of phase 1 (282). All described trial designs have advantages and 
disadvantages and there is currently no general agreement yet regarding the optimal 
trial design. At this moment, the choice of trial design largely depends upon the aim of 
the study and the balance between the required evidence and the feasibility of collect-
ing this evidence in a timely manner (280,281).
Regardless of the challenge of the choice of an appropriate design of clinical trials for 
personalized medicine strategies, it can be challenging to recruit a sufficiently large 
sample. Although the total required sample size of the trials might be smaller due to 
a larger expected efficacy, the total source population of eligible patients is also much 
smaller. Accordingly, the recruitment of patients may take much longer, which will 
increase the development time of the new medicines and technologies. In order to 
solve this problem, international collaborations between research centers worldwide 
are needed to speed up the inclusion of the required patient numbers. Notwithstanding, 
worldwide collaboration might be practically difficult if the standard clinical practice 
differs among countries. Another disadvantage of worldwide collaboration is that only 
one treatment modality may be studied at a time. This problems is solved by new de-
signs like the ‘pick-a-winner’ design which start with the inclusion of several treatment 
modalities and use interim analyses to select the treatment with the most promising 
results for further evaluation (283). However, a major disadvantage of this design is the 
high chance for incorrect decision about treatment (dis)continuations.
All new designs are mainly developed to show the efficacy of personalized medicine 
strategies. However, randomized clinical trials have strict in- and exclusion criteria to 
limit the bias of other factors such as comorbidities and poor performance status in the 
assessment of the treatment effect. The disadvantage of the strict in- and exclusion crite-
ria is the lack of generalizability towards the real clinical practice. Patients excluded from 
clinical trials are often older, less fit and have more comorbidities than included patients 
(284). An assessment of the treatment effect in daily practice, the effectiveness, requires 
additional data. This data might be derived from patient registries which are increas-
ingly being set up to assess the cost-effectiveness of new medicines in daily practice. 
However, it has been shown that the selection of an adequate control group is difficult 
due to the absence of randomization in daily practice. Treatment choice is largely driven 
by patient and disease characteristics (285). Consequently, cost-effectiveness analyses 
using real word data are often biased due to differences in patient and disease charac-
teristics between treatment groups. A historical cohort might be a better comparator 
as a group with similar patient and disease characteristics can be selected. However, 
not infrequently, historical controls are not available for the assessment of personalized 
medicine strategies because tests for biomarkers have not been performed in the past. 
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Patient registries should address this problem to enable real-world cost-effectiveness 
analyses of personalized medicine strategies. A possible solution is to expand existing 
registries with the storage of patient material for future analyses if feasible regarding 
legal and ethical boundaries.
The assessment of the performance of diagnostic tests
The test strategy is another critical component in the evaluation of personalized medicine 
strategies in addition to the consequences of a treatment change. Since the qualitative 
performance of the test largely influences the proportion of patients with a treatment 
change, it is important that the performance of the test is adequately assessed in cost-
effectiveness analysis of personalized medicine strategies. Within this perspective, it is 
important to recognize that different definitions of performance can be used. The strict 
definition of performance assesses whether the test correctly identifies a (molecular) 
abnormality (286). The disadvantage of this definition is that it assumes that a current 
test is used as a gold standard, while it is questionable whether a gold standard can be 
defined for newly developed technologies. A broader definition of performance relates 
to the performance of risk prediction, for example whether tests correctly distinguish 
responders from non-responders before the start of the treatment (287). This broader 
definition is better applicable to personalized medicine strategies because treatment 
choice depends on several factors including age, performance status and disease char-
acteristics. All these different measures can be included in the prediction algorithm and 
adjustments to the algorithm can also easily be assessed.
The assessment of the impact of the test strategy on health outcomes and costs
The impact of the test strategy on the cost-effectiveness of personalized medicine 
strategies is determined by the costs and the application of the test. The most obvious 
effect is that the cost of a personalized medicine strategy increase with higher costs of 
the test. The application of the test refers to the decision about the patient group to be 
tested, i.e. is the test applied to all patients with a specific disease or only a subset of 
these patients? This decision determines the size of the subgroup for whom treatment 
changes as proportion of the total tested population. This thesis showed that the ICER 
increases for smaller subgroups. Since both the costs and the application of the test 
can be influenced by the manufacturer, scenario analyses regarding different costs and 
applications are very informative to select a cost-effective testing strategy. These adjust-
ments to the testing strategy may not only be beneficial for the manufacturer, but also 
for patients as it is more likely that personalized medicine strategies will be reimbursed 
if these are cost-effective.
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In this thesis, it was assumed that testing only influences health outcomes by means of a 
treatment change. Consequently, differences in health outcomes were not observed for 
patients without a treatment change. However, there may be situations in which the test 
itself has an impact on health outcomes. For example, invasive tests like colonoscopy 
may reduce short-term quality of life due to discomfort and pain. Other tests may have 
more severe complications such as infection or death. Furthermore, tests may yield ben-
efits or harms for patients if uncertainty about the diagnosis and prognosis is resolved 
regardless of any changes in treatment (288). Future studies should assess how these 
additional benefits and harms of personalized medicine strategies can be included in 
cost-effectiveness analyses and reimbursement decisions. A critical element for these 
studies is whether all benefits and harms can be adequately measured by the QALY 
concept. Short-term changes in quality of life have little impact on the QALY, but are 
important if patient preferences are also part of reimbursement decisions. Furthermore, 
it is unknown whether the value of knowing (resolving uncertainty about diagnosis 
and prognosis) is already included in the QALY concept or whether additional outcome 
measures are needed.
A complicating factor in the assessment of the personalized medicine strategies is that 
it is expected that new tests, like whole genome sequencing of tumor samples and full 
body imaging scans, are able to detect several abnormalities at a time. The result of the 
test is no longer dichotomous, i.e. presence or absence of one abnormality, but con-
sists of a combination of abnormalities. Cost-effectiveness analyses of these new tests 
require the assessment of different treatment options for all possible combinations of 
abnormalities. Besides an expansion of the number of strategies to be evaluated, whole 
genome sequencing of tumor and full body imaging scans have a substantial risk of 
incidental findings due to the broad application of the tests (289). Incidental findings 
are results which were not anticipated when ordering the test. These findings require 
additional testing and treatment to adequately treat the abnormality detected (290). It 
should be discussed whether and how the costs and effects of these incidental findings 
can be incorporated in cost-effectiveness analyses of personalized medicine strategies.
oTher relevanT consiDeraTions For successFul imPlemenTaTion oF 
PersonalizeD meDicine sTraTegies.
It is expected that a more standardized method to analyze and report the cost-
effectiveness of personalized medicine strategies improves the implementation of the 
strategies as the consequences of the strategies are more transparent. However, better 
methodological guidelines are not sufficient for a successful implementation of new 
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personalized medicine strategies. Adaptation in the development and reimbursement 
of the personalized medicine strategies are also required.
More valuable personalized medicine strategies might be introduced to the market 
if the development of these strategies is guided by early cost-effectiveness analyses 
(41,291). These early analyses can identify the potential of the strategy by evaluating the 
required targets in terms of costs of the test and treatment, application of the test and 
treatment effectiveness. The strategy can be adjusted early in the development process 
without wasting resources on the development of unsuccessful strategies. Furthermore, 
the data collection can be improved as the early assessment may also identify the most 
influential parameters for which additional data is required.
The reimbursement of personalized medicine strategies should be based upon integral 
financing of both the test and treatment. Although the diagnosis-related groups aim 
for a more integrated financing system by combining diagnosis and treatment in one 
declaration form, it is not adequately working in current practice. Each hospital division 
is still responsible for their own budget and personalized medicine strategies often lead 
to additional costs in one division, while the benefits are accrued by another division. 
For example, laboratories need to invest in new genetic tests, while the clinical depart-
ment saves money by applying a less costly treatment. A more integral financing system 
might improve the incentives for laboratories to implement new technologies.
Besides an integral method of financing personalized medicine strategies, it is recom-
mended to apply value-based pricing according to the added value of both the test 
and targeted treatment. The added value of the targeted treatment can be determined 
by the (cost-)effectiveness of the new treatment in the selected subgroup, while tests 
have added value if new subgroups are identified or if the identification of existing 
subgroups is improved. This type of value-based pricing allow higher reimbursement 
levels for treatments targeted to newly identified subgroups to cover the costs of testing 
as well. A standardized reimbursement level for all personalized medicine strategies is 
either not sufficient for strategies related to newly identified subgroups or overcom-
pensates strategies for subgroups already identified in clinical practice. Consequently, 
value-based pricing stimulates innovation for both existing and new subgroups while 
allowing a more sustainable health care.
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summary
Treatment for cancer is nowadays moving towards a more personalized approach, be-
cause it has been shown that only a selective group of patients responds to the available 
treatments. Furthermore, disease susceptibility and prognosis also differ from patient 
to patient. The selection of treatment according to individual patient characteristics is 
called ‘personalized medicine’ and may be based upon both genetic and non-genetic 
information. It is expected that the number of personalized medicine strategies will 
largely increase in the future due to the growing evidence about the association between 
genetic aberrations and prognosis or treatment response. Since techniques to identify 
genetic aberration can be very expensive, cost-effectiveness analyses of personalized 
medicine strategies are required to allow for a sustainable health care in the future. This 
thesis assess the cost-effectiveness of personalized medicine strategies in acute myeloid 
leukemia (AML) and aims to contribute in methodology for strategies in other areas.
AML is a specific type of leukemia which is characterized by a proliferation of immature 
myeloid cells (blasts) in the bone marrow. The proliferation of blasts reduces the devel-
opment of normal blood cells which lead to increased risk of bleedings and infections 
and make patients feel tired and weak. The rapid increase of blasts in patients with AML 
requires immediate treatment to reduce the number of blasts and restore the normal 
blood functioning. Intensive treatments, including high-dose chemotherapy and stem 
cell transplantations, are required to cure the disease. Unfortunately, these treatments 
are often only feasible in younger patients, resulting in a better prognosis for these 
patients. The 5-year overall survival rate is 55% and 9% in patients aged 18-44 and 65-74 
years, respectively. Another important prognostic factor besides age is the presence of 
cytogenetic and molecular aberrations. Many different aberrations have been identified 
and some of these are already defined as a distinct disease entity by the World Health 
Organization.
There is high potential for personalized medicine strategies in AML due the to the het-
erogeneity nature of the disease. At this moment, a targeted treatment is only available 
for one AML subgroup. The application of this targeted treatment is already standard 
clinical practice and dramatically improved the prognosis of that subgroup. The current 
options to further personalize AML treatment are only available for younger aged pa-
tients (age < 60 years) and include the selection of treatment according to expected risk 
of relapse. Patients with a low risk of relapse can be cured with a less intensive treatment 
(high-dose chemotherapy instead of (allogeneic) hematopoietic stem cell transplanta-
tion) than patients with a high risk of relapse. Information about the prognostic impact 
of newly identified subgroups in AML resulted in a reclassification of patients from the 
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intermediate risk group to either the low or high risk group. This thesis assessed the 
impact of these reclassifications on health outcomes and costs.
estimation of input parameters
The analyses started by measuring the costs of all treatments in acute myeloid leukemia 
(Chapter 2). The costs were distinguished in three treatment phases: induction treat-
ment, post-remission treatment and 1-year follow-up. Post-remission treatment con-
sisted of high-dose chemotherapy, autologous hematopoietic stem cell transplantation 
(HSCT) and allogeneic HSCT from a sibling or matched unrelated donor (MUD). Costs 
were based on the resource use of all adult patients diagnosed with de novo primary 
or secondary AML who started with induction chemotherapy in 2008 or 2009 in three 
university hospitals in the Netherlands. Treatment for AML is very expensive; the costs of 
induction chemotherapy are about €45,000 and the costs of post-remission treatment 
ranges between €33,277 and €82,041. A large proportion of these costs is caused by 
the long hospital stay (about four weeks) during treatment. An allogeneic HSCT from 
a MUD is the most expensive treatment option due to the costs of donor searching, 
HLA-typing and additional diagnostic tests. The treatment of graft-versus-host disease 
as a complication of an allogeneic HSCT resulted in significantly higher follow-up costs 
after these procedures.
The most common effect measure in cost-effectiveness analyses is the quality-adjusted 
life year (QALY), a combined measure of mortality and morbidity. This measures weights 
the gain in life years by a utility value for the quality of life. Perfect health is represented 
by a utility value of 1 and death with a utility value of 0. These utility values are of-
ten derived from generic preference-based questionnaires such as the EQ-5D. These 
questionnaires are applicable to all diseases and the utility values were calculated from 
preferences of the general public. Many clinical studies, however, use disease-specific 
instruments which do not incorporate these preferences in the scoring algorithms. 
Consequently, the results of these studies cannot be used to estimate quality of life utili-
ties. This problem was also observed in acute myeloid leukemia. Therefore, two different 
methods were applied in this thesis to derive utilities from a cancer-specific quality 
of life questionnaire (QLQ-C30). These methods were also applied to disease-specific 
questionnaire in two other disease areas, multiple sclerosis and rheumatoid arthritis, to 
find generic pattern for these methodology.
Chapter 3 describes the application of the first method to estimate utility values from 
disease-specific quality of life questionnaire, which is called mapping. Mapping predicts 
the EQ-5D score based upon responses to the questionnaire. The prediction is derived 
from regression analysis and is therefore only feasible if the EQ-5D and the disease-
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specific questionnaire are included in the same study. With respect to the QLQ-C30, the 
mapping algorithm was developed in a sample of patients with multiple myeloma and 
tested in sample of patients with Non-Hodgkin lymphoma. Model selection was based 
upon statistical significance of predictors, logical consistency, parsimony and predictive 
ability. The selected mapping algorithm depends on the overlap of the items on the 
disease-specific instrument with the EQ-5D and the population in which the algorithm 
was developed. Ideally mapping functions are developed in a representative sample of 
all patients to improve external validity. A comparison between the mapping algorithms 
for the three disease-specific questionnaires showed the best performance for the QLQ-
C30. This finding was in line with the expectations, because the QLQ-C30 had the largest 
correlation with the EQ-5D. The mapping algorithm for the QLQ-C30 as developed in 
the Multiple Myeloma patient sample was able to predict utilities in the Non-Hodgkin’s 
sample. Furthermore, the predicted utilities for the four performance states followed the 
same pattern as the observed EQ-5D utilities. However, the differences in utility scores 
between the performance states were slightly smaller.
The second method to calculate utility values for disease-specific questionnaires is 
applied in chapter 4 and include the direct valuation of disease-specific health states. 
The direct valuation was performed for the same disease-specific questionnaires as for 
which mapping algorithm were developed. The aim of the study was to assess the com-
parability of utility values from these disease-specific questionnaires to utility values 
from generic questionnaires. The disease-specific questionnaires were first reduced in 
content, because respondents can maximal value nine items. Reduction was based on 
three criteria: i) fit to the Rasch model, ii) standard psychometric criteria and iii) clinical 
relevance. Once the questionnaires were reduced, a subset of all possible health states 
was selected for valuation. Respondents from the general public valued these health 
states by means of the time-trade-off method similar to the protocol used in the valu-
ation of the EQ-5D. The preference values observed for the selected health states were 
used to estimate values for all potential health states through statistical modeling. The 
results of the study showed significant higher utility values for all three disease-specific 
questionnaires compared to utility values derived from generic preference-based ques-
tionnaires. The higher average values are caused by the smaller range of utility values 
indicating that the disease-specific questionnaires do not capture very poor health. The 
preference-based instrument for cancer (QLQ-PBM) appeared to be more sensitive to 
small changes in health as a substantial proportion of patients reported problems on 
this instrument while reporting no problems on the EQ-5D. Furthermore, both the QLQ-
PBM and EQ-5D were able to detect differences between patients with and without side 
effects. No evidence was found for an improved discriminative ability or responsiveness 
of the QLQ-PBM compared to the EQ-5D. In fact, both instruments were able to detect 
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differences over time, but the absolute difference in utility was consistently higher for 
the EQ-5D.
A comparison of the two methods to estimate utility values for the QLQ-C30 showed that 
utility values resulted from the mapping algorithm were best comparable to those from 
the EQ-5D. However, the algorithm excluded items which were not adequately captured 
by the EQ-5D. Therefore, the use of the QLQ-PBM is preferred if these excluded scales 
are considered essential for measuring quality of life in patients with acute leukemia. 
Otherwise, the EQ-5D, or the mapping algorithm if the EQ-5D is absent, should be used 
in cost-effectiveness analyses to allow comparisons with other diseases. An assessment 
of the validity of both the EQ-5D and the QLQ-PBM In acute leukemia patients was 
required to judge which questionnaire can best be used in the cost-effectiveness analy-
ses of personalized medicine strategies in AML. This assessment was feasible with the 
results of a quality of life study in acute leukemia survivors in which both questionnaires 
were included. The results of this study are described in chapter 6. A newer version of 
the EQ-5D, with five answer levels for each domain instead of three, was included as it 
was assumed that this version was more sensitive to small changes in health. According 
to this study, no problems were indicated regarding the feasibility, validity and reliabil-
ity of the EQ-5D in acute leukemia patients. Both questionnaires had a good internal 
consistency and only six and seven out of the 111 respondents did not fully complete 
the EQ-5D and QLQ-PBM, respectively. Furthermore, both instruments were able to 
distinguish between severity levels. However, a substantial larger proportion of patients 
reported full health on the EQ-5D compared to the QLQ-PBM.
The quality of life study was initially set up to assess the impact of AML and its treatment 
on health-related quality of life (HRQOL) by comparing the HRQOL of AML survivors 
with the HRQOL in the general population as described in chapter 5. Questionnaires 
were sent to patients diagnosed with acute leukemia between 1999 and 2011 at a single 
academic hospital and still alive in 2012. It was found that AML survivors had a worse 
quality of life than the general population. Problems were more frequently reported 
regarding all functioning scales, pain, dyspnea, fatigue, appetite loss and financial dif-
ficulties. The impaired quality of life was especially found in patients without a paid job. 
This is an important problem as the group accounts for about 25% of all AML survivors in 
our study. The study also indicates factors possibly associated with a poor HRQOL. These 
factors include lack of social support, allogeneic HSCT as post-remission treatment and 
younger age. However, due to the insufficient power of the study no definite conclu-
sions can be drawn.
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cost-effectiveness analyses
A decision-analytic model was developed and validated to assess the cost-effectiveness 
of personalized medicine strategies in acute myeloid leukemia. The development and 
validation was an iterative process and the results were continuously checked with 
clinical experts and input data for face validity and internal validity. Detailed informa-
tion about the development and validation can be found in chapter 7. A discrete-event 
simulation was developed to adequately capture the heterogeneity of the disease and 
the impact of several disease and patient characteristics on important health outcomes 
such as complete remission rate, risk of relapse and death. A fictive dataset was simulated 
with individual disease paths. For each patient, the disease paths was determined by the 
estimation of the time to concurrent events from survival functions including relevant 
patient and disease characteristics. The event with the shortest time to occurrence was 
always selected for each patient. Both patient and disease characteristics as well as rel-
evant clinical outcome measures of the final developed model were compared with the 
original data. No striking differences were found between the model and the original 
data indicating a good internal validity of the model. The model results were also in line 
with the reported survival in other clinical trials. However, the generalizability of the 
model to a broader patient population has not been proven yet.
As described before, the personalized medicine strategies under study consist of reclas-
sification of patients to either the low or high risk group. Separate cost-effectiveness 
analyses were performed for the two reclassification types and reported in chapter 8. As 
a consequences of the reclassification, treatment changes for the new risk groups; a less 
intensive treatment is administered to patients with a low risk and a more intensive treat-
ment to patients with a high risk. The cost-effectiveness analysis was first restricted to the 
assessment of the consequences of the treatment changes while neglecting the costs 
of identifying the new subgroups, because many published studies used this restricted 
approach. It was found that the less intensive treatment for low risk patients resulted 
in better health outcomes at lower costs. The new treatment was therefore dominant 
for this subgroup. Health was also improved by the more intensive treatment for high 
risk patients, but at substantial higher costs. The incremental cost-effectiveness ratio 
(ICER) of the treatment change for that subgroup was €130,065 per QALY gained. The 
inclusion of the consequences of the test resulted in higher ICERs for both personalized 
medicine strategies. It was found that the severity of the underestimation of the ICER 
depends upon the costs of the test, the incremental effects of the treatment change and 
the prevalence of the subgroup with a treatment change. According to these findings, 
a formula was developed that enables the separate assessment of the consequences of 
the test and treatment approach in personalized medicine strategies.
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recommendations for future research
Chapter 9 discusses the main findings and implications of this thesis. It was shown that 
it is cost-effective to treat patients with a low risk of relapse with a less intensive treat-
ment. However, more cost-effective treatments are required for patients with a high risk 
of relapse. The new treatment for these patients is very costly and has negative conse-
quences in terms of quality of life. Besides improved treatment for this specific subgroup, 
targeted treatments for other AML subgroups are also required. Other improvements 
in the treatment of AML may be achieved by better supportive care programs which 
may improve quality of life. Furthermore, costs can largely be reduced if patients can be 
treated in an outpatient setting. More effective, but less toxic, treatment might enable 
this outpatient setting.
Preferably, new clinical studies include quality of life as a secondary outcome. Although 
it seems that the EQ-5D is valid for acute leukemia patients, it is recommended to in-
clude both the disease-specific QLQ-C30 and generic EQ-5D to test the validity of the 
instruments in larger longitudinal studies. Furthermore, both direct and indirect costs 
should be measured in future studies to adequately assess the impact of new treatment 
strategies on the total costs.
The findings from the case-study in AML also contribute to the methodology of cost-
effectiveness analyses of personalized medicine strategies in other diseases areas. It is 
recommended to always include the costs of testing in cost-effectiveness of personal-
ized medicine strategies to avoid biased results. The use of the formula may enable an 
efficient approach to add the costs of testing to the analysis. Data collection and analysis 
of health outcomes and costs can still be restricted to the subgroup with a treatment 
change. Standardized use of the formula also improves the interpretation of the results 
by better comparability between studies. Furthermore, the formula can be used early in 
the development process to guide further development and data collection.
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samenvaTTing
De behandeling van kanker wordt in toenemende mate afgestemd op de individuele 
kenmerken van de patiënt. De achterliggende reden hiervoor is dat slechts een beperkte 
groep patiënten reageert op de beschikbare behandelingen en die groep patiënten is 
steeds beter op voorhand te identificeren. Naast response kunnen ziekteprognose en 
de kans op het ontwikkelen van ziektes ook sterk verschillen tussen individuen. Verschil-
lende soorten informatie kunnen worden gebruikt om de juiste behandeling te selec-
teren, zoals leeftijd, comorbiditeiten, afwijkende laboratoriumwaarden en moleculaire 
afwijkingen. Aangezien steeds meer verbanden worden gevonden tussen moleculaire 
afwijkingen en ziekteprognose of behandeleffect, wordt verwacht dat het aantal geïndi-
vidualiseerde behandelstrategieën sterk zal toenemen in de toekomst. Het onderzoeken 
van de kosteneffectiviteit van deze nieuwe strategiëen is daarom essentieel om een be-
taalbare gezondheidszorg te blijven garanderen in de toekomst. Dit proefschrift onder-
zoekt de kosteneffectiviteit van verschillende geïndividualiseerde behandelstrategieën 
in acute myeloïde leukemie (AML). Naast belangrijke bevindingen voor AML levert het 
proefschrift ook aanbevelingen voor de methodologie van kosteneffectiviteitsanalyses 
van geïndividualiseerde behandelstrategieën in andere ziektegebieden.
AML is een specifieke vorm van leukemie dat wordt gekenmerkt door een ongecontro-
leerde toename van onvolgroeide myeloïde cellen (blasten) in het beenmerg. De sterke 
toename van de blasten beperkt de ontwikkeling van normale bloedcellen waardoor 
patiënten een verhoogd risico hebben op bloedingen en infecties. Aangezien AML 
een zeer heterogene ziekte is met veel verschillende cytogenetische en moleculaire 
afwijkingen is er veel potentie voor het toepassen van geïndividualiseerde behandel-
strategieën. Op dit moment is slechts één gerichte behandeling beschikbaar voor een 
specifieke AML subgroup. Deze behandeling heeft de prognose voor de die subgroup 
aanzienlijk verbeterd. Met de huidige kennis kan de behandeling van AML alleen verder 
geïndividualiseerd worden door de behandeling af te stemmen op de verwachte kans 
op terugkeer van de ziekte (relapse). Patiënten met een kleine kans op relapse kunnen 
worden behandeld met een minder intensieve behandeling (hoge dosis chemotherapie 
in plaats van een (allogene) stamceltransplantatie) dan patiënten met een hoge kans op 
relapse. Informatie over de prognostische impact van nieuwe geïndenticeerde subgroe-
pen van AML heeft geresulteerd in een herclassificatie van patiënten in de verschillende 
risicogroepen. De gevolgen van deze herclassificatie op gezondheidsuitkomsten en 
kosten zijn onderzocht in dit proefschrift.
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achterhalen van de inputs voor de kosteneffectiviteitsanalyse
De eerste stap in de analyse was het bepalen van de kosten van de verschillende 
behandelingen voor AML (hoofdstuk 2). Alle kosten werden onderscheiden in drie 
behandelfases: inductie behandeling, post-remissie behandeling en 1-jaar follow-
up. De post-remissie behandeling bestond uit hoge-dosis chemotherapie, autologe 
stamceltransplantie en een allogene stamceltransplantatie van een sibling (broer/zus) 
of een donor afkomstig uit een donor bank. Alle kosten waren gebaseerd op het zorg-
gebruik van volwassen patiënten die in 2008 of 2009 waren gestart met een inductie 
behandeling in drie universitaire ziekenhuizen in Nederland. Uit de studie bleek dat de 
behandeling voor AML erg duur is. De kosten van één inductie chemokuur bedroegen 
ongeveer €45.000 en de kosten voor de post-remissie behandeling variëren tussen de 
€33.277 en €82.041. Een aanzienlijk deel van de kosten wordt veroorzaakt door de lang-
durige ziekenhuisopname (ongeveer vier weken) tijdens de behandeling. Een allogene 
stamceltransplantatie van een ongerelateerde donor (afkomstig uit de donorbank) is 
de duurste behandeling. De hogere kosten worden veroorzaakt door de kosten voor 
het zoeken van een donor, HLA-typering en aanvullende diagnostische testen. De 
kosten voor de follow-up na allogene stamceltransplantaties waren significant hoger 
dan andere follow-up kosten door de behandeling van graft-versus-host-disease als 
complicatie van de stamceltransplantaties.
De meest gebruikte effectmaat in kosteneffectiviteitsanalyes is het voor kwaliteit ge-
corrigeerde levensjaar (quality-adjusted life year oftewel QALY). De QALY combineert 
mortaliteit en morbiditeit in één maat door elk gewonnen levensjaar te wegen met een 
utiliteit voor de kwaliteit van dat leven. Perfecte gezondheid heeft een utiliteit van 1 en 
dood een utiliteit van 0. Deze utiliteiten zijn vaak afgeleid van generieke vragenlijsten 
zoals de EQ-5D om vergelijkingen tussen ziektes te kunnen maken. In veel klinische 
studies, ook in AML, wordt deze vragenlijst echter niet altijd meegenomen, maar wordt 
gebruik gemaakt van een ziektespecifieke vragenlijst. Oorspronkelijk was het niet mo-
gelijk op basis van deze ziektespecifieke vragenlijsten kwaliteit van leven utiliteiten. Het 
gevolg hiervan is dat de QALY niet gebruikt kan worden als uitkomstmaat in kosteneffec-
tiviteitsanalyses. Om dit probleem op te lossen, zijn in dit proefschrift twee verschillende 
methoden toegepast om utiliteiten te achterhalen voor een kankerspecifieke vragenlijst 
(QLQ-C30). Deze methoden zijn ook toegepast op ziektespecifieke vragenlijsten in twee 
andere ziektegebieden (multipele sclerose en rheumatoïde arthritis) om generieke 
uitspraken te kunnen doen over de gebruikte methodologie.
Hoofdstuk 3 beschrijft de toepassing van de eerste methode, ‘mapping’ genoemd. Bij 
mapping wordt de score op de EQ-5D voorspeld op basis van de items van de ziekte-
specifieke vragenlijst. Deze voorspelling is alleen mogelijk als patiënten zowel de EQ-5D 
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als de ziektespecifieke vragenlijst hebben ingevuld. Voor de QLQ-C30 is het mapping 
algoritme afgeleid uit een studie met patiënten met multipel myeloom en getest in pa-
tiënten met non-Hodgkin lymfoom. Verschillende criteria, zoals statische significantie, 
logische consistentie, eenvoud en voorspellend vermogen, zijn gebruikt om de voor-
spellend algoritme te ontwikkelen. UIt de studie bleek dat de kwaliteit van het algoritme 
afhankelijk is van de populatie die gebruikt is voor de voorspelling en de overlap tussen 
de items op de ziektespecifieke vragenlijst en de EQ-5D.
De tweede methode voor het bepalen van utiliteiten voor ziektespecifieke vragenlijsten 
is toegepast in hoofdstuk 4 en betreft een directe waardering van ziektespecifieke 
gezondheidstoestanden. De eerste stap in de analyse was het inkorten van de ziek-
tespecifieke vragenlijsten, omdat respondenten maximaal negen verschillende items 
kunnen waarderen. De volgende criteria werden gebruikt voor de selectie van de items: 
i) overeenstemming met het Rasch model, ii) standard psychometrische criteria en iii) 
klinische relevantie. Respondenten uit het algemeen publiek hebben een subset van 
gezondheidstoestanden gewaardeerd met de time trade-off methode die ook gebruikt 
was in de waardering van de EQ-5D. De utiliteiten van niet-gewaardeerde gezondheids-
toestanden zijn vervolgens geschat met behulp van statistische modelleertechnieken. 
De utiliteiten voor de ziektespecifieke vragenlijsten bleken significant hoger te zijn 
dan die van de EQ-5D. Dit kan mogelijk verklaard worden door de kleinere range van 
utiliteiten bij ziektespecifieke vragenlijsten. Het lijkt dat zeer slechte gezondheid, als 
gevolg van bijvoorbeeld comorbiditeit, niet wordt opgepikt door de ziektespecifieke 
vragenlijsten. Een vergelijking tussen de utiliteiten van de EQ-5D en de QLQ-PBM laat 
zien dat kleine verschillen in gezondheid beter worden geïdentificeerd door de QLQ-
PBM. Beide instrumenten waren echter in staat om een onderscheid te maken in de 
kwaliteit van leven bij patiënten met en zonder bijwerkingen. Er was ook geen bewijs 
gevonden voor een verbeterde responsiviteit van de QLQ-PBM.
Een vergelijking van de twee methoden om utiliteiten te berekenen voor de QLQ-C30 
laat zien dat mapping leidt tot utiliteiten die het beste vergelijkbaar zijn met die van de 
EQ-5D. Het nadeel van mapping is echter dat items die niet adequaat worden opgepikt 
door de EQ-5D ook niet zullen worden opgenomen in het mapping algoritme. Deze 
items kunnen wel zijn opgenomen in de QLQ-PBM. Op basis van deze informatie is de 
vraag welk instrument het best gebruikt kan worden voor het meten van kwaliteit van 
leven utiliteiten bij patiënten met acute leukemia. In principe wordt de EQ-5D aangera-
den voor kosteneffectiviteitsanalyses omdat de resultaten vergeleken kunnen worden 
met andere ziektes. Een noodzakelijke voorwaarde is dan wel dat de EQ-5D valide is voor 
de desbetreffende patiëntenpopulatie. De validiteit van zowel de EQ-5D als de QLQ-
PBM bij acute leukemie is onderzocht in hoofdstuk 6. Zowel de EQ-5D als de QLQ-PBM 
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hadden een goede interne consistentie en slechts zes en zeven respondenten hadden 
respectievelijk de EQ-5D of de QLQ-PBM niet volledig ingevuld. Daarnaast waren beide 
vragenlijsten in staat om een onderscheid te maken naar ernst van de ziekte. Wel werd 
perfecte gezondheid veel vaker gerapporteerd op de EQ-5D dan de QLQ-PBM. Op basis 
van deze studie is geen reden gevonden om te twijfelen aan de validiteit van de EQ-5D.
De cross-sectionele kwaliteit van levenstudie was in eerste instantie opgezet om de 
kwaliteit van leven te meten bij patiënten die in het verleden (tussen 1999 en 2011) 
waren gediagnosticeerd met AML. Door deze resultaten te vergelijken met de kwaliteit 
van leven in de algemene populatie kon inzicht worden gekregen in de invloed van 
AML en de bijbehorende behandelingen op de kwaliteit van leven. De AML patiënten 
rapporteerden een slechtere kwaliteit van leven dan de algemene populatie. Ze had-
den vaker problemen met verschillende vormen van functioneren en ervaarden vaker 
pijn, dyspneu, vermoeidheid, gebrek aan eetlust en financiële problemen. Een lagere 
kwaliteit van leven was voornamelijk gevonden bij jongere patiënten zonder betaalde 
baan. Dit is een belangrijk probleem want in totaal was 25% van de respondenten niet in 
staat om te werken als gevolg van AML. Uit de studie bleek ook dat een allogene stam-
celtransplantatie, gebrek aan sociale steun en een lagere leeftijd geassocieerd waren 
met een slechtere kwaliteit van leven. Vanwege het relatief kleine aantal respondenten 
kunnen hier echter nog geen definitieve conclusies aan verbonden worden.
kosteneffectiviteitsanalyses
Voor het berekenen van de kosteneffectiviteit van geïndividualiseerde behandelstrate-
gieën in AML is een analytisch beslismodel ontwikkeld en gevalideerd. De ontwikkeling 
en validatie was cyclisch proces, waarbij de resultaten continu werden gechecked met 
klinische experts en input data. Gedetailleerde informatie over dit proces is te vinden in 
hoofdstuk 7. Het model was een discrete-event simulatie om de heterogeniteit van AML 
goed mee te kunnen nemen in de analyses. Een fictieve dataset was gesimuleerd op 
basis van individuele ziektepaden. Deze individuele paden volgden uit schattingen van 
de tijd tot verschillende events waarbij rekening was gehouden met patient- en ziekte-
kenmerken. Voor iedere patient werd steeds de tijd tot het kortste event geselecteerd. 
Zowel de patient- en ziektekenmerken als de relevant klinische uitkomstmaten in de 
gesimuleerde dataset kwamen overeen met de originele data. Daarnaast was de over-
leving uit het model ook vergelijkbaar met de gerapporteerde overleving in klinische 
trials die niet gebruikt waren als input voor het model. De generaliseerbaarheid van 
het model naar een bredere patiëntenpopulatie was echter nog niet bewezen. De ge-
individualiseerde behandelstrategieën die geëvalueerd zijn in dit proefschrift betroffen 
een herclassificatie van patiënten uit de gemiddelde risico groep naar zowel de lage als 
de hoge risicogroep. Aparte kosteneffectiviteitsanalyses zijn uitgevoerd voor deze twee 
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herclassificatie opties (zie hoofdstuk 8). Een belangrijk gevolg van de herclassificatie was 
een verandering in de behandeling: een minder intensieve behandeling werd gegeven 
aan patiënten met een laag risico en een intensievere behandeling aan patiënten met 
een hoog risico.
Aangezien de kosten van de test vaak niet waren meegenomen in recent gepubliceerde 
kosteneffectiviteitsanalyses van geïndividualiseerde behandelstrategieën, was de ana-
lyse in eerste instantie beperkt tot een evaluatie van de verandering in behandeling. 
De minder intensieve behandeling voor patiënten met een laag risico leidde tot betere 
gezondheidsuitkomsten tegen lagere kosten. De nieuwe behandeling was dus domi-
nant voor deze subgroep. Betere gezondheidsuitkomsten werden ook bereikt met de 
intensievere behandeling voor patiënten met een hoog risico, maar tegen substantieel 
hogere kosten. De incrementele kosteneffectiviteitsratio (IKER) van de verandering van 
behandeling voor die subgroep was €130,065 per gewonnen QALY.
Het includeren van de kosten van de test zorgden voor een stijging van de IKER voor 
beide behandelstrategieën. De kosteneffectiviteit wordt dus overschat indien de 
kosten van de test buiten beschouwing worden gelaten. De ernst van de overschat-
ting is afhankelijk van de hoogte van de test, het verschil in gezondheidsuitkomsten 
als gevolg van de veranderde behandeling en de grootte van de subgroep voor wie 
de behandeling verandert. Op basis van deze bevindingen is een formule ontwikkeld 
waarmee de gevolgen van de test en behandeling apart kunnen worden geanalyseerd 
en gerapporteerd.
aanbevelingen voor toekomstig onderzoek
Hoofdstuk 9 bespreekt de belangrijkste bevindingen en implicaties van dit proefschrift. 
Het is kosteneffectief om AML patiënten met een laag risico te behandelen met een 
minder intensieve behandeling. De nieuwe behandeling voor patiënten met een hoog 
risico, de allogene stamceltransplantatie van een ongerelateerde donor, is erg duur en 
heeft negatieve gevolgen voor de kwaliteit van leven. Kosteneffectievere behandelingen 
zijn daarom noodzakelijk voor deze subgroep. Verder kan de zorg voor AML verbeterd 
worden door meer aandacht te besteden aan ondersteunende zorg en het ontwik-
kelen van meer gerichte behandelingen voor andere subgroepen. Deze meer gerichte 
behandelingen kunnen mogelijk de behandelkosten verlagen indien een langdurige 
ziekenhuisopname niet meer noodzakelijk is.
Nieuwe klinische studies in AML moeten kwaliteit van leven meenemen als secondaire 
uitkomstmaat, omdat patiënten nog veel gezondheidsproblemen ervaren als gevolg van 
de ziekte of behandeling. Indien zowel de QLQ-C30 als de EQ-5D worden meegenomen 
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als kwaliteit van leven instrument, kan de validiteit van de EQ-5D bij acute leukemie ook 
nog verder worden onderzocht. Daarnaast moeten zowel directe als indirecte kosten 
worden gemeten in die studies om een adequaat oordeel te geven van de impact van 
nieuwe behandelstrategieën op de totale kosten.
De bevindingen uit dit proefschrift dragen ook bij aan de methodologie van kostenef-
fectiviteitsanalyses van geïndividualiseerde behandelstrategieën in andere ziektegebie-
den. De kosten van de test moeten altijd worden opgenomen in die analyses om een 
overschatting van de kosteneffectiviteit te voorkomen. Met behulp van de ontwikkelde 
formule kunnen de kosten van de test op een efficiënte wijze worden toegevoegd aan 
de analyses. De data verzameling en analyse kan nog steeds beperkt zijn tot de subgroep 
voor wie de behandeling verandert. Gestandaardiseerd gebruik van de formule zal ook 
de interpretatie van de resultaten verbeteren omdat vergelijkingen met andere studies 
beter te maken zijn. Tot slot kan de formule gebruikt worden in een vroeg stadium van 
productontwikkeling om richting te geven aan verder ontwikkeling en data verzame-
ling.
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lisT oF aBBreviaTions
AIC Akaike information criteria
AML Acute myeloid leukemia
APL acute promyelocytic leukemia
CEBPAdm CCAAT enhancer binding protein double mutations
CR Complete remission
CS-PBM Condition-specific preference-based measure
DAS28 Disease activity score
DES discrete-event simulations
DFS Disease-free survival
EDSS Expended Disability Status Scale
EGFR epidermal growth factor receptor
EQ-5D EuroQol five-dimenisonal
EQ-5D-3L Euroqol five dimensional - three level questionnaire
EQ-5D-5L Euroqol five dimensional - five level questionnaire
EQ-VAS EuroQol visual analogue scale
Erasmus MC Erasmus Medical Center
ES Effect size
ESR Erythrocyte sedimentation rate
EVI1 ecotropic virus integration-1
FACT-B Functional Assessment of Cancer Therapy-Breast
FLT3-ITD Internal tandem duplication of the fms-like tyrosine kinase-3 gene
FN False negative
FP False positive
GVHD graft-versus-host disease
HADS Hospital-Anxiety and depressions scale
HAQ Health assessment questionnaire
HDC high-dose conditioning
HOVON Hemato-oncology association for adults in the Nederlands
HR Hazard ratio
HRQOL Health-related quality of life
HSCT Hematopoietic stem cell transplantation
HUI Health utility index
ICER Incremental cost-effectiveness ratio
IDH isocitrate dehydrogenase
MAE Mean absolute error
MS Muliple sclerosis
MSIS-29 Multiple Sclerosis Impact Scale 29
MUD Matched unrelated donor
NICE National Institute of Health Care Excellence
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NPM1 nucleophosmin-1 gene mutations
OMEP orthogonal main effects plan
OS Overall survival
PBM Preference-based measure
PSA Probabilistic sensitivity analysis
QALY Quality-adjusted life year
QL scale Global quality of life scale of the QLQ-C30
QLQ-C30 Quality of Life Questionnaire for Cancer 30
QLQ-PBM Quality of Life Questionnaire - Preference Based Measure
RCT Randomized controlled trial
REACH Rotterdam Early Arthritis CoHort
RIC Reduced-intensity conditioning
RMSE Root mean square error
SD Standard deviation
SF-36 Short-Form 36
TN True negative
TP True positive
TRM Treatment-related mortality
TTO Time trade-off
UCB Umbilicial cord blood
WBC White blood cell
WHO World Health Organization
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DankwoorD
Promoveren is eigenlijk wel te vergelijken met een maken van een (hele grote) ‘Wasgij’ 
puzzel. Bij aanvang van mijn promotietraject had ik geen idee hoe mijn proefschrift 
er uiteindelijk uit zou gaan zien. Het enige dat ik wist was dat het ‘iets’ te maken zou 
hebben met de kosteneffectiviteit van nieuwe diagnostische mogelijkheden bij acute 
myeloïde leukemie. In de afgelopen jaren heb ik de puzzel beetje bij beetje opgelost 
en werd het eindresultaat steeds zichtbaarder. Op sommige momenten verliep het 
schrijven van mijn proefschrift heel soepel, maar er waren ook momenten dat het even 
duurde voordat ik een passend stukje vond. Gelukkig hoefde ik de puzzel niet helemaal 
alleen op te lossen en daarom wil ik in dit dankwoord iedereen bedanken die, op zijn of 
haar manier, een bijdrage heeft geleverd aan mijn proefschrift.
In de eerste plaats ben ik mijn promotoren, Carin Uyl-de Groot en Bob Löwenberg, en 
copromotor Ken Redekop dankbaar voor hun waardevolle begeleiding tijdens mijn 
promotietraject. Beste Carin, jouw passie om te zorgen voor een goede behandeling 
voor iedere patiënt is een voorbeeld voor mij. Ik hoop daar in de toekomst zeker nog 
meer aan bij te dragen. Ik ben je verder zeer dankbaar voor jouw steun om me verder 
te ontwikkelen op het gebied van onderwijs. Jouw betrokkenheid beperkte zich echter 
niet alleen tot het professionele vlak, maar je had ook altijd aandacht voor mij als mens. 
Helaas bleek er wel een selectie effect te zijn bij het lezen van de korfbaluitslagen in de 
krant, waardoor je mijn prestaties mogelijk onderschat hebt.
Beste Bob, ik vind het ontzettend fijn dat je bereid was om voor mij een tweede promo-
tor te zijn. Ik heb van jou niet alleen veel geleerd over acute myeloïde leukemie, maar 
ook hoe ik mijn eigen onderzoeken moet positioneren in een groter geheel. Ik heb de 
samenwerking met jou als heel positief ervaren.
Beste Ken, de tijd die wij samen hebben besteed aan inhoudelijke discussies hebben 
mijn proefschrift aanzienlijk verbeterd. Het was heel fijn dat jouw deur altijd open stond 
en je altijd tijd vrij maakte om uitgebreid van gedachte te wisselen over de problemen 
waar ik tegen aanliep. Je hebt mij veel wijze lessen geleerd op het gebied van onderzoek 
en onderwijs. Ik bewonder jouw gave dat je altijd in staat bent om treffende beeldspra-
ken te vinden voor welk onderwerp dan ook. Zelfs bij het doceren van gezondheidseco-
nomie weet je een link te leggen met de serie ‘The Big Bang Theory’. Je ziet dat ik in dit 
dankwoord ook een poging doe, maar ik kan jou nog lang niet evenaren.
De artikelen in mijn proefschrift waren niet tot stand gekomen zonder de hulp van de 
co-auteurs. In het bijzonder wil ik Matthijs bedanken voor de prettige samenwerking 
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tijdens onze kwaliteit van leven studies. Mijn artikelen zijn zeker ook verbeterd door 
vakinhoudelijke discussies met collega-onderzoekers op de werkvloer en bij congres-
sen, zoals LoLaHESG en ISPOR.
Verder wil ik de promotiecommissie bedanken voor het kritisch doornemen van mijn 
proefschrift en het stellen van uitdagende vragen tijdens de verdediging.
Lieve Jennifer en Nicole, ik vind het heel fijn dat jullie naast mij staan tijdens de verde-
diging.
Jen, het grootste gedeelte van mijn promotietraject had ik de eer om een kamer met 
jou te delen. Ik heb genoten van onze tweetalige brainstormsessies over modellen, 
vroege HTA, artikelen, onderwijs, toekomstige carrièremogelijkheden en, misschien 
wel het belangrijkste, ons sociale leven. Jouw gedrevenheid voor het bereiken van je 
persoonlijke doelen zijn een voorbeeld voor mij!
Nicole, we hoefden al nooit te zoeken naar een gespreksonderwerp als we elkaar za-
gen, maar toen jij ook aan een promotietraject begon raakten we helemaal nooit meer 
uitgepraat. Heel fijn om een zo’n goede vriendin te hebben die precies weet hoe het 
is om te promoveren. Ik hoop dat we samen nog veel wijntjes zullen drinken op onze 
geaccepteerde artikelen!
Bij het leggen van een puzzel is het essentieel om soms even afstand te nemen en op 
een later moment weer verder te kijken. Op dat moment zie je ineens passende stukjes 
die je eerder over het hoofd zag. Gelukkig was de sfeer bij BMG zo goed dat hier ook de 
mogelijkheid toe was. Sociale hoogtepunten waren voor mij de vrijdagse kroket en deel-
name aan de Roparun. Buiten werktijd waren er ook meer dan genoeg mogelijkheden 
om de aandacht even ergens anders op te richten tijdens bijvoorbeeld het korfballen en 
gezellige etentjes of uitjes met familie en vrienden.
Lieve papa en mama, het klinkt heel cliché om te zeggen dat ik zonder jullie dit proef-
schrift niet had geschreven, maar het is echt waar. Papa, van jou heb ik mijn aanleg 
voor statistiek meegekregen terwijl ik de passie voor de gezondheidszorg van mama 
heb geërfd. Ik vind het dan ook extra bijzonder dat mijn proefschrift zo duidelijk een 
product is van jullie twee werelden. Verder was het ook heel fijn om op zondag te kun-
nen ontspannen tijdens een heerlijk diner in Trattoria Toscane. Lieve Carli en Lennert, die 
etentjes zijn een stuk gezelliger met jullie erbij. Bij deze wel het verzoek om me voortaan 
bij een plagerij over mijn lengte aan te spreken met mijn nieuwe titel!
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Lieve Peter, dankjewel dat je mij hebt gesteund door mij de vrijheid te geven om mijn 
eigen doelen na te streven, maar er wel altijd voor mij te zijn bij een tegenslag. Jij tovert 
altijd weer een lach op mijn gezicht!
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